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Thesis Abstract 
Clostridium difficile infection (CDI) is the leading cause of nosocomial diarrhoea in the 
developed world and community-acquired infection is increasing in incidence. The current 
‘gold standard’ for diagnosing CDI is stool culture, followed by a cell cytotoxicity 
neutralisation assay. However, these methods are labour intensive and time consuming, so 
are seldom used. More rapid tests for diagnosing CDI, for example, toxin enzyme 
immunoassays, are less sensitive and/or specific. Accurate and early detection, especially at 
the appropriate point of need (PoN), is crucial for the successful treatment of CDI and 
minimising transmission of the disease between patients.  
In this study, a novel bioinformatics approach was used to identify protein sequence 
diagnostic biomarkers that are unique for bacteria within a particular group of interest 
(GOI). This approach incorporated a previously designed system, IDRIS, to mine all fully 
annotated genomes within the NCBI RefSeq database, together with a bioinformatics 
workflow that was designed and applied within this project. The workflow uses several 
bioinformatics tools to identify biomarkers that are a minimum of 15 amino acids, are 
unique to a GOI and are surface accessible within whole cells. Biomarkers from surface 
accessible proteins were selected as they would provide targets that facilitate PoN detection 
of whole cells, by minimising the need for time consuming pre-treatment of samples.  
The most promising target identified was a 16 amino acid biomarker within the surface layer 
protein, SlpA. Monoclonal antibodies (mAbs) were produced against this unique biomarker 
and were shown to bind specifically to whole C. difficile cells, including strains from each of 
the 13 surface layer type clades, which represent the entire C. difficile species. The selected 
mAb did not bind to species closely related to C. difficile, highlighting the molecules promise 
for PoN CDI detection. The sensitive and specific binding of the developed mAb highlights 
the value of the bioinformatics approach, which could be used to provide similar results for 
other bacteria, including other pathogens.  
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Chapter 1 General introduction 
1.1 Biosensors and point of need testing 
Biosensors are devices that combine biological recognition molecules with physical or 
chemical transducers. The detection element can be qualitative, for example a colour 
change, or can be quantitative, for instance a digital readout (Newman and Setford, 2006). 
In 1962, Leland C. Clark designed the original biosensor, when he expanded his innovative 
oxygen electrode to create the first glucose meter (Clark and Lyons, 1962). The basic design 
of this glucose sensor has been the foundation for several different enzyme sensors and in 
1970, Anton Clemens produced a quantitative sensor that could be used by the patient to 
self-monitor blood glucose levels (Tonyushkina and Nichols, 2009). This advancement in 
technology, along with the discovery of insulin, has been said to be the most important in 
controlling diabetes mellitus (Clarke and Foster, 2012).   
Another highly successful biosensor is the pregnancy test, which utilises a sandwich based, 
enzyme-linked immunosorbent assay (ELISA) and a lateral flow strip. A sandwich ELISA 
detects antigens between two layers of antibodies. One antibody layer is bound to a solid 
surface and the secondary antibodies are fluid and conjugated to a detection molecule, such 
as gold nanoparticles (Zhou et al., 2015). The antigen binds to the stationary antibodies and 
the fluid, secondary antibodies bind and sandwich the antigen, producing a positive signal, 
such as a detectable colour (Figure 1-1 A). In pregnancy tests this assay is performed using 
lateral flow strips, porous strips that substances can travel through (Figure 1-1 B). 
Antibodies bound to the strip are used to detect the hormone, human chorionic 
gonadotropin, which is produced by fertilised ova (Peters, 2008). Conjugated secondary 
antibodies then bind to the hormone, producing a positive coloured line. Both the blood 
glucose monitor and the pregnancy test are examples of for rapid point of need, testing at 
or near the site of patient care, (PoN) sensors. 
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Figure 1-1. Diagram of a sandwich enzyme-linked immunosorbent assay (A) showing the stationary antibodies capturing, 
and the gold conjugated Abs sandwiching, the antigen. Diagram (B) is a sandwich ELISA in use in a lateral flow strip. The 
conjugated antibodies produce a coloured line when bound to the antigen. 
PoN biosensors that are rapid, specific and sensitive are essential for swift diagnosis and the 
best possible patient outcome (Byrne et al., 2009). They are a vital element of an affordable, 
worldwide healthcare system (Sharma et al., 2015). It is also crucial for PoN sensors to be 
simple to use and provide an easily understandable output (Brandt, 2012). Typically, rapid 
biosensors are used for medical diagnostics, however, they are also used for environmental 
monitoring (Ramnani et al., 2015), veterinary medicine (Mettler et al., 2005) and the food 
industry, for example in early detection of salmonella (Taban et al., 2013). 
Phenotypic methods are the most common means of identifying bacteria in clinical 
laboratories (Janda and Abbott, 2002), however, there are many other techniques that can 
be used. These bacterial identification techniques include, Southern blot hybridisation of 
specific DNA fragments (Nilsson et al., 2000), PCR amplification of genes or regions of 
interest (Harper-Owen et al., 1999) and microarrays of specific DNA sequences (Mitterer et 
al., 2004). Traditional bacterial typing technologies are often difficult to standardise, lack 
sufficient ease of use and are not usually suitable for PoN (Jakupciak and Colwell, 2009). 
Fast and user-friendly PoN sensors would have a huge impact on the early diagnosis and 
treatment of pathogen related infections (Veigas et al., 2015) and in turn could reduce the 
transmission rate of infection (Goldenberg et al., 2012). The quick response of accurate 
treatment could also lower the use of incorrect antimicrobials and therefore, reduce the 
spread of antimicrobial-resistant bacteria (Ramirez-Rosales and Cantu-Llanos, 2012). The 
majority of available PoN sensors are not specifically for bacteria and include urine analysis, 
blood-glucose testing and blood-gas analysis (Shearer et al., 2009; Remes-Troche, 2012). 
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However, there are some bacterial PoN tests, including tests for Group A Streptococcus (Li 
et al., 2011) and bacterial vaginosis (Bradshaw et al., 2005). 
Two of the major pathogens in the developed world are methicillin-resistant Staphylococcus 
aureus (MRSA) (Barra-Carrasco et al., 2013) and Clostridium difficile (C. difficile), which 
cause a high percentage of infections and economic burden (Leekha et al., 2013).  Currently 
there is no single PoN sensor for either of these pathogens that is rapid, sensitive, easy to 
use and specific.   
In order to create a PoN sensor that meets all of the necessary criteria, a biomarker that can 
be used to identify and distinguish the bacteria must be characterised. For PoN bacterial 
diagnosis, it is important to minimise the pre-treatment of samples and, therefore, reduce 
the time taken to perform the test. Ideally the biomarker should be on the surface of, or 
secreted by the bacteria, so the cells do not need to be lysed prior to testing. The biomarker 
also needs to be present at a high enough concentration to be detected in complex samples 
such as serum or faeces (Giljohann and Mirkin, 2009). Genomic and proteomic data can be 
used not only to determine biomarkers that are unique to bacteria, but when analysed with 
subcellular localisation bioinformatics tools the data can also be used to differentiate 
between the biomarkers that are surface exposed and those that are not (Tiwari and 
Srivastava, 2014).  
The subject of this thesis is the exploration and proof of concept of a novel ‘top-down’ 
bioinformatics-laboratory approach, to characterise bacterial biomarkers for use in PoN 
sensors. Although this case study uses C. difficile, which will be discussed in detail within this 
introduction, the bioinformatics approach and downstream laboratory analysis can be 
utilised for biomarker discovery for any organism of interest. C. difficile was selected for the 
case study as it is a pathogenic organism that caused a worldwide epidemic in 2000 (Carroll 
and Bartlett, 2011). Also, C. difficile associated outcomes would benefit from PoN diagnosis 
however, there currently is no PoN test used (Goldenberg et al., 2014).   
1.2 Biomarkers 
A definition of biomarker from the U.S. National Institute of Health is “a biological 
characteristic, objectively measured (i.e. with acceptable accuracy and reproducibility) and 
 4 
 
used as an indicator for a physiological or pathological process, or of the activity of a 
medicine.” (De Gruttola et al., 2001; Group., 2001). The term biomarker therefore covers a 
broad variety of possibilities. The term ‘bacterial biomarker’ narrows the scope to a 
biological characteristic of a bacterium. A bacterial biomarker can take several forms, firstly, 
the presence of a bacterial species can indicate a particular condition, such as sepsis (Mohan 
and Harikrishna, 2015). Secondly, the presence of host biomarkers such as cytokines or 
procalcitonin, which can be measured to identify the presence of a bacterial infection 
(Holub et al., 2013). Thirdly, the presence of a bacterial gene, or part of a gene, established 
with sequence-based identification (Jarvinen et al., 2009). Finally, protein biomarkers can be 
used to identify specific bacteria using whole-cell matrix-assisted laser desorption 
ionization–time of flight mass spectrometry (Fagerquist, 2013). However, this diagnostic 
method is not suitable for PoN testing, since the required equipment is typically large and 
expensive (Suarez et al., 2013). Any biomarker detection that requires culture of the 
microorganism are often discounted for use in PoN sensors due to the time-consuming 
nature of the method (Emerson et al., 2008). 
Accuracy is fundamental to the use of biomarkers for either screening or diagnostic 
purposes and is outlined as the ability to correctly classify subjects into clinically relevant 
groups, for example those infected, or not, with C. difficile (Soreide, 2009). The diagnostic 
accuracy of a PoN test, when incorporating the detection of a biomarker, is determined by 
two aspects. The first is the accuracy of the biomarker detection molecule and second, the 
exclusive presence of the biomarker within the organism to be detected (Giljohann and 
Mirkin, 2009). The discovery of biomarkers has traditionally been carried out using a 
knowledge driven approach by reference to the literature and user expertise and experience 
(Bravo et al., 2014). Large-scale screening studies and taxonomic analysis can also reveal 
bacterial traits that may act as suitable biomarkers for a particular species or strain 
(Szafranski et al., 2015). However, with the advent of high-throughput genomic scale 
studies, the systematic discovery of biomarkers now becomes possible through the 
comparative analysis of ‘omics’ type datasets (Segata et al., 2011).    
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1.3 Computational determination of biomarkers 
Traditional methods of biomarker identification analysed particular genes or proteins of 
interest using techniques such as Northern blotting, 2D-PAGE electrophoresis or microarray 
data (Jemal et al., 2002; Leirdal et al., 2004; Jarvinen et al., 2009). However, more recently, 
bioinformatics has emerged as a major tool in biomarker identification (Li et al., 2002; Zhang 
et al., 2014).  
The amount of genomic and proteomic data that is accessible has grown exponentially over 
the past three decades as shown by Figure 1-2 taken from The European Nucleotide Archive 
statistics page1 which is part of the European Bioinformatics Institute (EMBL-EBI, 2015). 
With the necessary computational power and skills, this huge amount of data can be mined 
to search for possible biomarkers that are unique to a particular bacterial species, or that 
differentiate strains within species. The available sequence data allows biomarkers that are  
fragments of proteins to be identified, unlike traditional methods that usually searched for 
entire proteins (Rabilloud and Triboulet, 2013). Furthermore, this data and computational 
skill enables a novel ‘top-down’ approach, were the sequence databases are searched prior 
to laboratory work. Traditional phenotypic approaches usually use a ‘bottom-up’ approach 
in which laboratory work identifies a target that is then searched for within bioinformatics 
databases, to determine specificity to the species in question (Song et al., 2010). 
 
                                                     
1 http://www.ebi.ac.uk/ena/about/statistics  
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Figure 1-2. Increase in sequence data taken from The European Nucleotide Archive (ENA) , which is part of the European 
Bioinformatics Institute http://www.ebi.ac.uk/ena/about/statistics and shows the exponential rise, since 1982, of 
annotated DNA sequences (blue) and the number of DNA bases (black) contained within ENA. 
 
Computational pipelines are often utilised for comparative biomarker discovery, in various 
ways and for a multitude of functions. One of the most common use of pipelines involves 
mass spectrometry proteomic analysis of samples, followed by a computational search of 
proteomics databases to identify the protein (Higdon and Kolker, 2007; Song et al., 2010; 
Zhang et al., 2014). This pipeline has more recently been used to determine proteins that 
are potential biomarkers for the differentiation of disease and health (Zhang et al., 2014). 
Genomic data has also been analysed using computational pipelines, including 
transcriptomics data from microarrays and more recently next generation sequencing, to 
determine biomarkers from gene expression data (Allison et al., 2006; Prassas et al., 2012; 
Simon and Roychowdhury, 2013). The most straightforward genome pipeline analyses the 
putative protein products predicted to be encoded by a bacterial genome sequence. A 
comparison is carried out between all the proteins from one genome with those in another 
to determine the genes, encoding proteins, that are similar between strains (termed 
orthologues) and those that might be unique to a given strain, and thus potential 
biomarkers (Zhao et al., 2015).  Bioinformatics tools have also been used to model graphs of 
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protein similarity data, to enable easy visualisation of protein similarity networks (Enright 
and Ouzounis, 2001). 
1.4 Clostridium difficile overview 
Clostridium difficile (C. difficile) is a Gram-positive, spore forming, anaerobic bacillus, which 
causes C. difficile infection (CDI) (Hernández-Rocha et al., 2013). In developed countries, CDI 
is the foremost source of nosocomial diarrhoea (Evans and Safdar, 2015) and, in many 
areas, C. difficile has a greater mortality and morbidity rate than methicillin-resistant 
Staphylococcus aureus (MRSA) (Tam Dang et al., 2012; Howerton et al., 2013). The 
economic burden of CDI is huge, in the United States alone it has been estimated at over $3 
billion per year (Howerton et al., 2013). Currently, there is not a single CDI diagnostic test 
that is used as the worldwide standard as there is variance in the accuracy, cost and 
operational speed of the differing tests (Hansen et al., 2010). These tests will be described in 
detail within section 1.14 an accurate and rapid, PoN diagnostic system would reduce the 
rates of morbidity, mortality and costs associated with CDI (Barbut et al., 2014).   
1.5 Clostridium difficile background 
In 1935, Hall and O’Toole first described C. difficile, naming it Bacillus difficilis due to their 
difficulty in isolating the organism and its slow growth in culture. The bacillus was isolated 
from the stools of healthy neonates where it resided within the normal intestinal flora of 
these infants (Hall and O'Toole, 1935). The bacterium was later renamed Clostridium difficile 
and in 1978 was shown to be a pathogen when Bartlett and colleagues demonstrated that 
the bacteria produced the cytotoxin found in the stools of pseudomembranous colitis (PMC) 
patients (Bartlett et al., 1978a; Bartlett et al., 1978b; Larson et al., 1978). C. difficile can 
affect both humans and animals, and colonisation can be asymptomatic or cause CDI 
(Bartlett and Gerding, 2008). Toxigenic C. difficile strains, those producing toxins, cause CDI 
primarily after the administration of antibiotics (Bartlett and Gerding, 2008). The infection is 
often nosocomially acquired, however, community-acquired CDI is on the increase (Gupta 
and Khanna, 2014).  
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1.6 Symptoms of Clostridium difficile infection 
The symptoms of CDI can range from mild self-limiting diarrhoea, cramping or fever through 
to life threatening PMC (Loo et al., 2005). CDI can infrequently progress to fulminant CDI 
(FCDI), at a rate of around 1-3 % of total CDI (McMaster-Baxter and Musher, 2007). FCDI 
includes, developing colonic perforation and toxic megacolon, an acute form of colon 
distension, which has a high mortality rate of 38 % to 80 % (Foglia et al., 2012). The 
symptoms of FCDI include severe abdominal pain, dehydration, hypotension, oliguria or 
anuria, and marked leucocytosis (McMaster-Baxter and Musher, 2007). 
1.7 C. difficile toxins and pathogenicity locus 
C. difficile has two toxins that are recognised as the main virulence factors for CDI, toxin A 
(TcdA) and toxin B (TcdB). These toxins are both large, TcdA has a molecular weight of 
308kDa and TcdB is 270kDa, homologous to each other and both cytotoxic and enterotoxic 
(Rupnik et al., 2009; O'Donoghue and Kyne, 2011; Calderaro et al., 2013). The tcdA and tcdB 
genes are encoded in a 19.6-kb pathogenicity locus (PaLoc) which also contains 3 other 
genes tcdR, tcdE and tcdC (Figure 1-3) (O'Connor et al., 2009). Non-toxigenic strains of 
C. difficile, that do not produce either TcdA or TcdB, lack the PaLoc and do not induce 
symptoms of CDI (Kachrimanidou and Malisiovas, 2011). 
 
Figure 1-3. The C. difficile pathogenicity locus . PaLoc contains the genes encoding toxins A and B and the tcdC gene, a 
putative repressor of toxin A and B production. 
 
TcdA and TcdB are monoglucosyltransferases that catalyse the addition of glucose to the 
host Rho proteins (Davies et al., 2011). This modification inactivates the Rho-type GTPases, 
which can no longer polymerise actin filaments, causing cell disruption, collapse of the 
cytoskeleton and cell death (Carroll and Bartlett, 2011; Yang et al., 2015; Zhang et al., 2015).  
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There is some controversy over which toxin is largely responsible for virulence in C. difficile 
(King et al., 2015). Early studies reported that TcdA was the essential virulence toxin (Rupnik 
et al., 2009) whereas, other studies indicated that only TcdB was required for virulence, 
showing 100-1000 fold more toxicity, to cells in vitro, than TcdA (Lyras et al., 2009). 
However, Kuehne and co-workers showed that both TcdA, TcdB cause C. difficile virulence 
(Kuehne et al., 2010; Kuehne et al., 2014). The variety in results may be caused by 
differences in animal models and mutant strains used. The contradictory findings do show 
that neither of the toxins can be ignored in the pathogenicity of C. difficile.  
C. difficile can also produce a third toxin, an actin-ADP-ribosylating toxin, called C. difficile 
transferase (CDT) , also known as a binary toxin (Schwan et al., 2009). CDT consists of two 
unlinked polypeptides, CDTa and CDTb that are encoded by the CdtLoc, found in 
approximately 6 %-28 % strains (Carroll and Bartlett, 2011; Goldenberg and French, 2011). 
CDT causes microtubule-based protrusions from intestinal epithelial cells that facilitate 
C. difficile colonisation (Schwan et al., 2009). Some C. difficile strains that only produce CDT 
display pathogenicity, even without the main virulence factors TcdA and TcdB, however, 
these strains are uncommon (Eckert et al., 2014). 
1.8 Transmission of Clostridium difficile and route of infection 
C. difficile is spread via the faecal-oral route, either through vegetative cells or resilient 
spores (Cohen et al., 2010). C. difficile, in either form, is excreted in carriers’ faeces, 
transmitted by person-person or person-object contact, and re-enters the gut via ingestion. 
The key reservoirs for C. difficile are colonised people, either asymptomatic or CDI patients, 
and inaminate objects, on which spores can survive for months (Gerding et al., 1995; 
Fordtran, 2006).  
The gut is usually protected from intestinal pathogens, such as C. difficile, by the host 
microbiota, a population of commensal bacteria that inhabit the gastrointestinal mucosal 
surfaces (Guarner, 2006; Dethlefsen et al., 2008; Ubeda et al., 2010). The microbiota 
provides both physical and chemical barriers, which confer pathogenic resistance via the 
occupation of mucosal attachment sites, production of antimicrobial substances and 
consumption of nutrient sources (Servin, 2004; Sekirov et al., 2010; Ubeda et al., 2010). It 
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has been shown by Dethlefsen and colleagues that more than 5,600 bacterial taxa exist 
within this gut microbiota (Dethlefsen et al., 2008).  
Figure 1-4 provides an excellent overview of the route of CDI and was kindly provided by Dr 
Susan Poutanen2, taken from work performed with Simor (Poutanen and Simor, 2004). This 
figure will be used throughout this section to describe transmission of CDI. Once ingested, 
the majority of vegetative cells are destroyed by the stomach acid however, the hardy 
C. difficile spores can survive this acidic environment (Poutanen and Simor, 2004). If the gut 
microbiota is disrupted, usually via the use of broad spectrum antibiotics, it can allow the 
ingested C. difficile spores to germinate into vegetative cells (Figure 1-4). These, and any 
pre-existing vegetative C. difficile cells, then have the space to proliferate (Chang et al., 
2008). When toxigenic strains of C. difficile colonise the colon, toxins A and or B are 
produced, causing damage to the intestinal mucosa (Voth and Ballard, 2005). The toxins 
then inactivate host rho-proteins, causing disruption of the cytoskeleton and cell apoptosis 
(Rea et al., 2012). The resulting disruption of the gut epithelial cells leads to watery 
diarrhoea, pseudomembrane formation and colitis (Poutanen and Simor, 2004). These 
symptoms are exacerbated by toxin-mediated recruitment of a proinflammatory host 
immune response (Prevention, 2008). 
 
                                                     
2 Departments of Laboratory Medicine and Pathobiology and Medicine, University of Toronto 
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Figure 1-4. How C. difficile causes CDI. C. difficile is ingested in the form of vegetative cells or spores. The stomach acid 
kills the vegetative cells however the spores survive, germinating into vegetative cells which can produce toxins. The 
toxins cause damage to the gut epithelium and induce a host proinflammatory response, leading to CDI (Poutanen and 
Simor, 2004).  
 
1.9 Asymptomatic carriage of Clostridium difficile 
Asymptomatic carriage of C. difficile is relatively common, the organism is present in the 
stool of around 5 %-7 % of healthy adults (Foglia et al., 2012; Galdys et al., 2014) ranging up 
to 30 % of patients in long-term care facilities (Riggs et al., 2007). It has been reported that 
colonisation of C. difficile occurs in 70 % of infants up to the age of three, when the rate of 
carriage then declines to the values found among healthy adults (Bryant and McDonald, 
2009). This colonisation of infants, occasionally with toxigenic strains, rarely leads to CDI, 
the reasons for which are not understood. However, several postulations have been made 
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including, the neutralising effect of maternal antibodies and the lack of mature receptors for 
C. difficile toxins (Eglow et al., 1992; Gerding et al., 2012). There is some evidence that 
screening for asymptomatic C. difficile carriers, upon admission to hospital, could reduce the 
number of CDI cases (Lanzas and Dubberke, 2014). 
1.10 Causes and risk factors of Clostridium difficile infection 
The major risk factors for CDI are antibiotic exposure, hospitalisation and advanced age, 
usually over 65 years (Taslim, 2009; Carroll and Bartlett, 2011; He et al., 2013). CDI is 
predominantly regarded as a nosocomial disease, affecting patients often with underlying 
disorders (Fordtran, 2006; Tattevin et al., 2013) with more than 300,000 nosocomial cases 
per year in the United States (Rupnik et al., 2009). However, there has been a worldwide 
increase in community-acquired CDI, even within reasonably healthy people (Prevention, 
2008; Gupta and Khanna, 2014).  
The risk of CDI in people aged 65 or over has been shown to be 10 times greater than in the 
younger population (Pépin et al., 2004). In the U.S. in 2008, 93 % of deaths related to CDI 
were in patients older than 65 years of age. Also in this year, C. difficile was reported as the 
eighteenth leading cause of death in this age group (Miniño et al., 2010). The increased risk 
of CDI in the elderly may be due to age-related changes in gut microbiota and immune 
senescence (Simor et al., 2013). Unlike other enteric infections, C. difficile has an elevated 
rate of relapse (Eyre et al., 2012). Recurrence of CDI is a large problem, with up to 30 % of 
patients developing a second episode (Howerton et al., 2013) and 60 % of these patients 
being affected by further recurrences (Kachrimanidou and Malisiovas, 2011). Being aged 65 
and over is a major risk for recurrent CDI (Buffie et al., 2012). The relapse rate is likely to be 
due to the high prevalence of spore contamination within primary-care facilities and 
decreased gut microbiota from previous treatment. 
Initially, clindamycin was considered as the main antibiotic risk factor for CDI however, 
fluoroquinolones and broad-spectrum β-lactam agents have recently been validated as 
principal triggers (Tattevin et al., 2013). The rise in fluoroquinolone risk, is parallel to the 
increase in fluoroquinolone-resistant strains (Rupnik et al., 2009). Kachrimanidou and 
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Malisiovas assert that 85 % of CDI patients have received antibiotics within the 28 days prior 
to disease onset (Kachrimanidou and Malisiovas, 2011). 
Although it has not been fully studied, there is evidence that CDI has been previously 
initiated by transmission from asymptomatic C. difficile carriers (Clabots et al., 1992). These 
carriers may have the potential to contribute significantly to the disease transmission in 
long-term care facilities (Riggs et al., 2007). Although it is not currently recommended, there 
have been studies that suggest screening for CDI would lower the rate of infection (Cohen et 
al., 2010; Leekha et al., 2013; Lanzas and Dubberke, 2014). The main reason for the lack of 
screening is due to the traditional, accurate C. difficile detection methods, such as toxigenic 
culture, being time-consuming, costly and labour-intensive. Therefore, if a rapid, accurate 
and cost-effective technique was available, screening for asymptomatic carriers could occur 
and the associated risk of such carriers transmitting C. difficile could be decreased (Lanzas 
and Dubberke, 2014). 
1.11 Clostridium difficile spores 
C. difficile sporulates during unfavourable conditions, producing metabolically dormant, 
endospores (Carroll and Bartlett, 2011). These spores, unlike the vegetative C. difficile, can 
tolerate oxygen and survive in the environment for prolonged lengths of time (Buffie et al., 
2012). Spores are shed in the faeces of CDI patients at an estimated rate of between 1×104 
and 1×107 spores per gram of stool (Dawson et al., 2011). These spores are also extremely 
difficult to eradicate (Alfa et al., 2010) as they have resistance to heat, bleach and radiation 
(Babakhani et al., 2012). The great persistence and high number of C. difficile spores, means 
that they are prevalent on hospital surfaces and re-infection is a problem (Eyre et al., 2012). 
Spore contaminated objects within the nosocomial setting range from thermometers and 
tube feeding equipment, to toilets and carpets (Fordtran, 2006). This pervasiveness of 
spores provides an environmental, transmission reservoir for CDI (Lawley et al., 2012).  
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1.12  Hypervirulent Clostridium difficile strains 
The large increase in incidence of CDI between 2000 and 2010 has been ascribed to an 
epidemic strain designated restriction endonuclease type B1, North American pulsed-field 
type 1, PCR ribotype 027 (BI/NAP1/027) (Buckley et al., 2011; Carroll and Bartlett, 2011). 
This fluoroquinolone-resistant C. difficile variant has caused outbreaks in the United States, 
Canada and across Europe, and is associated with an increased mortality rate of 15 % and 
recurrence rate of 47 % (Cartman et al., 2010).  In 2007/08, at the height of the C. difficile 
epidemic, BI/NAP1/027 caused more than 40 % of CDI cases in the UK (Brazier et al., 2008). 
He and associates report that fluoroquinolone resistance was the key factor in the rapid 
emergence of BI/NAP1/027 during the early 2000s (He et al., 2013). The BI/NAP1/027 strain 
has been classed as ‘hypervirulent’ and as such, has an increased virulence compared with 
usual strains due to its amplified toxin production (Heeg et al., 2012) - producing toxins A 
and B, 16 and 23 times greater, respectively, than non-epidemic strains (Vaishnavi, 2011). 
The BI/NAP1/027 strain contains alterations to the tcdC gene within the PaLoc region. The 
tcdC gene (Figure 1-3), which is thought to be a repressor of toxin A and B production, has 
an 18-bp deletion (Bartlett et al., 1978b; Carroll and Bartlett, 2011) and contains a nonsense 
mutation at position 117 (Cartman et al., 2010). This genetic shift results in the production 
of a truncated protein which is less effective at minimising toxin A/B production (Miller et 
al., 2002; Carter et al., 2011). This protein mutation is hypothesised to be a contributor to 
the increased levels of the toxin production, associated with the hypervirulent BI/NAP1/027 
variant (Warny et al., 2005; Carter et al., 2011).  
There is some evidence that C. difficile BI/NAP1/027 hypersporulates, producing a greater 
number of spores compared with non-epidemic strains (Wilcox and Fawley, 2000; Merrigan 
et al., 2010). Although Heeg and colleagues have shown that sporulation rates within variant 
strains differ, hypersporulation could play a factor in the high transmission rate of epidemic 
BI/NAP1/027 strains (Heeg et al., 2012). Hypervirulent strains are also linked with the 
production of the binary toxin CDT, which is thought to aid pathogen attachment and 
colonisation (Kelly et al., 1994; Schwan et al., 2014). 
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1.13 Clostridium difficile related mortality rates 
Since 1978, CDI has accounted for 20-25 % of all cases of antibiotic-associated diarrhoea 
(AAD) (Bartlett, 2007) and at least 90 % of pseudomembranous colitis incidences (Bartlett et 
al., 1978b; Kelly et al., 1994). Between 0.5 % and 1.5 % of all hospital admissions develop 
CDI (O'Brien et al., 2007), within which the mortality rate is 1.5-6 % (Miller et al., 2002; Loo 
et al., 2005) and 6-30 % suffer from pseudomembranous colitis (McMaster-Baxter and 
Musher, 2007). In many areas, C. difficile has a greater mortality and morbidity rate than 
methicillin-resistant Staphylococcus aureus (MRSA) (Tam Dang et al., 2012; Leekha et al., 
2013).   
Between 2000 and 2005, incidences of CDI, in the United States (US) and parts of Europe, 
tripled and the associated morbidity and mortality rates increased (Gerding et al., 2008; 
Rupnik et al., 2009). The rising rates in CDI were attributed to the hypervirulent strain 
BI/NAP1/027 (Loo et al., 2005; McDonald et al., 2005) and it was estimated that in the U.S. 
up to 20,000 patients die annually from CDI (Rupnik et al., 2009). 
A total of 14,165 CDI cases were reported within the NHS between April 2014 and March 
2015, which was a 6 % increase on the 2013/14 rates, however, when compared to the 
epidemic of 2007/08, it remains a huge reduction in cases (Gerver et al., 2015). The most 
recent mortality rates associated with CDI in England and Wales are for 2012, when 1646 
deaths were attributed to the infection, equating to 15.3 deaths per million population 
(National Statistics, 2013). Again, this is a large decrease compared to 2007 when 4056 
deaths were attributed to CDI (Hudson, 2010). Infection rates are not down to the pre-
epidemic numbers, however, the introduction of antimicrobial stewardship, infection 
control barriers and education of health-care workers and patients has caused a significant 
decrease in CDI cases and deaths (Ghose, 2013). 
1.14 Current diagnosis techniques for Clostridium difficile infection 
There are several methods for diagnosing CDI, however, no single technique  has been 
implemented universally (Hansen et al., 2010). The two key factors for any diagnosis are 
sensitivity and specificity. Sensitivity is the accuracy in which the method can detect those 
with CDI and does not produce false negatives. Specificity is the accuracy in which the 
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method determines those that are ‘disease-free’ and does not produce false positives 
(Parikh et al., 2008). Since non-toxigenic strains do not cause CDI, C. difficile can be present 
within samples without infection (Kachrimanidou and Malisiovas, 2011). Therefore, to 
diagnose CDI, determining the presence of C. difficile is not enough, either toxin A or B 
needs to be identified too (Crobach et al., 2009). 
Initially CDI should be predicted through clinical diagnosis and then confirmed with 
laboratory methods, suspected CDI patients should have a history of antibiotic use coupled 
with diarrhoea with a characteristic foul odour (Bartlett and Gerding, 2008). The majority of 
laboratory diagnostic methods are performed using stool as the test sample, however, the 
range of tests vary widely.   
1.14.1 Enzyme immunoassays 
Toxin enzyme immunoassays (EIAs), the CDI diagnostic method most routinely used in 
American laboratories, detects toxins A, B or both (Calderaro et al., 2013). Detection is 
performed using antibodies against the specific toxins either via solid-phase, well type, or 
membrane assays (Barra-Carrasco et al., 2013). These assays are fairly rapid and inexpensive 
however, they have relatively low sensitivity and specificity (Johnson et al., 2001; Lalande et 
al., 2011). Bartlett and Gerding state that EIAs should not be used as a stand-alone test for 
CDI, as the EIAs for toxin A only or both toxins can miss ∼40 % of diagnoses (Bartlett and 
Gerding, 2008) , compared with stool culture (Delmee et al., 2005) and the cell cytotoxicity 
assay (Shanholtzer et al., 1992). A great deal of research is currently being performed to find 
methods that can amplify the toxin signal, therefore improving the sensitivity of toxin tests 
(Song et al., 2015).   
There are also EIAs that detect the presence of glutamate dehydrogenase (GDH), a 
metabolic enzyme produced by C. difficile and also many other bacteria (Commichau et al., 
2008; Harper et al., 2010; Burnham and Carroll, 2013). Typically, bacterial GDHs are 
cytoplasmic or membrane-associated proteins however, GDH can also be found in the 
extracellular culture medium of C. difficile (Girinathan et al., 2014). GDH EIAs tend to have 
high sensitivity as the enzyme is produced in large quantities and therefore few false 
negatives are produced (Tenover et al., 2011). However, GDH EIAs do not detect the 
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C. difficile toxins and are unable to determine the C. difficile strains that are actually causing 
infection, therefore, the test is poorly specific (Goldenberg et al., 2010). Other bacteria also 
possess GDH, and so these EIAs can display cross-reactivity, for example with C. sordellii 
(Lyerly et al., 1988; Burnham and Carroll, 2013). Although GDH EIAs are a good screen for 
CDI they are not suitable for use as a standalone test (Brecher et al., 2013) 
1.14.2 Nucleic acid amplification techniques 
In 2010, the US Food and Drug Administration (FDA) approved the first commercial real-
time C. difficile polymerase chain reaction (PCR) assay (Kvach et al., 2010). The PCR 
diagnostic method amplifies regions in either the tcdA or tcdB genes. Some commercially 
available kits also amplify the tcdC gene deletion to detect the hypervirulent strain 
BI/NAP1/027 (Barra-Carrasco et al., 2013). PCR comes under the category of nucleic acid 
amplification techniques (NAATs), which provide diagnosis for C. difficile that is sensitive and 
specific. It has been stated that NAATs are superior to all other methods, with the exception 
of toxigenic culture (Carroll and Bartlett, 2011). However, because NAATs are highly 
sensitive at detecting toxigenic C. difficile and not the toxins themselves, studies have 
reported that it has caused positive results for patients who are perhaps carriers of toxigenic 
C. difficile but do not have clinical CDI (Planche et al., 2013; Koo et al., 2014).  Another 
disadvantage of NAATs are the associated cost as they require expensive equipment and 
technical skills to perform the technique (Kufelnicka and Kirn, 2011; Buchan and Ledeboer, 
2014). 
1.14.3 Stool culture 
Stool culture (SC) is a highly sensitive method for detecting C. difficile, however, this 
technique is not specific as SC cannot differentiate between asymptomatic carriers and CDI 
sufferers, as it does not detect toxins (Bartlett and Gerding, 2008). For the method, stool 
samples are subjected to alcohol shock, inoculated onto cycloserine cefoxitin fructose agar 
plates, and grown anaerobically. Colonies are determined as C. difficile by morphology, 
Gram stain and latex agglutination. This determines if the sample is positive or negative for 
CDI (Peterson et al., 2007; Eastwood et al., 2009). 
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1.14.4 Cell cytotoxicity neutralization assay 
The cell cytotoxicity neutralization assay (CCNA) is used directly with stool specimens. The 
supernatants from faecal samples are anaerobically incubated with cultured cells, such as 
Vero cell lines (Kachrimanidou and Malisiovas, 2011), for at least 24 hours. If the cell 
monolayer shows a typical cytopathic effect, via cell rounding, then a toxin antiserum is 
added. If the cell rounding is reversed then a positive result for toxigenic C. difficile is 
recorded (Hernández-Rocha et al., 2013). CCNA is not generally used in clinical settings as it 
is time consuming and requires technical equipment for the upkeep of cell lines (Reller et 
al., 2010). CCNA has often been used as the reference standard, when assessing other 
C. difficile diagnostic methods, yet the CCNA technique is not standardised, with 
Laboratories using different cell lines and techniques (Calderaro et al., 2013). These 
differences lead to varying results for the sensitivity and specificity of the technique. Overall, 
CCNA is regarded as relatively specific, however, Cohen and associates believe that it is too 
insensitive to be used as a reference standard (Cohen et al., 2010).   
1.14.5 Toxigenic culture 
Toxigenic culture (TC) is the gold standard for diagnosing C. difficile, in the sense that it is 
the most sensitive and specific method and is often used as a comparison for the success 
rates of other CDI determining techniques (Peterson et al., 2007). During toxigenic culture, 
faecal samples are treated in the same manner as SC. Positive C. difficile colonies are then 
tested for toxin production using the CCNA method described above (Hernández-Rocha et 
al., 2013). This method is laborious and slow, requiring 72-96 hours, thus it is not practical 
for clinical settings and therefore seldom used (Lalande et al., 2011). 
1.14.6 Overview of the advantages and disadvantages of all CDI diagnostic 
tests 
There have been many studies on the sensitivity and specificity of CDI diagnosis and 
variations occur between studies, such as differences in the ‘gold standard’ reference, for 
which all the other methods are tested against, and dilutions/storage times of samples. 
These variations mean that the results of such studies are inconsistent, although there is a 
general trend for each diagnostic. Table 1-1 provides an overview of the ‘pros and cons’ of 
different CDI diagnostic tests (O'Brien et al., 2007; Hansen et al., 2010; Shetty et al., 2011; 
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Fraser and Swiencicki, 2013; Issarachaikull et al., 2015). The table demonstrates the lack of 
reasonably priced, rapid, sensitive and specific diagnostic systems. 
Table 1-1. A comparison of the sensitivity, specificity, cost and completion time, for differing CDI diagnostic methods , 
providing an overview of the related advantages and disadvantages. 
Method Sensitivity 
(%) 
Specificity 
(%) 
Cost ($) Time 
(hours) 
Advantages Disadvantages 
Toxin Enzyme 
Immunoassays 
Low High 5-15 < 2 Rapid and 
simple to use 
Low sensitivity 
Glutamate 
Dehydrogenase 
Medium Med/high 5-15 < 1 Rapid and can 
be used as 
initial screening 
tool 
Requires further 
toxigenic testing 
Nucleic acid 
amplification 
tests (PCR) 
High High 40-50 1-4 Relatively 
sensitive and 
specific 
Requires expensive 
specialist equipment 
and skills 
Cell Cytotoxicity 
Neutralisation 
Assay 
High High 20-30 24-48 High specificity Labour intensive, slow, 
requires specialist 
equipment 
Stool Culture High Med/high 20 > 48 Sensitive  Slow and not specific 
for toxigenic strains 
Toxigenic 
Culture 
High High 10-30 ≥ 96 Highly sensitive Labour intensive, very 
slow, requires 
specialist equipment 
 
1.14.7 Current recommendations for diagnosing CDI 
Current UK and European guidelines for CDI diagnosis do not recommended toxin EIAs for 
use as a stand-alone test, due to their lack of sensitivity (Crobach et al., 2009; Wilcox, 2013). 
However, toxin EIAs or GDH EIA are recommended as part of a two test algorithm, which 
begins with a test for the presence of C. difficile using either NAATs or GDH EIA, followed by 
toxin EIA (Crobach et al., 2009; Wilcox, 2013). If the initial test is negative then the second 
test is not performed (Bartlett, 2007).  
1.15 Current treatment for Clostridium difficile infection 
Accurate and early detection is crucial for the successful treatment of CDI and for 
minimising transmission of C. difficile from patient to patient (Barbut et al., 2014). 
Treatment for CDI is dependent on the severity of the infection and whether it is the initial 
infection or relapse. Metronidazole is used in initial episodes of mild-to-moderate CDI and 
vancomycin is usually administered for the first episode of severe CDI (Cohen et al., 2010). 
Vancomycin is not used for moderate CDI as there is concern that its use may select for 
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vancomycin-resistant enterococci (Al-Nassir et al., 2008).  This antibiotic treatment directly 
suppresses C. difficile, presumably allowing recovery of the indigenous microbiota, thus 
restoring pathogenic resistance (Chang et al., 2008). Howerton and associates state that the 
failure rate of CDI treatment, with first-line antibiotics, can reach 38 % (Howerton et al., 
2013).  
The narrow-spectrum antibiotic, fidaxomicin, is more effective against C. difficile in vitro 
than vancomycin (Louie et al., 2011). Furthermore, this antibiotic has no activity against 
Gram-negative bacteria and therefore causes limited damage to the host’s microbiota 
(Karas et al., 2010; Ghose, 2013). In vivo trials of fidaxomicin have shown similar results to 
vancomycin, and lower rates of recurrence (Crook et al., 2012). In 2012, fidaxomicin was 
approved for the treatment of CDI in Europe (Wilcox, 2013), however, mainly due to the 
cost, fidaxomicin is not universally used (Bartsch et al., 2013).  
An emerging area of CDI treatment is with the use of monoclonal antibodies against either 
toxin A or B. A phase II study, which administered the monoclonal antibodies with 
antibiotics, saw a reduced CDI recurrence rate, down to 7 % compared with 25 % in the 
patients which received only antibiotics (Lowy et al., 2010). Unfortunately, due to the huge 
cost of clinical testing and getting the necessary approvals, no monoclonal antibodies for 
the treatment of CDI have yet come to market.  
Faecal microbiota transplantation (FMT) is the transplantation of faeces from a healthy 
donor to CDI patients either by nasogastric tube, colonoscopy or enema and is another 
treatment used to reduce recurring CDI (Rohlke and Stollman, 2012; Rodriguez et al., 2015). 
The faeces convey the healthy microbiota to the new host, re-establishing the host’s ability 
to defend itself from C. difficile colonisation. FMT has been shown to be successful in 
preventing CDI recurrence in 87 % of patients (Cammarota et al., 2014) and in a study 
comparing FMT with vancomycin, recurrent CDI was resolved using FMT 13 out of 16 
patients compared with only 4 out of 13 for vancomycin (Drekonja et al., 2015). 
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1.16 The Clostridium difficile S-Layer  
Although toxins A and B have been shown to be major virulence factors in CDI, other 
features influencing C. difficile colonisation of the host, may also play a key role (Vedantam 
et al., 2012). The C. difficile surface layer (S-Layer), is involved in pathogen-host interactions 
and has been linked as a potential virulence factor (Spigaglia et al., 2013). 
The C. difficile S-layer is a paracrystalline structure that completely coats the outer surface 
of vegetative cells (Reynolds et al., 2011). Unlike other bacterial S-layers, which are made of 
one protein, the C. difficile S-layer consists of two proteins, the high molecular weight 
(HMW) and the low molecular weight (LMW) surface layer proteins (SLPs) (Fagan and 
Fairweather, 2011). These SLPs are post-translationally cleaved from a single precursor 
protein, SlpA (Dang et al., 2012). The precursor protein is encoded by the slpA gene which, 
after translocation to the cell surface (Calabi et al., 2001), is post-translationally cleaved by 
the cysteine protease Cwp84 to form the individual LMW and HMW SLPs (Kirby et al., 2009; 
Dang et al., 2012). The site of cleavage has been shown to be highly conserved across 
C. difficile strains (Calabi et al., 2001). Post-cleavage, the two SLPs associate into 
heterodimers and form a large percentage of the S-layer (Drudy et al., 2004). A diagram of 
the C. difficile cell surface, with the LMW and HMW SLPs forming the S-layer is provided in 
Figure 1-5. The cytoplasmic membrane is surrounded by a thick peptidoglycan cell wall and 
the entire cell is encapsulated with the S-layer which is mainly made from the mature LMW 
and HMW SLPs that are cleaved from SlpA. The S-layer also contains some other cell wall 
proteins such as the adhesion protein Cwp66 (Dingle et al., 2013). 
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Figure 1-5. Structure of the Gram-positive C. difficile cell surface . A lipid bilayer forms the cytoplasmic membrane which 
is surrounded by a thick peptidoglycan cell wall. The entire cell is encapsulated with the S-layer which is made mainly 
from the mature LMW and HMW SLPs that are cleaved from SlpA. The S-Layer also contains some other cell wall 
proteins. 
 
The slpA and cwp66 genes are located within the 36.6-kb cell wall protein (cwp) gene 
cluster, which also encodes the ATPase SecA2 to which the secretion of both SlpA and 
Cwp66 are dependent on (Fagan and Fairweather, 2011; Dingle et al., 2013). SlpA has 28 
paralogs, including Cwp66, each of which are predicted to be surface associated (Sebaihia et 
al., 2006). 
The HMW SLP is formed from the more conserved C-terminal end of SlpA, whereas, the 
highly variable N-terminal forms the LMW SLP after cleavage (Cerquetti et al., 2000). Both 
SLPs vary in sizes between variant C. difficile strains, with LMW SLP ranging between 36-
45kDa and HMW SLP 48–56 kDa (Calabi et al., 2001; Karjalainen et al., 2002).  
The SLPs are involved in the mechanism of gut colonisation and in the process of adhesion 
to the intestinal mucosa (Cerquetti et al., 2002). Calabi and colleagues showed strong and 
specific binding of purified SLPs to human epithelial cells and gastrointestinal tissues, with 
recombinant HMW SLP binding with a much higher affinity than the LMW SLP. When anti-
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HMW antibodies were introduced the binding of the SLPs to human cells was reduced 
(Calabi et al., 2002).  
Fagan and Fairweather state that “SlpA is the most highly expressed protein in C. difficile, 
accounting for 10-15 % of total cellular protein” and it has been shown that SlpA is also 
highly expressed in all stages of growth (Savariau-Lacomme, 2003; Fagan and Fairweather, 
2011). 
1.17 Aims and Objectives 
The main aim of this project was to determine the effectiveness of a novel bioinformatics 
workflow in identifying bacterial biomarkers that are unique to organisms within a group of 
interest. C. difficile was used as a case study within this project with the aim of identifying a 
unique surface associated biomarker that could be used in a point of need (PoN) sensor to 
detect the bacteria.  
The initial objective was to develop a workflow that could differentiate surface associated 
biomarkers. The biomarker could be part of, or a whole protein that was unique to 
C. difficile and found within no other sequenced organisms. The biomarker must also be 
common to all strains of C. difficile. 
The second objective was to validate the biomarker for potential use in a PoN sensor using 
laboratory methods. This objective included establishing the presence of the biomarker 
within multiple C. difficile strains, whilst confirming the absence of the biomarker in closely 
related species.    
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Chapter 2 Laboratory methods 
2.1 Bacterial storage and growth 
All C. difficile strains were cultured in brain heart infusion broth (BHI) supplemented with 
0.5 % yeast extract and 0.1 % L-cysteine (Sigma), or cooked meat broth (Sigma) and on 
plates made from C. difficile agar base (Sigma) with C. difficile C.D.M.N. – selective 
supplement (Oxoid), 1 vial to every 500ml C. difficile agar, and 7 % sheep’s blood. C. sordellii 
and P. anaerobius were cultured in BHI or on soy-tryptone agar (15 g/l tryptone, 5 g/l 
soytone, 5 g/l NaCl, 15 g/l agar) supplemented with 7 % sheep’s blood.  C. hiranonis was 
cultured in PY + X medium (Table 2-1 and Table 2-2). All incubations were anaerobic, using 
anaerobic jars and Anaerocult A gas packs (Merck), at 37oC. The broths were incubated for 
12-16 h and the agar plates were incubated for 48 h. 
Table 2-1. PY + X medium for growth of C. hiranonis  
Ingredients  Quantity 
Tryptone 5 g/l 
Peptone (pepsin digested) 5 g/l 
Yeast 10 g/l 
Salt solution (see Table 2) 40 ml/l 
L-Cysteine 0.5 g/l 
D-Glucose 5 g/l 
 
Table 2-2.Salt solution used in the PY + X medium for C. hiranonis culture 
Ingredients Quantity 
CaCl2 x 2 H2O 0.25 g/l 
MgSO4 x 7 H2O 0.5 g/l 
K2HPO4 1 g/l 
KH2PO4 1 g/l 
NaHCO3 10 g/l 
NaCl 2 g/l 
For short term storage, cultures were anaerobically kept on agar plates at room 
temperature. For long term storage, liquid cultures were grown to exponential phase (OD600 
0.4-0.6) and mixed with sterile glycerol to a final concentration of 25 % and stored at -80oC.    
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2.2 Bacterial strains 
Table 2-3. List of bacterial strains used throughout this project 
Species 
Strain Type 
C. difficile 630 Reference Strain 
C. difficile R002* Ribotype 
C. difficile R005* Ribotype 
C. difficile 118497G* Clinical isolate 
C. difficile 128703G* Clinical isolate 
C. difficile 994535* Clinical isolate 
C. difficile Ox160 SLTS 
C. difficile Ox575 SLTS 
C. difficile Ox858 SLTS 
C. difficile Ox1121 SLTS 
C. difficile Ox1145 SLTS 
C. difficile Ox1192c SLTS 
C. difficile Ox1342 SLTS 
C. difficile Ox1396 SLTS 
C. difficile Ox1424 SLTS 
C. difficile Ox1437a SLTS 
C. difficile Ox1523 SLTS 
C. difficile Ox1533 SLTS 
C. difficile Ox1896 SLTS 
C. difficile Ox2404 SLTS 
B. subtilis BSB1 Lab strain 
E. coli  Rosetta pLMW1-262-1 Lab strain 
C. sordellii ATCC 9714 Lab strain 
C. hiranonis DSM-13275 Lab strain 
P. anaerobius ATCC 27337 Lab strain 
S. aureus ATCC 29213 Lab strain 
 
C. difficile strains marked with an asterisk were kindly donated by Dr Kerry Hill from the 
Freeman Hospital, Newcastle upon Tyne. The C. difficile Oxford strains (Ox), are the 14 S-
Layer type strains, which were kindly donated by Dr Kate Dingle, Nuffield Department of 
Medicine, Oxford.  The E. coli Rosetta pLMW1-262-1 was kindly donated by Professor Neil 
Fairweather, Imperial College London, and was used to produce the recombinant LMW SLP.  
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2.3 DNA Extraction 
Cultures of bacteria were grown as described in section 2.1.1, 50 ml O/N and DNA extraction 
was performed with a DNeasy Blood and Tissue kit (Qiagen), following the protocol for 
Gram-positive bacteria, with the volume of elution buffer decreased to 30 µl. The DNA was 
quantified using a NanoDrop3 spectrophotometer.  
2.4 Polymerase chain reaction (PCR) 
Clone Manager Version 94 was used to model PCR primers. The ‘PCR clone wizard’ tool was 
followed, with differing inputs depending on the target. The presence of primers, in all 
C. difficile genomes, was checked using Jalview in ‘clustalx’ view. The extracted DNA was 
amplified using Phusion polymerase (NEB), the conditions shown in Table 2-4 and the 
designed primers:                              
Forward SlpA - ATGAGTATAGCTCCAGTTGC  
Reverse SlpA – ATCTTCATCACCATCTCCTGC 
Table 2-4. PCR conditions used with Phusion polymerase 
Temperature Time Stage Cycle number 
98 oC 30 s Initial denaturation 1 
98 oC 10 s Denaturation 30 
x oC = Tm (lowest) – 5 oC 20 s  Anneal 30 
72 oC 30 s/kb of product Extension 30 
72 oC 5 min Final Extension 1 
4 oC hold   
 
2.5 Agarose Gel Electrophoresis 
The PCR products were separated on a 0.8 % w/v agarose/TAE buffer gel with 0.5 µl/ 10 ml 
agarose Safe View (NBS biologicals), at 90 v for 1 h, with a 1kb DNA ladder (Promega), to 
determine the product’s size.  
                                                     
3 A micro-sample spectrophotometer that can be used to measure DNA, RNA and protein. From Thermo 
Scientific. http://www.nanodrop.com/Default.aspx 
4 Scientific & Educational Software copyright 1994-2007 http://www.scied.com/pr_cmbas.htm 
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2.6 DNA Sequencing 
The PCR product was purified using a Qiagen QIAquick PCR Purification Kit and quantified 
using the Nano-Drop spectrophotometer with ND1000 V3.7.1 software. Samples with values 
over 40 ng/µl were sent for sequencing by Geneius Laboratory5 with the primers:                                                                                                                             
Forward SlpA  - ATGAGTATAGCTCCAGTTGC  
Reverse SlpA – ATCTTCATCACCATCTCCTGC 
2.7 Low pH glycine, surface protein extraction 
Cells from O/N, 50 ml liquid cultures were harvested via centrifugation at 2700 x g for 15 
min 4oC and washed in 10 ml 0.1 M PBS. The cell pellet was resuspended in 500 µl, 0.2 M 
glycine pH 2.2 and incubated at RT for 30 min. Finally, the solution was centrifuged at 2700 x 
g for 15 min and the supernatant was removed and neutralised with 2 M Tris, pH 7.  
2.8 Determination of protein concentration  
An indication of protein concentration was gained using a Nano-Drop spectrophotometer 
with ND1000 V3.7.1 software. To determine protein concentrations more accurately, a 
bicinchoninic acid (BCA) assay kit (Thermo scientific) was used, as per the manufacturer’s 
instructions, using BSA as the standard protein. If required, samples were diluted to get the 
absorbance values within the range of the standard curve, an example of a standard curve is 
displayed in the Appendices Figure 9-1.   
2.9 Sodium Dodecyl Sulphate-polyacrylamide gel electrophoresis 
Proteins were separated according to their molecular weights by discontinuous sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Briefly, samples were 
mixed 2:1 with loading buffer (1.8 ml 10 % SDS (w/v), 1.8 ml 50 % glycerol (v/v), 0.5 ml 1 M 
Tris/HCl pH 6.8, 0.1 % bromophenol blue (w/v) and 0.5 ml β-mercaptoethanol), boiled for 10 
min and pulse spun in a centrifuge prior to being loaded onto a polymerised acrylamide gel 
                                                     
5 http://www.geneiuslabs.co.uk/ 
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at 10 % (v/v). Samples were either whole cells or 5 µg protein sample. The gels were used in 
a BioRad gel tank system and a voltage of 80-150 V was applied for 1-2 h, with a lower 
voltage being applied as the samples migrate through the ‘stacking gel’. The recipe for the 
stacking and separating gels are shown in Table 2-4. Gels were then stained, with constant 
agitation, in coomassie staining solution (1 g/L coomassie brilliant blue R250, 50 % methanol 
(v/v), 40 % ddH2O (v/v) and 10 % acetic acid (v/v)) for 1 h and destained in destaining 
solution (30 % methanol (v/v), 60 % ddH2O (v/v) and 10 % acetic acid (v/v)) until background 
was cleared.   
Table 2-5. SDS-PAGE recipe for both the stacking and resolving part of two gels. 
Component Stacking gel Resolving gel (10 %) 
ddH2O 2.45 ml 3.1 ml 
Buffer (I & II)1 1.25 ml(II) 2.5 ml (I) 
Acrylamide solution2 0.75 ml 3.3 ml 
10% SDS 50 μl 100 μl 
2% TEMED 250 μl 500 μl 
1.4% APS 250 μl 500 μl 
1 Buffer I, 1.5 M Tris/HCl, pH 8.8; Buffer II, 0.5 M Tris/HCl, pH 6.8. 
2 Acrylamide  
2.10 Scanning of SDS-PAGE gels 
Gels were placed inside a plastic wallet and scanned using an Epson Perfection V350 
scanner and professional software package.  
2.11 Western blot 
Proteins were separated by SDS-PAGE and transferred on to pre-activated Amersham 
hybond PVDF blotting membrane (GE Healthcare) using a BioRad wet-blot system. The 
membrane was activated upon submersion in methanol for 15 s and equilibration in transfer 
buffer (20 mM Tris, 192 mM glycine, 0.1 % SDS (w/v), 20 % methanol (v/v)). Transfer 
occurred on ice with transfer buffer, at 350 mA for 1 h. The PVDF membrane was incubated 
overnight at 4oC with blocking buffer (0.1 M PBS, 5 % non-fat milk powder (w/v) and 0.05 % 
tween-20 (v/v)). The membrane was then incubated with the primary antibody diluted in 
blocking buffer at RT for 1.5 - 2 h. The membrane was then washed with blocking buffer 4 
times for 5 min each. The membrane was then incubated at RT for 1 h with peroxidase-
conjugated goat anti-mouse IgG (Fc specific) (Sigma), diluted 1:120,000 in blocking buffer. 
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The membrane was washed for 15 min with PBS with 0.05 % tween-20 (v/v) and then 
another 4 x 5 min with PBS only. For visualisation of antibody binding, the membrane was 
treated with the Enhanced Chemiluminescence (ECL) kit from Amersham, GE Healthcare, as 
per manufacturer’s instructions. The bands were viewed using an ImageQuant LAS4000mini 
biomolecular imager (GE Healthcare) and processed with the accompanying software and 
ImageJ.  
2.12 Production of HMW SLP monoclonal antibodies  
The biomarker recognition molecules that were selected for this project were monoclonal 
antibodies (mAbs). AbMART, a monoclonal antibody manufacturing service, was employed 
to produce mAbs against the C. difficile biomarker (Table 4-1). To produce the mAbs, 
AbMART used synthetic linear peptides, 10 amino acids in length, as the antigen. To retain 
some level of confidentiality and as a confirmatory exercise of the bioinformatics work 
performed within this project, the entire C. difficile 630 HMW SLP sequence, taken from 
NCBI YP_001089306.1 (Appendices, section 9.3) was sent to AbMART, rather than the 
specific biomarker sequence. AbMART utilised bioinformatics techniques to analyse the 
HMW SLP sequence and provide possible epitope regions that were predicted to be exposed 
on the surface of the protein. The C. difficile biomarker was returned as a number of 
potential epitope sites, supporting the prediction obtained within this research that the 
biomarker is surface exposed. AbMART was then instructed to focus on the region 
containing the biomarker, in order to produce the mAbs.  
2.13 Hybridoma culture and production of antibody 
All cell culture reagents were purchased from Sigma. Hybridoma cells were grown at 37oC in 
a 5% CO2 incubator, in basic media (RPMI 1640, 10 % foetal calf serum (FCS) (v/v), 100 mg/l 
penicillin-streptomycin and 2 mM glutamine (w/v)), initially with the addition of 10 % 
Condimed (v/v) to aid recovery. When cells were fully confluent they were grown in media 
with reducing FCS content until they were able to grow efficiently in serum free media 
(10 %, 5 %, 2 %, 0.5 %, serum free). Large scale growth of the cells was performed in 
specialist media, EX-CELL® 610-HSF Serum-Free Medium for Hybridoma Cells, Low-protein, 
with L-glutamine, to which 100 mg/l penicillin-streptomycin was added. Cells were left in 
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this media for 8-10 days until many of the cells were dead, the supernatant was then 
harvested at 13000 rpm for 5 mins. 
2.14 Antibody purification via affinity chromatography 
Antibody purification was performed with an ÄKTA start and a HiTrap Protein G HP, 1 ml 
column (GE Healthcare Life Sciences) and all solutions were filtered and degassed. The 
column was flushed ≥ 10 ml of wash buffer (20 mM phosphate pH 7.2) and a minimum of 
260 ml cell culture supernatant was added to the column at a 4:5 ratio with 100 mM Na 
phosphate, pH 7.2. The column was washed with 20 ml wash buffer and eluted with 10 ml, 
100 mM glycine/HCl, pH 2.0 in 1 ml fractions. UV absorbance chromatograms for the 
purification were collected using a chart recorder and OD280 was of the purified antibody 
was determined via NanoDrop spectrophotometer.  
2.15 Isotyping of mAbs 
Rapid Mouse Isotyping Kit - Gold Series (Cambridge Bioscience) was used to type the mAbs 
according to the manufacturer’s instructions. Briefly, 40 µl cell culture supernatant was 
added to lateral flow strip 1 in order to indicate the Ig type. If IgG was indicated then the 
strip 2 was utilised to determine the IgG type and if the light chains were Kappa or Lambda 
again with 40 µl cell culture supernatant. Both strips were read within 15 min of adding the 
supernatant.  
2.16 Whole cell Enzyme-linked immunosorbent assay  
Overnight bacterial cultures were grown to an OD600 0.6 and 8 ml of culture was centrifuged 
at 2700 x g for 10 min and washed three times with 0.1 M PBS. The cells were resuspended 
in 6ml 50mM carbonate/bicarbonate buffer, pH 9.6 and 150 μl was added to the wells of a 
Nunc Maxisorp 96 well, flat-bottomed plate (Affymetrix eBioscience) and left O/N at 4oC. 
Cells were checked for adherence to the ELISA plate using an inverted microscope, however 
quantitative analysis of cell adhesion could not be performed. The cell solution was 
removed and washed 3 x with 0.1 M PBS, 0.05 % tween pH 7.4 (PBS-T), the plate was then 
blocked in blocking buffer (PBS-T with 5 % non-fat milk), for either 2 h at room temperature 
or O/N at 4oC. The blocking buffer was removed and the plate was washed twice with PBS-T. 
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The mAbs were diluted to differing concentrations (10 µg/ml – 0.1 ng/ml) in blocking buffer 
and 100 µl was added to the wells and incubated O/N at 4oC. The plate was washed 4 x PBS-
T before the secondary antibody, peroxidase-conjugated goat anti-mouse IgG (Fc specific) 
(Sigma), was diluted 1:20,000 in blocking buffer and added to the wells. The plate was 
incubated for 2 h at RT before removing and washing the plate 4 x PBS-T. One 
Ophenylenediamine (OPD) tablet was added to 50 ml substrate buffer (0.05 M citric acid, 
0.05 M Na2HPO4, pH 5) and then 50 µl of 30 % hydrogen peroxide (v/v)was added. To each 
of the wells, 150 µl of the OPD/substrate solution was added, developed for 30 min and the 
absorbance read at 450 nm with a plate reading spectrophotometer. Alternatively, the OPD 
reaction was stopped with 100 µl stop solution (2 M H2SO4) and the absorbance read at 490 
nm. 
2.17 Overproduction of recombinant C. difficile 630 LMW-SLP  
E. coli Rosetta containing pET 28a pLMW1-262-1, was kindly donated by Neil Fairweather, 
Imperial College London and was grown aerobically, O/N at 37oC in either LB agar or LB 
broth, both with 50 mg/l kanamycin and 12.5 mg/l chloramphenicol (kan/chl). 
For large scale expression, 20 ml LB broth, 50 mg/l kanamycin and 12.5 mg/l 
chloramphenicol was inoculated with E. coli Rosetta pLMW1-262-1 and grown O/N at 37oC 
with constant agitation at 200 x rpm. This 20 ml culture was used to inoculate 1 l LB broth 
kan/chl and grown at 30oC until OD600 0.6. Protein expression was induced with the addition 
of IPTG to a final concentration of 1 mM and the culture was grown for 5 h at 30oC.  
To determine solubility of protein 1 ml aliquots were removed pre-induction and hourly 
upon induction. The cells were pelleted, the supernatant was removed and the cells were 
resuspended in 1ml 25 mM Tris/HCl, 200 mM NaCl, pH 7.5. DNase (Sigma) and protease 
inhibitor cocktail (Sigma) was added to both the resuspended cells and the supernatant 
before the cells were lysed following the sonication method. Both the lysed cells and 
supernatant were analysed via SDS-PAGE to determine the location of the majority of the 
expressed protein.  
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2.18 Immobilised metal affinity chromatography (IMAC) 
IMAC was used to purify recombinant C. difficile 630, LMW SLP. The recombinant LMW SLP 
protein was labelled with a 6 x His-tag and therefore, purification was performed with a 
gravity column of affinity resin with bound bivalent nickel. The E. coli Rosetta containing pET 
28a pLMW1-262-1 cell supernatant was harvested at 10000 x g for 20 min at 4oC. The nickel 
column was washed with equilibration buffer (25 mM Tris/HCl, 200 mM NaCl, 5 mM 
imidazole, pH 7.5) and the cell supernatant was loaded on to the column at a 1:1 dilution 
with equilibration buffer. The column was then washed with wash buffer (25 mM Tris/HCl, 
200 mM NaCl, 20 mM imidazole pH 7.5) and elution was performed stepwise with additions 
of imidazole (50 – 300 mM imidazole) in elution buffer (25 mM Tris/HCl, 200 mM NaCl, x 
mM imidazole pH 7.5). The protein containing fraction was dialysed into 10 mM HEPES pH 
7.5, 150 mM NaCl. 
2.19 Sonication of bacterial cells 
DNase and protease inhibitor cocktail (both Sigma) were added to the cell solution pre-lysis 
and sonication was performed on ice. Cells were disrupted with a digital sonifier (Branson) 
using 10 % increments in sonication power (10 % - 40 %) for 30 s on and 1 min off cycles.  
2.20 Fluorochrome labelling of bacteria 
C. difficile strains and the three closely related species were labelled with the following 
method. Bacteria were grown to exponential phase OD600 0.5, 3 ml was washed with 0.1 M 
PBS and fixed in 4 % paraformaldehyde for 20 min at RT. The cells were washed 3 x PBS and 
to quench the remaining PFA, the pellet was resuspended in 1ml of 20 mM NH4Cl2 for 15 
min. The cells were pelleted and again washed in 3 x PBS. The pellet was resuspended in 0.5 
ml PBS, 2 % BSA and 5 µg/ml mAb at RT for 1 h. Cells were washed 3 x PBS and resuspended 
in 0.5 ml PBS, 2 % BSA and 1 drop Alexa Fluor 594, goat anti-mouse IgG (life technologies) 
and incubated for 30 min at RT in the dark. Cells were washed 3 x PBS and resuspended in 
100 µl PBS and for IF microscopy or 500 µl for flow cytometry. C. difficile controls were 
produced following the same protocol however either the primary mAb or secondary 
antibody incubation step was removed.  
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2.21 Immunofluorescent microscopy 
Glass slides were prepared with 1 % (w/v) agarose in sterile water and 500 µl molten 
agarose was pipetted onto a Hendley-Essex multispot microscope slide with a plain glass 
microscope slide (VWR) placed on top to spread out the agarose, which was allowed to 
solidify for 2 min. The top slide was slid off to reveal a smooth layer of agarose and 1 µl of 
fixed immunofluorescent cells added to each spot and covered with a cover slip. Microscopy 
was performed using a Nikon M200 inverted microscope and Nikon 100x 1.30 oil objective 
coupled to a Photometrics CoolSNAP HQ CCD camera. The system was controlled and 
images acquired with MetaMorph v7.7.80 software, aided using the Nikon Ultimate Focus 
plugin. Phase contrast images were obtained using an exposure time of 100 ms, and 
1000 ms for fluorescence images with ET-mCherry filter (Chroma 49008 ET560/40x). 
2.22 Flow Cytometry 
Fluorochrome labelled cells were produced as above and analysed using a Fortessa X20 flow 
cytometer with a Yellow/Green laser 561 nm, band pass filter 610/20. A laser beam with an 
optimal wavelength of 590 nm is required for excitation of Alexa Fluor 594, which upon 
excitation, emits maximum fluorescence at 617 nm. The operational software package that 
was used with the Fortessa X20 flow cytometer was BD FACSDiva. For each sample 100,000 
to 1,000,000 events were recorded, and a dot plot display of forward scatter (FSC) versus 
side scatter (SSC) was used to gate the negative sample of just fixed cells with no 
fluorescence.  
FlowJo software version 7.6 was used to analyse the flow cytometry data. Briefly, the data 
was viewed using a histogram plot with the 561_610/20 fluorescence on the x-axis. The 
event count was normalised when overlaying results to display the % of max on the y-axis. 
To achieve the % of max, the fluorescence value which has the largest cell count, for each 
sample, is changed to 100 % and therefore, samples containing different numbers of cells, 
when normalised, all have a peak at 100 % of max (Treister and Roederer, 2015). This 
normalisation allows the fluorescence intensity and distribution of cell percentage across 
this intensity, for each sample, to be easily compared. 
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The median and percentage robust coefficient of variance (% rCV) were calculated using the 
FlowJo analysis software. 
The median is the relative intensity value below which 50 % of the events are found; i.e., it is 
the 50th percentile. In general, the median is a more robust estimator of the central 
tendency of a population than the mean. 
The %rCV = 100 * 1/2( Intensity[at 84.13 percentile] – Intensity [at 15.87 percentile] ) / 
Median. The robust CV is not as skewed by outlying values as the CV.  
The flow cytometry results were subjected to statistical analysis, see section 2.1.28. 
2.23 Immunogold labelling and transmission electron microscopy 
C. difficile and C. sordellii cultures were grown O/N to OD600 0.5 and 1.5ml was removed, 
washed in 0.1 M PBS and fixed in 1 ml 4 % paraformaldehyde (PFA) at RT. The cells were 
washed 3 x PBS and to quench the remaining PFA, and the pellet was resuspended in 1ml of 
20 mM NH4Cl2 for 15 min. The cells were pelleted and again washed 3 x PBS. The pellet from 
each tube was resuspended in 200 µl H2O and immediately 5 µl of cell suspension was 
added to on 200 mesh, carbon-coated, plasma etched grid for 5 min before excess liquid 
was removed with filter paper, by touching edge for 10 s. Grids were then rinse in 10 µl PBS 
3 x 5 min before blocking with 10 µl normal goat serum 1:10 in PBS, 1 % BSA for 30 min. 
Rinse again with 10 µl PBS 3 x 5 min before incubating with 10 µl C. difficile  mAb, diluted 
1:25 in PBS, 1 % BSA for  1 h, RT. Grids were rinsed in 10 µl PBS 3 x 5 min before adding 10 µl 
anti-mouse IgG, 9-11 nm gold conjugated (Sigma), diluted 1:20 in PBS, 1 % BSA and 
incubating for 1 h at RT. Rinse grids 4 x 5 min with PBS and then 5 x 5 min with H2O, allow 
grids to air dry and negatively stain with 1.5 % phosphotungstic acid. The grids were viewed 
using a Philips CM100 TEM with Compustage and high resolution digital image capture, at 
varying magnifications. 
2.24 Dot Blot 
Dots were marked on to Amersham hybond PVDF blotting membrane (GE Healthcare) in 
pencil, to mark where to add the analyte. The membrane was activated upon submersion in 
methanol for 15 s and equilibration in transfer buffer (20 mM Tris, 192 mM glycine, 0.1 % 
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SDS, 20 % methanol). Serial dilutions of either whole cells or low-pH glycine extracted SLPs 
were added in 6 – 10 µl dots and left to dry for a minimum of 2 h. The serial dilutions were 
prepared in PBS and were prepared as the following undiluted, 1/2, 1/4, 1/100 and 1/1000 
depending on the experiment. The primary antibody that was being tested or purified SLPs 
were bound directly to the membrane and used as positive controls. The membrane was 
blocked in with blocking buffer (0.1 M PBS, 5 % non-fat milk powder and 0.05 % tween-20) 
for 1 h. The membrane was then incubated at RT for 45 min with the C. difficile mAbs, at 2.5 
– 10 µg/ml, diluted in blocking buffer. The membrane was then washed with 3 x PBS-T for 5 
min each. The membrane was then incubated at RT for 30 min with peroxidase-conjugated 
goat anti-mouse IgG (Fc specific) (Sigma), diluted 1:120,000 in blocking buffer. The 
membrane was washed for 15 min with PBS-T and then twice for 5 min with PBS only. For 
visualisation of antibody binding, the membrane was treated with the Enhanced 
Chemiluminescence (ECL) kit from Amersham, GE Healthcare, as per manufacturer’s 
instructions. The positive signals were viewed using an ImageQuant LAS4000mini 
biomolecular imager (GE Healthcare) and processed with the accompanying software and 
ImageJ.  
2.25 Size exclusion chromatography to purify the SLP-complex  
The SLPs from C. difficile 630 were extracted using the low-pH glycine technique (Calabi et 
al., 2001) The LMW/HMW SLP complex was purified from the SLPs using a Superdex200 
HiLoad 16/600 size exclusion column (GE Healthcare) and an Äkta Prime+ system (GE 
Healthcare). All solutions were filtered (0.45 µm) and degassed. The column was washed 
with 1.5 x volume H2O prior to equilibration with 1.5 x volume 10 mM HEPES pH 7.5, 150 
mM NaCl. The flow rate used was 1 ml/min with fractions of 1 ml or 2 ml collected and 
analysed by SDS-PAGE for protein content and purity and then BCA assay for concentration. 
2.26 Microscale thermophoresis (MST) 
MST was used to analyse the interactions of the mAbs and the purified C. difficile  630 
LMW/HMW SLP complex. The protocol was carried out as per manufacturer’s instructions 
and as described in (Jerabek-Willemsen et al., 2011) using a Monolith NT.115TM series MST 
machine. 
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The purified SLP complex was fluorescently tagged, as per manufacturer’s (Nanotemper) 
instructions, using the amine reactive dye (NT-647 N-hydroxysuccinimide (NHS)). Before 
beginning the experiment, the concentration of fluorescent protein, LED power and capillary 
coating (standard, hydrophobic, hydrophilic, and premium) was optimised to provide the 
required 200-1500 fluorescent units. The LED power used was 90 % and the capillary coating 
was standard. The unlabelled mAb was serially diluted 1:1, 16 times, in 0.1 M PBS with 0.05 
% Tween, to a total of 10 µl, before 10 µl of fluorescent dye was added, taking into account 
the dilution effect of combining the labelled and unlabelled proteins. An initial ‘Cap scan’ 
was completed to measure the fluorescence of each sample and determine any anomalous 
samples. Experiments were performed using a Monolith NT.115TM series, MST machine and 
the resulting temperature jump and subsequent thermophoresis data was used to trace 
unlabelled ligand concentration against normalised fluorescence trace (FNorm). The 
dissociation constant (Kd) was estimated using the Nanotemper Analysis software. 
2.27 Lateral flow strip production 
Lateral flow strip, pore size approx. 15um (Sartorius) was added to a support strip of card. A 
control line, 1 mg/ml rabbit anti-mouse IgG (Sigma), diluted in 50mM 
carbonate/bicarbonate buffer, pH 9.6, was drawn on to the membrane using a 20 µl pipette 
tip. The HMW/LMW SLP complex was also made to 1 mg/ml in carbonate buffer and the 
‘test’ line was drawn below the control. The membrane was left to dry for a minimum of 
2 h. The strip was then blocked for 15 min at RT in 1 % non-fat milk powder (w/v) and 1 % 
empigen (v/v) (Sigma) with gentle agitation. A strip of absorbent pad was added to the top 
of the strip, at the end where the control line is and a section was left at the bottom with no 
membrane as an area to load the sample. 
2.28 Gold conjugation of IgG 
The antibody was diluted to 15 µg/ml in 5mM TES buffer, 1 % SDS (w/v), 5 mM EDTA and 
10 mM Tris-HCl, pH 7.4. A 1 ml aliquot of 20nm (BBI solutions) was centrifuged for 20 min at 
13,000 rpm. The supernatant was removed and the gold pellet was resuspended in 1 ml of 
the pre-prepared antibody solution and incubated at RT for 2 h before adding 100 µl 200 
mg/ml BSA in dH20, vortexed and incubated for a 1.5 h. The sample was then centrifuged 
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for 20 min at 13,000 rpm. The supernatant was removed and the pellet resuspended in X ml 
PBS, pH 7.4 with 0.05 % Tween (v/v) and 2 % BSA (w/v) until and OD280 of around 5 was 
achieved.  
2.29 Statistical analysis 
Statistical analysis of results was performed using the, IBM SPSS version 21. Several tests 
were employed depending on the data. Means were compared using a One-way ANOVA 
with Bonferroni and Tukey post hoc tests. The flow cytometry data was analysed using a 
Mann-Whitney test and a Wilcoxon Signed Ranks test. A statistical significance value of 
P= < 0.05 was used throughout the analysis.  
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Chapter 3 Bioinformatic approaches to bacterial biomarker 
identification and selection 
3.1 Introduction 
In the context of this project a biomarker was defined as a putative epitope that was unique 
to a group of bacterial strains, known as the group of interest (GOI), and had the potential 
to act as a diagnostic target. A novel bioinformatics approach was utilised that identifies 
unique biomarkers using existing genome sequence data. The aim of this bioinformatics 
approach was to identify proteins, or protein fragments that could be used as epitopes for 
the development of diagnostic reagents such as antibodies or aptamers however, it could 
also be used to differentiate strains within species or identify particular traits of interest. 
The approach builds on previous work from the AptamemsID project in which cloud 
computing workflows were developed for the identification of peptide signatures as 
putative biomarkers (Flanagan et al., 2014). Identification of these peptide signatures 
required exploitation of all fully annotated, bacterial genomes contained within RefSeq 
(Pruitt et al., 2002 ).  
There are more than 1400 species of microorganisms that cause disease within humans 
(Taylor et al., 2001; Ecker et al., 2008) and 2764 organisms in NCBI RefSeq with fully 
sequenced genomes, each on average encoding approximately 4000 proteins (Brocchieri 
and Karlin, 2005). To determine which protein or fragment is unique to the GOI, each of 
these proteins must be compared to all of the other proteins from all other genomes. This 
all-against-all comparison is an extremely computationally demanding task and to achieve 
the results in a reasonable time frame requires a parallel computing approach or the use of 
cloud computing. Although the bioinformatics approach could be used to determine 
biomarkers for any organism with a fully annotated genome within RefSeq, the focus of this 
project was to perform the analysis using C. difficile as a case study. Only biomarkers that 
were predicted to be surface associated were selected in order to aid the rapidity of any 
related PoN detection sensor. The surface association of the target would provide 
accessibility to the sensor and would negate the need for time-consuming pre-treatment of 
cells. 
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3.1.1 The IDRIS system 
The bioinformatics workflow used within this project utilised a system, from here on termed 
the IDRIS system, which was developed by Keith Flanagan6 and colleagues as part of the 
AptaMemsID and i-sense projects. This system performed a comparative analysis of the 
predicted proteomes of all complete genome sequences within the NCBI RefSeq database. 
Initially the IDRIS system utilised RefSeq release 47 (2011/05) and then automatically 
updated the system with each new fully annotated genome added to RefSeq. Two cloud 
computing workflows, ApID1 and ApID2 (Flanagan et al., 2014), are utilised within the IDRIS 
system and were created using the computing platform Microbase7. A diagram of the entire 
IDRIS system is provided in Figure 3-2. The initial workflow, ApID1 splits the translated 
amino acid sequences from these RefSeq genomes in to 15 amino acid strings, termed 
tokens. The ‘tokenisation’ of the amino acid sequences is performed by a sliding window 
that moves across the annotated genomes, one amino acid at a time, depositing each of 
these tokens into the TokenDB (Figure 3-1).  
 
Figure 3-1. ‘Tokenisation’ of the amino acid sequences from the NCBI RefSeq database . A 15 amino acid sliding window 
moves step wise, one amino acid at a time, across the translated sequences, forming tokens that are then deposited into 
the TokenDB. 
Additionally, ApID1 uses the annotated protein sequences and the subcellular localisation 
tools, SignalP, LipoP, PSORTb and TMHMM (which are described further in section 4.1.2) to 
                                                     
6 ICOS, School of Computing Science, Newcastle University 
7 http://www.microbasecloud.com/ 
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predict the subcellular localisation of each protein. The results from these tools are 
deposited into the subcellular localisation database (Figure 3-2). 
 
Figure 3-2. The IDRIS system . All complete bacterial genomes within the NCBI RefSeq database are used as the input for 
the IDRIS system. The ApID1 data processing workflow takes the amino acid sequences and splits them into 15 amino 
acid tokens, depositing them in to the TokenDB. ApID1 also predicts the subcellular localisation of the translated 
proteins, using the subcellular localisation tools, SignalP, LipoP, PSORTb and TMHMM. The results from these tools are 
placed into the subcellular localisation database. A GOI is created within the ApID2 data mining workflow, and the 
workflow searches the TokenDB for tokens that are common to all bacterial strains within this GOI. The common tokens 
are then searched for similarity against the remaining tokens within the TokenDB. Only tokens that are unique to the 
GOI but are found within all strains of the GOI are provided by ApID2 as results. When the tokens that are unique to the 
GOI are identified, ApID2 then mines the subcellular localisation database for the protein data that is associated to the 
relevant tokens. 
Within the second workflow, termed ApID2, a bacterial GOI is created and the TokenDB is 
mined for tokens that are common to all of the strains within this GOI. ApID2 then searches 
the TokenDB for these common tokens, which are also unique to the GOI. That is, the 
system checks that the token is not located within the predicted proteins from any other 
bacteria, based on the genome sequence, except those that are within the GOI. The 
TokenDB uses an exact sequence matching approach to determine whether any two tokens 
are the same or different. Consequently, a token annotated by the system as unique, may 
still exist in other organisms with amino but with one or more amino acid changes. In the 
worst case, a token listed as unique to a particular GOI may only differ by a single amino 
acid to another token in an organism outside of that GOI. As a result, the manual analysis, 
within the bioinformatics approach, was necessary to determine the tokens that could be 
used as a C. difficile biomarker. 
An overview of how ApID2 performs this search has been provided in Figure 3-3, with 
C. difficile as the GOI. When the tokens that are unique to the GOI are identified, ApID2 then 
mines the subcellular localisation databases for the data for the token associated proteins 
(Figure 3-2).  
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Figure 3-3. An example of ApID2 searching the TokenDB for a specified group of interest . The set of tokens common to 
all organisms defined in the GOI (in this case C. difficile) is found. The token database is then searched for each of these 
‘common’ tokens to determine whether they occur in any other organism. If a given token is found in an organism 
outside those defined in the GOI, then it is filtered from the result list since it is not unique to the GOI. The tokens that 
are present in all members of the GOI, and do not have an exact match outside the GOI are classified as ‘GOI-unique’ 
and returned to the user for further analysis. 
The 2015 version of the IDRIS system integrates a Web-based browser – termed the IDRIS 
browser. The browser provides a simple graphical user interface, which can be used to 
query the IDRIS system to find peptide tokens, or complete proteins, that are unique to a 
given group of bacterial genomes of interest and to view the cellular location prediction for 
that protein.  
In this study, the original 2012 IDRIS system was used by Keith Flanagan to predict unique 
tokens whose parent proteins could be surface associated. The updated 2015 IDRIS system, 
including Web-browser, was then used within the results of this project to update the 
results and ensure that any unique biomarkers were still valid. 
The 2012 IDRIS system contained 888,314,351 distinct tokens from around 1400 organisms, 
three of which were C. difficile strains. Whereas, the updated 2015 system held 
1,350,122,042 distinct tokens, from 2764 organisms, nine of which were C. difficile strains. 
This huge amount of additional data in the 2015 IDRIS system, highlights the need for the 
validation of the initially identified tokens. The results of the original C. difficile search, 
performed by Keith Flanagan, presented 9793 protein IDs that contained at least one unique 
token. These proteins were used in the downstream subcellular localisation workflow.  
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3.1.2 Predicting protein localisation within the cell 
Computational tools to predict the protein structure and function of sequences play a major 
part in microbiological research, providing the ability to rapidly identify cell-surface-exposed 
proteins and thus enable the discovery of diagnostic biomarkers (Gardy and Brinkman, 
2006). Owing to the importance of this analysis, many protein subcellular localisation tools 
have been developed over the past 25 years (Restrepo-Montoya et al., 2009). 
The subcellular localisation prediction within this project used a number of tools (SignalP, 
LipoP, PSORTb and TMHMM), which were automatically performed with ApID2 and 
manually checked. There were 9793 proteins that were predicted using the IDRIS system to 
contain tokens unique to C. difficile and the subcellular localisation results of each protein 
were provided in a spreadsheet. The results were filtered via the following options, SignalP 
D- score ≥ 0.45, LipoP SPI, PSORTb final localisation - cell wall and TMHMM ≥ 1 
transmembrane region count. Once the proteins had been analysed by the localisation tools 
and were filtered via the above scores, the 9793 proteins containing possible tokens were 
reduced to 28 that were positive for all four localisation tools (Appendices Table 9-1). 
Therefore, these 28 proteins were classed as exposed on the surface of C. difficile. These 28 
proteins were manually checked using the web interfaces for each tool and more 
information of each tool is given below. 
3.1.2.1 SignalP  
A signal peptide is an N-terminal amino acid sequence that controls entry into the secretory 
pathway and determines protein localisation either within organelles integrated into the cell 
membrane, or secreted (Nielsen et al., 1997). Signal peptides are usually 15-40 amino acids 
in length and are cleaved during translocation across the membrane (Nielsen, 1998). SignalP 
(Petersen, 2011) is a tool that is used to predict the presence of a signal peptide region 
within proteins. The proteins identified as containing unique tokens were analysed using 
SignalP version 4.1, with the Gram-positive organism group selected. The C- score is the raw 
cleavage score and produces a ‘high’ value to mark the first amino acid after the signal 
peptide has been cleaved - the first amino acid of the mature protein. The S- score is highest 
at amino acid positions that SignalP predicts are part of the signal peptide and low at the 
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amino acid positions forecast to be within the mature protein. The Y- score is an average of 
the C- score and the slope of the S- score, providing a better cleavage site prediction than 
the C- score alone. The D- score is a weighted average of the mean S- and maximum Y- 
scores and was used to discriminate between signal peptides and non-signal peptides. The 
presence of a signal peptide was determined by a D- score ≥ 0.45, and it was the D- score 
alone that was used as the deciding factor for continuing investigation with proteins or 
disregarding them. 
3.1.2.2 LipoP  
LipoP discriminates between lipoprotein signal peptides, other signal peptides and N-
terminal membrane helices by analysing the protein sequence for particular sites. LipoP 
(Juncker et al., 2003) was designed for use with protein sequences from Gram-negative 
bacteria. However, it has also been shown to perform well with sequences from Gram-
positive bacteria, identifying 92.9% of lipoproteins in a Gram-positive test set (Rahman, 
2008). The cleavage site for signal peptidase type I SpI indicates a signal peptide is present, 
whereas signal peptidase type II SpII indicates a lipoprotein. Bacterial lipoproteins are a set 
of membrane proteins that have many different functions (Kovacs-Simon et al., 2011) but 
are anchored to the cell membrane (Juncker et al., 2003). Therefore, LipoP (version 1.0) was 
used to determine the proteins that had a cleavage site for SpI. 
3.1.2.3 PSORTb 
PSORTb version 3.0.2 (Yu et al., 2010), incorporates several algorithms to predict the 
transmembrane helices and the cellular position of proteins. For Gram-positive bacteria 
these localisation predictions can be cytoplasmic, cytoplasmic membrane, cell wall or 
extracellular. A final prediction of cell wall localisation was selected for this project. 
3.1.2.4 TMHMM 
TMHMM (Transmembrane hidden Markov model) is a membrane protein topology 
prediction method based on a hidden Markov model (Krogh et al., 2001). TMHMM predicts 
the number of transmembrane helices within a protein, providing evidence of its location. 
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3.1.2.5 Phobius 
Although not part of the automated IDRIS system, Phobius was executed manually as a 
verification step of the localisation tools. Phobius is a combined transmembrane topology 
and signal peptide predictor (Kall et al., 2004) and was used to verify the presence of a 
signal peptide and the predicted non-cytoplasmic localisation of the protein.  
3.1.3 Surface Layer type clades 
A project led by Dr Kate Dingle, Nuffield Department of Clinical Medicine, used large-scale, 
whole genome sequencing to determine the diversity and evolution of the SlpA gene within 
57 C. difficile strains. Using the SlpA sequences, the researchers were able to group strains 
within the C. difficile species into 13 surface layer type (SLT) clades (Dingle et al., 2013). 
Currently, all sequenced C. difficile strains fall in to these 13 clades which therefore, 
represent the known SlpA diversity within the C. difficile species. 
3.1.4 The Pathosystems Resource Integration Centre 
The Pathosystems Resource Integration Centre (PATRIC) provides bioinformatics data on 
bacterial pathogens (Wattam et al., 2014), including phylogenetic information about 
C. difficile and closely related organisms. The phylogenetic trees displayed on the PATRIC 
website8 are constructed with an automated pipeline that utilises the amino acid sequences 
from each genome. Genomes can be submitted to PATRIC via NCBI GenBank, RefSeq, or 
collaborator request. The PATRIC automated pipeline identifies homologous proteins in a 
two round process.  In the first round, the annotated proteins of a single genome from each 
distinct species is selected and are searched against each other using the alignment tool 
BLAT9 and the top hits are clustered with MCL10, defining the initial seed sets for the 
homology groups.  In the second round, the seed sets are aligned using MUSCLE11 and 
                                                     
8 https://www.patricbrc.org/portal/portal/patric/Home  
9 http://genome.ucsc.edu/FAQ/FAQblat.html  
10 http://www.micans.org/mcl/  
11 http://www.ebi.ac.uk/Tools/msa/muscle/  
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hidden Markov models (HMMs) are built with hmmbuild12.  All genomes are searched with 
hmmsearch13, the results of which are used to define the homology groups that are aligned 
with MUSCLE and poorly aligned groups are removed with Gblocks14. The main tree is 
estimated using FastTree15, with random samples of 50% of the homology groups from the 
MUSCLE alignment. 100 of these 50% homology group trees are made using FastTree and 
the support values on the main tree indicate the number of times a particular branch was 
observed in the support trees. PATRIC was used within this project to determine the species 
that are most similar to C. difficile. 
 
3.2 Bioinformatics methods 
3.2.1 The bioinformatics approach used to predict unique, surface 
associated C. difficile biomarkers 
The manual section of the bioinformatics approach (Figure 3-4) was performed within this 
project and details are to follow. The initial two steps of the approach were automated 
within the IDRIS system, which was developed and performed by Dr Keith Flanagan16. More 
detail about the IDRIS system can be found in Chapter 5. The bioinformatics approach was 
followed in order to predict biomarkers that were unique to C. difficile, exposed on the 
surface of the bacteria and expressed in all stages of organism growth. 
                                                     
12 http://www.csb.yale.edu/userguides/seq/hmmer/docs/node19.html  
13 http://www.csb.yale.edu/userguides/seq/hmmer/docs/node26.html  
14 http://molevol.cmima.csic.es/castresana/Gblocks.html  
15 http://www.microbesonline.org/fasttree/  
16 ICOS, School of Computing Science, Newcastle University 
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Figure 3-4. The bioinformatics approach consists of an automated part and a manual part. The automated section is 
performed by ApID2 within the IDRIS system and uses TokenDB to identify bacterial tokens that are unique to a 
specified organism group of interest. The protein sequences containing the identified tokens are then analysed by a 
number of subcellular localisation prediction tools again using ApID2. For the work presented here, only the proteins 
indicated to be surface-associated are of interest. A manual workflow containing bioinformatics analysis steps are then 
performed using a variety of tools to determine a biomarker within the protein that is unique to and yet common to all 
strains within the chosen group. The biomarker position within the protein is then identified before searching for 
evidence of the expression of the protein.   
 
3.2.2 Manual subcellular localisation of proteins 
Although the subcellular protein localisation tools were performed within the automated 
IDRIS system manual confirmation of some of the IDRIS system results was also performed. 
In addition to the tools used within the approach, Phobius, a combined transmembrane 
topology and signal peptide predictor was also used to analyse the protein sequences. The 
tools were applied via their relevant web pages to the individual protein sequences in FASTA 
format. 
The options selected for each tool are provided within Table 3-1. When the option was 
given, Gram-positive was selected and also output with graphics was chosen. The results 
were filtered via the following options, SignalP D- score ≥ 0.45, LipoP SPI, PSORTb final 
localisation - cell wall and TMHMM ≥ 1 transmembrane region count. 
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Table 3-1. The five tools used to predict the subcellular localisation of proteins , performed manually. The table contains 
the options chosen when available for the input sequence and the output. 
Tool Gram Output format Organism 
SignalP v 4.1 Gram-positive Standard  
LipoP 1.0 server  Standard  
PSORTb v. 3.0.2 Gram-positive Normal Bacteria 
TMHMM v2.0   Extensive with 
graphics 
 
Phobius  Long with graphics  
 
3.2.3 Identifying unique protein regions using BLAST, MUSCLE and Jalview 
The identification of the unique biomarkers, within the ‘unique token’ containing proteins 
provided by the IDRIS system, was performed manually. The IDRIS system uses an exact 
sequence matching approach to determine whether any two tokens are the same or 
different. Consequently, a token annotated by the system as unique, may not be wholly 
unique. In the worst case, a token listed as unique to a particular GOI may only differ by a 
single amino acid to another token in an organism outside of that GOI. As a result, manual 
analysis was necessary to determine the biomarkers that were at least 15 amino acids in 
length and had a minimum of four amino acids difference from the closest related 
sequence. 
To locate the biomarkers that met the minimum four amino acid threshold, the individual 
protein sequences were searched for similarity to other proteins within UniProt – release 
15.0 using BLAST (Uniprot-Consortium., 2012). The sequences of the proteins with the most 
similarity were downloaded in their FASTA format, for SlpA the most similar 22 proteins 
were used. The sequences were then aligned using EBI MUSCLE version 3.5 (Edgar, 2004) 
and the resulting sequence alignment was viewed using Jalview version 2.6.1 (Waterhouse 
et al., 2009). Within Jalview, the amino acids coloured via ‘percentage identity’ with the 
regions with >80 % similarity coloured in dark purple and the regions with no similarity are 
coloured in white. Sequences of 15 amino acids or more, which were identical in all of the 
C. difficile proteins and not present in any other bacterium, were manually identified and 
selected for downstream analysis.  
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Jalview was also used to predict the hydrophobicity of the amino acids within any conserved 
sequences. The colour selection used was ‘hydrophobicity’, which uses colours hydrophobic 
and hydrophilic amino acids, red and blue respectively. Unique regions with hydrophilic 
sections of 5 continuous amino acids or more were retained for further analysis. 
The regions that were predicted to be unique and contain hydrophilic sections, were 
entered into NCBI BLASTP 2.2.26 (Altschul et al., 1990) and searched for similarity against all 
organisms within NCBI’s non-redundant DB. Only sequences retaining the minimum five 
amino acid difference from other sequences were continued as promising biomarkers. 
BLASTP searches were often performed with the C. difficile species excluded from the 
search. This exclusion enabled the closest related sequence that was not located within 
C. difficile to be identified. 
The similarity searches performed with NCBI BLASTP were also used to produce 
phylogenetic trees of the SlpA protein by selecting the top 15 hits and the ‘distance tree of 
results’ on the BLASTP results page. The following phylogenetic tree options were used to 
construct the tree:- ‘Fast Minimum Evolution’ was selected for ‘Tree method’, ‘0.85’ for 
‘Max Seq Difference’, ‘Grishin (protein)’ for ‘Distance’ and finally a ‘slanted cladogram’ was 
chosen for ‘Layout’.  
3.2.4 Identify biomarkers that are conserved across C. difficile  
The sequences for all complete C. difficile genomes (Table 3-2) were downloaded from NCBI 
in FASTA format and searched with BLASTN for similarities, to create comparison files. The 
genome files were entered into the Artemis Comparison Tool (ACT) (Carver et al., 2005) with 
one designated as the reference sequence and one as the subject sequence. The 
comparison files were also loaded into the ACT, which was then used to display the 
comparisons of the C. difficile genomes. ACT provides a six-frame translation of the DNA 
sequence, and displays pairwise comparisons between two or more genome sequences, 
which can be used to identify regions of similarity. However, since there were nine 
C. difficile strains, the ACT viewing window was not large enough to display the translated 
amino acid sequences. Instead, the biomarker was searched within the amino acid 
sequences and highlighted within the DNA sequences of the comparisons, as this allowed 
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space for the visualisation of conservation. The red bands represent the forward matches 
and blue bands the reverse matches between the genomes, with the intensity of the colour 
being proportional to the percent identity of the match. White areas are displayed where 
there is no BLAST similarity present and therefore indicate variable regions. A searched 
sequence that is matched turns yellow and if the sequence is conserved throughout the 
strains, all will display the same yellow sequence (Carver et al., 2005). 
Table 3-2. The C. difficile strains contained within the NCBI database, which have fully sequenced and annotated 
genomes. 
C. difficile strain NCBI Taxon ID 
630 272563 
2007855 699033 
BI1 699034 
CD196 645462 
R20291 645463 
CF5 699036 
M120 699035 
M68 699037 
ATCC 42355 499175 
 
3.2.5 Identifying the biomarker position within the protein  
The following method was used to identify the biomarkers that were exposed on the 
protein surface. Initially a search of the protein data bank, RSCB PDB17 was performed to 
identify if it contains any structures for the proteins. For this project, the protein structures 
were not solved and therefore predictions of protein structures had to be made by sending 
the protein sequence to I-TASSER protein structure and function predictor (Zhang, 2008). I-
TASSER uses LOMETS (Wu and Zhang, 2007) and SPICKER (Zhang and Skolnick, 2004) to 
construct five full-length atomic models of the sequence.  
These I-TASSER models were then observed using the UCSF Chimera software package that 
was downloaded onto a local machine. Chimera was developed by the Resource for 
Biocomputing, Visualization, and Informatics at the University of California, San Francisco 
(supported by NIGMS P41-GM103311) (Pettersen et al., 2004). The view was selected to 
show the protein surface and the biomarker was coloured red on the resulting images.  
                                                     
17 www.rcsb.org  
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3.2.6 Determining expression of the biomarker containing protein 
A thorough literature search is one of the most effective ways to determine if a protein of 
interest is in fact expressed. The protein literature search was performed using NCBI 
Pubmed18 and Science Direct19, with protein expression at different stages of growth being 
a key feature of the positive proteins. 
Another method to evidence protein expression was using microarray data downloaded from 
the Gene Expression Omnibus (GEO) (Edgar et al., 2002). The interpreted dataset was for 
C. difficile 630, GSE25474 – ‘Comparison of the expression profiles of 630E strain after 4h and 
10 h of growth’ and GSE25475 - ‘Comparison of the expression profiles of 630E strain and a 
sigH mutant after 10 h of growth’ (Saujet et al., 2011). These gene expression profiles were 
made under laboratory conditions, with C. difficile 630 grown anaerobically in brain heart 
infusion broth for different growth periods.  The expression values were downloaded from 
GEO and entered into an Excel spreadsheet. The values were ordered from high to low, with 
a total of 15744 unique probe results for each microarray chip. Therefore, position 1 in the 
spreadsheet is the gene with the highest expression value and position 15744 in the 
spreadsheet is the gene with the lowest expression value. The positions of the genes of 
interest, within the ordered results, were noted and their percentage position within the total 
gene number was calculated. For example, if the gene of interest was in position 221 then 
(221/15744)*100 would provide a percentage of 1.4% showing that the gene is expressed 
within the top 1.4 % of all genes under those particular experimental conditions.   
3.2.7 Identifying protein domains 
The C. difficile SlpA sequence was submitted to InterProScan (Jones et al., 2014) version 5, via 
the Web page, using the default settings. The sequence was analysed by InterProScan by 
comparing it to the protein signatures and predictive models contained within the InterPro 
Consortium (Mitchell et al., 2015).  
                                                     
18 http://www.ncbi.nlm.nih.gov/pubmed 
19 http://www.sciencedirect.com/  
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3.2.8 Identifying species that are closely related to C. difficile   
The SlpA sequence was analysed using BLASTP and a ‘distance tree of results’ was produced 
on the BLASTP results page using the top 15 hits. The following phylogenetic tree options 
were used to construct the tree:- ‘Fast Minimum Evolution’ was selected for ‘Tree method’, 
‘0.85’ for ‘Max Seq Difference’, ‘Grishin (protein)’ for ‘Distance’ and finally a ‘slanted 
cladogram’ was chosen for ‘Layout’. 
3.2.9 Average Nucleotide Identity calculator 
The average nucleotide identity (ANI) calculator20 (Rodriguez-R and Konstantinidis, 2014) 
estimates the average nucleotide identity between two genomes to determine the 
likelihood that the sequences are from the same species or not. If the ANI value is above 
95 % then the sequences are predicted to be from the same species. The identity is 
predicted using both one-way ANI and two-way ANI between two genomic datasets, as 
calculated by Goris and colleagues, 2007. The FASTA sequences of bacterial genomes were 
downloaded from NCBI and uploaded via the Web page to the ANI calculator, two 
sequences at a time.  
3.2.10 Aligning bacterial genomes to view regions of conservation, insertion 
and deletion 
The complete C. difficile genomes of strains 630 and R20291 were used as reference 
genomes for the alignment of contigs present in C. sordellii draft genomes. The sequences 
were aligned with CONTIGuator 2 (Goris et al., 2007) by uploading the C. difficile FASTA 
sequence into the ‘Reference file’ input and the C. sordellii genomes into the ‘Contig file’ 
input. The criteria for the ‘Contigs profiling’ was kept at the default settings.  
  
                                                     
20 http://enve-omics.ce.gatech.edu/ani/  
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3.3 Bioinformatics Results 
The bioinformatics approach (Figure 3.4) was developed within this project and used to 
determine biomarkers that were predicted to be accessible from the surface of whole 
C. difficile cells. The results of each step will be described in detail within this section.   
3.3.1 Predicting protein localisation within the cell 
Once the 9793, token-containing, C. difficile proteins were identified within the TokenDB, 
the next ApID2 automated step was the downstream analysis of the location of these 
proteins within the cell ‘Surface associated?’ step (Figure 3.4). Only proteins that were 
surface-associated were deemed as positive and manually checked using the web interface 
for the localisation tools. Throughout this section, the surface layer protein SlpA (NCBI 
Accession YP_001089306) was used as an example of a positive prediction, as this protein 
was determined to contain the most promising biomarker. In addition to the positive SlpA 
result, an example of a negative result for each tool is also provided.  
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3.3.1.1 SignalP 
For SlpA (Figure 3-5 A), all signal peptide scores predict the cleavage site to be between 
position 24 and 25. Therefore, the signal peptide was 24 amino acids in length and position 
25 was the first amino acid of the mature protein. Figure 3-5 also shows an example of a 
negative SignalP result from the analysis of the protein sodium:amino acid symporter, 
GenBank accession YP_003214646 (Figure 3-5 B). All scores for this protein are low and 
therefore none of the amino acids were predicted to be involved with a signal peptide.  
The SlpA D- score was 0.783, indicating the presence of a signal peptide. The D- score for 
sodium:amino acid symporter was 0.146 therefore, no signal peptide was predicted and the 
protein was disregarded from further analysis.   
 
Figure 3-5. SignalP analysis of C. difficile 630 SlpA YP_001089306 (positive example, A) and Sodium:amino acid 
symporter YP_003214646 (negative example, B). The scores for SlpA determine that a signal peptide exists, which is 
cleaved between amino acids 24 and 25. The C- score (red) is the raw cleavage score and produces a high value to mark 
the first amino acid after the signal peptide has been cleaved, and therefore indicates the first amino acid of the mature 
protein. The S- score (green) is highest at amino acid positions that are predicted to be part of the signal peptide and low 
at the amino acid positions forecast to be within the mature protein. The Y- score  (blue) is an average of the C- score 
and the slope of the S- score, providing a better cleavage site prediction than the C- score alone. In contrast, all scores 
for ‘Sodium:amino acid symporter’ are low, indicating that no signal peptide has been predicted. 
3.3.1.2 LipoP 
Figure 3-6 (A) shows the LipoP prediction of the SpI site for the C. difficile SlpA protein. The 
proteins that were deemed negative either had no putative cleavage sites and were 
predicted to be cytoplasmic proteins, or they were classed as having a lipoprotein signal 
peptidase SPII such as the C. difficile stage II sporulation protein D (NCBI accession  
 
 
  
A B 
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YP_003213187.1) (Figure 3-6 B). All proteins with SpI were progressed to the next 
localisation tool. 
  
Figure 3-6. LipoP predictions of C. difficile 630 SlpA (A) and stage II sporulation protein D, YP_003213187.1 (B). SlpA is 
predicted to have a signal peptide SpI cleavage site between amino acid 24 and 25, indicated by the red line. The stage II 
sporulation protein D, is predicted to have a SpII cleavage site. 
3.3.1.3 PSORTb 
PSORTb predicted that SlpA is non-cytoplasmic and is cell wall associated, predicting the 
surface localisation of the protein (Figure 3-7, top). In contrast, the tool predicted the ABC 
transporter permease, NCBI Accession YP_001088460, to be within the cytoplasmic 
membrane, with 8 membrane helices calculated (Figure 3-7, bottom). Only proteins that 
were predicted to be cell wall associated were used for further analysis. 
 
Figure 3-7. PSORTb analysis of C. difficile 630 SlpA (top blue) and ABC transporter permease (bottom black). SlpA is 
predicted to be localised to the cell wall and the ABC transporter permease to be located within the cytoplasmic 
membrane.  
 
A B 
 55 
 
3.3.1.4 TMHMM 
The TMHMM Server v. 2.0 result for SlpA predicts that there is a single transmembrane 
domain at the N-terminus (Figure 3-8 A), which corresponds to the signal peptide that 
remains within the membrane once it has been cleaved. The TMHMM result for the 50S 
ribosomal protein L15, (YP_003213150) indicated the absence of any transmembrane 
helices (Figure 3-8 B). A minimum of one transmembrane region was deemed to be a 
positive result for the purposes of this project. Proteins with zero transmembrane regions 
were disregarded. 
  
Figure 3-8. TMHMM predictions of C. difficile 630 SlpA (A) and ribosomal protein L15, YP_003213150 (B). SlpA is predicted 
to have one initial transmembrane region, indicated by the red signal at the beginning of the sequence. Most of the 
sequence is predicted to be outside of the membrane, indicated by the pink line. The result for YP_003213150, 50S 
ribosomal protein L15, predicts zero transmembrane regions on the protein. 
 
A B 
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3.3.1.5 Phobius 
Phobius was used as a verification step for the 28 proteins identified as surface associated 
by the IDRIS system. The Phobius results for SlpA (Figure 3-9), verified the results from the 
surface prediction pipeline by confirming a signal peptide, with the remainder of the protein 
being non-cytoplasmic.  
 
Figure 3-9. Phobius results for SlpA . A signal peptide (red line) is predicted at the N-terminal and the remainder of the 
protein is predicted to be non-cytoplasmic (blue line). The x-axis displays the number of amino acids and the y-axis is the 
probability that those amino acids are the predicted localisation. The first few amino acids have a signal peptide with a 
probability of one, which is the highest score, then reduces to zero indicating the end of the signal peptide. The non-
cytoplasmic signal is also predicted at a probability of one for the remainder of the sequence. 
  
3.3.2 Identifying unique biomarkers with a minimum of 15 amino acids 
3.3.2.1 Basic Local Alignment Search Tool 
To determine which of the 28 proteins contained a token that was suitable for sensitive 
detection, the Basic Local Alignment Search Tool (BLAST) was used to identify tokens that 
differed from the closest relative by a minimum of four amino acids. A BLAST search for the 
SlpA protein from C. difficile SlpA was carried against the Uniprot database (28/06/12) 
(Figure 3-10). The results with the greatest similarity to the SlpA protein were all from 
C. difficile, with the green colour indicating a high percentage identity of matched sequences 
to the subject.   
 57 
 
 
Figure 3-10. Uniprot BLAST of C. difficile 630 SlpA . The first column on the left is the protein accession ID, the second is 
the entry name, which includes the accession ID and associated species ID. The Query hit provides a visual means of 
recognising the identity of the subject and query sequence, where green indicates very high identity and red indicates low 
identity. The far right column provides the name of the protein and the organism in which it is located. All of the top hits 
(dark green) are within C. difficile strains. The related protein sequence was downloaded 28/07/12. 
3.3.2.2 Viewing the alignments of proteins 
The SlpA alignment (Figure 3-11) clearly shows a possible biomarker, outlined by the black 
box, which was 16 amino acids in length and conserved across all 22 C. difficile proteins. 
Using the colouring options within Jalview, the amino acids were coloured via their 
hydrophobicity, with blue depicting hydrophilic and red representing hydrophobic, 10 out of 
16 amino acids within the predicted biomarker were coloured blue/purple.     
 
Figure 3-11. The SlpA protein alignment of the top 22 hits from the Uniprot BLAST against C. difficile 630 SlpA. The 
sequences were viewed using Jalview and the amino acids coloured according to hydrophobicity (blue is hydrophilic and 
red is hydrophobic). The conserved biomarker, AKDGSTKEDQLVDALA, is highlighted by the black rectangle. 
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3.3.2.3 Searching for the SlpA biomarker within all fully sequenced C. difficile 
genomes 
The initial 2012 IDRIS system contained only three C. difficile strains 630, R20291 and 
CD196, which increased to nine as the complete genome sequences were added to NCBI 
RefSeq. To provide the evidence of the SlpA biomarker being common to all nine fully 
sequenced C. difficile strains, the genome sequences were compared using the Artemis 
Comparison Tool (ACT) (Carver et al., 2005). The genomes were searched for the SlpA 
biomarker amino acid sequence, and the corresponding DNA sequences were highlighted in 
yellow. All nine C. difficile strains contained the SlpA biomarker (Figure 3-12). The SlpA 
biomarker is seen to be conserved across all the strains, with the sequence surrounding the 
SlpA biomarker displaying some insertions and deletions between strains. 
 
Figure 3-12. Screenshots taken from the Artemis Comparison Tool showing comparisons of nine C. difficile genomes (A), 
and a zoomed view of the region containing the biomarker (B). Nine different sequence tracks are shown (grey with 
coordinate bars), one for each strain present in the comparison. Between these tracks, a series of coloured bands 
represent forward-matched regions (red) and inversions (blue) of each pairwise comparison. The yellow bands indicate 
the currently selected pairwise match. In addition, a smaller yellow highlighted area can be seen protruding into the grey 
sequence tracks and surrounded by the black box indicating the SlpA biomarker (A). It is this biomarker that is in the 
highlighted region included within the zoomed-in view (B). The highlighted sequence within the zoomed view is the DNA 
sequence that codes for the SlpA biomarker. ACT was searched by inputting the amino acid sequence of the biomarker, 
which was subsequently reverse-translated and displayed on the corresponding DNA sequence. 
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3.3.2.4 Determining the uniqueness of the SlpA biomarker 
The SlpA biomarker ‘AKDGSTKEDQLVDALA’ was searched for similarity using NCBI BLASTP, 
which searches the protein database using a protein sequence. The search was performed 
on 28/6/2012 and showed the biomarker located in its entirety (marked in red) within 
C. difficile only, with the top hits all being C. difficile proteins (Figure 3-13). 
 
Figure 3-13. BLASTP search for similarity of the SlpA biomarker AKDGSTKEDQLVDALA to other protein sequences within 
the NCBI database (28/06/12). The biomarker was 100 % conserved within C. difficile strains. 
 
A minimum difference of four amino acids between any possible biomarker and the closest 
related sequence, located in an organism not located within the GOI, was selected (the 
‘uniqueness threshold’).The closest similarity to the SlpA biomarker, which was much 
further down the hits shown within Figure 3-13 and was not located within C. difficile, was 
found in the two-component LuxR family transcriptional regulator from the Gram-negative 
species Novosphingobium nitrogenifigens (N. nitrogenifigens) (Figure 3-14). There were five 
differences between the two amino acid sequences and therefore the SlpA biomarker was 
still classed as unique to C. difficile.  
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Figure 3-14. BLASTP results (28/06/12) of the protein with the closest similarity to the SlpA biomarker that was not from 
a C. difficile strain. The protein that was most similar was the two-component LuxR family transcriptional regulator from 
Novosphingobium nitrogenifigens. 
The entire protein sequence of the two-component LuxR family transcriptional regulator 
was analysed using SignalP and was shown to be lacking a signal peptide, and therefore was 
not predicted to be transported out of the cytoplasm (Figure 3-15). 
 
Figure 3-15. SignalP results of the two-component LuxR family transcriptional regulator protein sequence . The results 
show that there is no signal peptide predicted. 
 
3.3.3 Structural prediction of SlpA and location of the biomarker 
3.3.3.1 The SlpA domains 
InterProScan (Jones et al., 2014) was utilised to analyse the SlpA protein sequence. The 
InterPro Consortium employs several databases, including PROSITE (Sigrist et al., 2002), 
HAMAP (Pedruzzi et al., 2015) and SUPERFAMILY (Gough et al., 2001), to gain the required 
protein signatures and predictive models. Figure 3-16 integrates the subcellular localisation 
results of an InterProScan version 5 analysis of C. difficile 630 SlpA, and the literature which 
states the LMW and HMW SLP cleavage position (Calabi et al., 2001). The domains are 
mapped on to the SlpA sequence, with the biomarker also highlighted at its amino acid 
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position, which is predicted to be within a putative cell wall binding domain.  
 
Figure 3-16. Combining the results from the surface localisation tools and an InterProScan of the sequence to show the 
domains and biomarker location on C. difficile 630 SlpA . The cleavage site of SlpA into the mature LMW AND HMW SLPs 
was taken from the literature.  
3.3.3.2 Predicting the structure of the HMW SLP and the surface location of the 
biomarker 
The hydrophobicity view within Jalview (Figure 3-18) was used to predict the largely 
hydrophilic biomarker location on the surface of the protein. However, further evidence of 
the location was required to show that the biomarker is accessible to potential PoN sensors. 
A search of the protein data bank, RSCB PDB21 for SlpA structures revealed that the protein 
structure for only LMW SLP had been solved, PDB ID: 3CVZ (Fagan et al., 2009). Neither the 
HMW SLP, which contains the biomarker, nor the whole complex was  structurally solved 
and subsequently, tools to predict protein structure were used. The HMW portion of SlpA 
was sent to the I-TASSER protein structure and function predictor (Zhang, 2008), which 
constructs five full-length atomic models of the sequence. Each model has a confidence 
score (C-score) that estimates the quality of the prediction and usually ranges from -5 to 2. 
These models were then observed using the viewing platform UCSF Chimera, developed by 
the Resource for Biocomputing, Visualization, and Informatics at the University of California, 
San Francisco (supported by NIGMS P41-GM103311) (Pettersen et al., 2004). The view was 
                                                     
21 www.rcsb.org 
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selected to show the surface of the protein and the biomarker was coloured red on the 
resulting images. All five models predicted the biomarker to be surface exposed (Figure 
3-17) and therefore if would likely be accessible to detection molecules. Model A had the 
greatest C-score with -2.68 and is therefore indicated to be the most likely structure of the 
HMW SLP. The C-scores of the remaining four models were as follows, -2.78 (B), -3.01 (C), -
3.10 (D) and -4.55 (E). 
 
Figure 3-17. Chimera images of the five HMW SLP structures predicted using I-TASSER . The PDB files were loaded, the 
surface of the protein was displayed in white, and the biomarker sequence highlighted in red. All five models displayed 
the biomarker as being surface-accessible. Model A had the greatest confidence score of -2.68, closely followed by B 
with -2.78. The confidence scores for the remaining three models were -3.01 (C), -3.10 (D) and -4.55 (E). 
3.3.3.3 Expression of SlpA  
As discussed in Chapter 1 section 1.16, SlpA is post-translationally cleaved into the LMW and 
HMW SLPs which non-covalently bind to form the S-Layer, a paracrystalline layer that 
encapsulates the C. difficile cell. SlpA is described in the literature as one of the most highly 
expressed C. difficile proteins, within all stages of growth (Savariau-Lacomme, 2003; Fagan 
and Fairweather, 2011).  
Microarray data for C. difficile was downloaded from the Gene Expression Omnibus (GEO) 
(Barrett et al., 2011) and used to determine expression of the slpA gene. The dataset used 
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was GSE25474 – ‘Comparison of the expression profiles of 630E strain after 4 h and 10 h of 
growth’ (Saujet et al., 2011) and GSE25475 - ‘Comparison of the expression profiles of 630E 
strain and a SigH mutant after 10 h of growth’, with all strains grown anaerobically in brain 
heart infusion (BHI) medium (Saujet et al., 2011). SigH is an alternative sigma factor, which is 
a key element in the initiation of C. difficile sporulation. There were six microarrays in total, 
three different conditions with two dyes for each: cyanine dye Cy3 and Cy5. The dyes 
fluorescently label the C. difficile cDNA, which hybridizes to the DNA on the microarray and 
provides a quantifiable fluorescent signal.  It is the fluorescence intensity that is measured 
to determine the expression of the particular gene. The results for the three conditions 
were very similar for both dyes. The slpA gene, named CD2793 in the data, was expressed in 
the top 6.4 % of genes for the 4 h growth, 1.2 % for 10 h growth and 2.4 % for 10 h growth 
of the SigH mutant. These results show that under differing conditions of growth stage and 
mutation, slpA remains one of the most highly expressed genes within C. difficile.  
3.3.4 Surface Layer type clades 
To enable additional analysis of the possible SlpA biomarker, Kate Dingle kindly sent 
sequences of the surface-layer type strains (SLTS) from each of the 13 groups. The SlpA gene 
from each SLTS and C. difficile 630 was translated into an amino acid sequence using 
Artemis genome browser, aligned with MUSCLE, with the resulting alignment viewed with 
Jalview. The amino acids were coloured via their percentage identity with dark purple 
defining >80 % identity across the sequences. The biomarker is denoted by the black box 
and is shown to be 100 % conserved across all 14 C. difficile strains (Figure 3-18).  
 
Figure 3-18. Jalview image of the alignments of SlpA sequences from the 13 SLTS and C. difficile 630 . Amino acids are 
coloured according to percentage identity, with the dark purple representing >80 % identity, purple >60 % and light 
purple >40 % sequence identity. The biomarker is denoted by the black box and displays 100 % sequence identity across 
all 14 C. difficile strains, SLTS Ox1121, Ox1342, Ox1192c, Ox1523, Ox1533, Ox1424, Ox160, Ox1437a, Ox1896, Ox575, 
Ox1396, Ox858, Ox1145 and the reference strain 630. 
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The sequences within Jalview were also explored to identify which of the 13 SLT clades 
C. difficile 630 belongs too.  With only 11 out of the 719 amino acids being different, 
C. difficile 630 was most similar to Ox1145, SLT 7, displaying 98.5% identity (Figure 3-19). 
 
Figure 3-19. Jalview image of the 11 differences out of 719 amino acids in the SlpA sequences between Ox1145 (SLT 
clade 7) and C. difficile 630 . In the case of these two sequences the dark purple represents amino acids with 100 % 
identity and the white represents amino acids with no similarity. 
 
3.3.5 Identifying species that are closely related to C. difficile  
To be able to perform appropriate laboratory tests for the specificity of detection molecules 
produced against the SlpA biomarker, it was important to identify species that were closely 
related to C. difficile. These species could then be tested to ensure they do not provide false 
positives, the lack of which is vital for a PoN sensor. The closely related species are more 
likely to have similar protein sequences and perhaps comparable epitopes to which 
detection molecules may be more likely to non-specifically bind to.     
The BLASTP results identified Clostridium hiranonis and Peptostreptococcus anaerobius as 
having protein sequences that were the most related to SlpA. Therefore, a ‘distance tree of 
results’ was produced on the BLASTP results page, using the top 15 hits. (Figure 3-20). 
Although, the C. hiranonis and P. anaerobius proteins were annotated as hypothetical, the 
protein search still highlights these strains as important to investigate further in future 
work.       
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Figure 3-20. Slanted cladogram of BLASTP results from a C. difficile 630 SlpA similarity search, excluding C. difficile . The 
search was performed on 27/2/13 and the results were viewed with the ‘Fast Minimum Evolution’ for tree method, 
‘0.85’ for max seq difference and ‘Grishin (protein)’ for distance.  
 
In addition to investigating the similarity of SlpA to other proteins, the similarity of full 
genome sequences to C. difficile was also explored using PATRIC. A screenshot of the 
phylogeny tree for Clostridium was taken on 28/2/2013, and displays the organisms that 
were closely related to C. difficile (Figure 3-21). The organisms with the ticks in the adjacent 
boxes were selected as the closely related species that required investigation within the 
laboratory work. The three were selected because C. sordellii was the species most closely 
related to C. difficile in PATRIC and both C. hiranonis and P. anaerobius were some of the 
top hits in the BLASTP search of the SlpA protein (Figure 3-20). Although C. bartlettii DSM 
16795 was also shown to be a closely related species within PATRIC, this species was not 
identified within the BLASTP search of SlpA and therefore was not selected. However, if the 
time and resources are available then this species should also be included in future work. 
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Figure 3-21. Phylogenetic tree of C. difficile and closely related species based on the amino acid sequence files from their 
genomes. Taken from PATRIC, The Pathosystems Resource Integration Centre (28/2/13). 
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3.3.5.1 Updating the search for SlpA sequence similarity 
Since the initial bioinformatics work performed in July 2012, many more fully annotated 
genomes and sequence files were added to the NCBI and Uniprot databases over the 
duration of the project.. BLASTP searches were performed frequently throughout the 
project to determine whether the SlpA biomarker remained unique to C. difficile. A recent 
similarity search of the SlpA biomarker sequence was performed on 13/11/15, again using 
BLASTP and with C. difficile excluded from the search. When compared to the top ‘non 
C. difficile’ hit in 2012, which was the N. nitrogenifigens two-component LuxR family 
transcriptional regulator, the more recent search had 25 proteins with higher sequence 
identity to the biomarker across 14 different organisms (Figure 3-22). There were two 
identical hits displayed for N. nitrogenifigens, the two-component LuxR family 
transcriptional regulator and the DNA-binding response regulator, which are highlighted 
with a red box (Figure 3-20).  
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Figure 3-22. BLASTP search results for the SlpA biomarker with C. difficile excluded from the search (13/11/15) . The 
result for N. nitrogenifigens, highlighted with a red box, has been shown in more detail below the main results table.   
The top three BLASTP results against the SlpA biomarker are shown in more detail in Figure 
3-23. The proteins that contain sequences with the greatest similarity to the biomarker are 
the ATP binding protein and S-Layer protein from C. sordellii 8483 (Figure 3-23 A), which 
displays 100 % identity with 93 % query cover, that is 15 out of the 16 amino acids. There 
are several other clostridia that also contain protein sequences with high similarity to the 
SlpA biomarker: C. argentinense CDC 2741 (Figure 3-23 B) also had two hits, which was 
second only to C. sordellii 8483. The protein sequence with the third greatest similarity to 
the biomarker was within C. senegalense JC122 (Figure 3-23 C). As shown in Figure 3-23 
there was only one amino acid difference between the biomarker and both C. sordellii 
proteins, ATP binding protein and S-Layer protein, three amino acid differences shown for 
 69 
 
the C. argentinense hypothetical protein and C. senegalense cell wall-binding protein. These 
variances are below the minimum four amino acid difference that was selected as the 
biomarker ‘uniqueness’ threshold. Therefore, any detection molecule chosen to bind to the 
SlpA biomarker may not have the necessary specificity and would require further laboratory 
analysis to confirm the binding specificity. However, it has been reported in several studies 
that antibodies and aptamers have extremely high specificities and even a single amino acid 
difference within the epitope is enough to diminish antibody/antigen binding (Zegers et al., 
1995; Zheng et al., 1995; Negri et al., 2012).  
 
Figure 3-23. Top three BLASTP results for the SlpA biomarker, with C. difficile excluded from the search (13/11/15). The 
query is the SlpA biomarker sequence and the subject is the protein sequence that shows high similarity. The top hit is 
located within C. sordellii 8483 (A), the protein with the second greatest similarity is within C. argentinense CDC 2741 (B) 
and the third hit is from C. senegalense JC122 (C).    
The subcellular localisation checks (the second step in the bioinformatics approach Figure 
3-4) were also performed, using all five of the proteins containing the highly similar 
sequence to the SlpA biomarker. All five proteins were predicted using SignalP to have a 
signal peptide and were classified as being cell wall associated. The location indicates that 
the proteins may interfere with the detection molecules, designed against the biomarker, 
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and therefore will require further testing before the specificity of the molecules can be 
categorised.  
3.3.5.2 Updating the search for closely related species 
Due to the changes displayed by the BLASTP search results of the SlpA biomarker performed 
on 13/11/15 (Figure 3-22), an update of the BLASTP search with the entire SlpA protein was 
also performed on 13/11/2015. The results were displayed as a slanted cladogram, with the 
same options selected as described in section 3.3.5.  This analysis revealed that C. sordellii 
8483 S-layer protein was the closest related protein to C. difficile SlpA with both C. hiranonis 
and P. anaerobius also featuring (Figure 3-24). The C. sordellii 8483 genome was added to 
the NCBI database on 09/06/2015 and therefore wasn’t included in the earlier 
bioinformatics work. 
 
 
 71 
 
   
Figure 3-24. Slanted phylogenetic tree of BLASTP results from a C. difficile 630 SlpA similarity search , excluding 
C. difficile. Search performed 13/11/15.  
 
3.3.6 Analysis of the C. sordellii 8483 genome  
The position of the C. sordellii 8483 genome in the PATRIC clostridia phylogeny was noted in 
2013. However, the sequence of this strain was not added to NCBI until 2015. Upon further 
investigation, the insertion date of the strain, displayed within PATRIC, was stated as 
December 2014, which is over a year later than the screenshot with C. sordellii 8483 was 
taken (Figure 3-21). Correspondence with the PATRIC authors confirmed that the sequence 
was submitted directly by a research group, before the official ‘insertion date’, to determine 
where C. sordellii 8483 would fit in the clostridia phylogeny tree. The high identity of the 
SlpA biomarker between C. difficile and this C. sordellii strain is not replicated in any other 
C. sordellii strains with sequences submitted to NCBI. For example, Figure 3-25 shows the 
top BLASTP hits for the biomarker search against C. sordellii ATCC 9714 (A) and C. sordellii 
VPI 9048 (B), exhibiting poor similarity (search performed 18/11/15). 
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Figure 3-25. BLASTP search showing similarity to the SlpA biomarker within C. sordellii ATCC 9714 (A) and C. sordellii VPI 
9048 (B) sequences, performed 18/11/15. 
A comparative genomics study was performed with C. sordellii 8483, VPI 9048, ATCC 9714 
and C. difficile 630 and R20291. The initial step looked at the genome sizes and number of 
associated proteins located within each of these strains, data taken from the NCBI database. 
The genome size and number of proteins for C. sordellii 8483 is much larger than those seen 
in other C. sordellii and C. difficile strains (Table 3-3).    
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Table 3-3. The genome size (bp) and the number of proteins found within C. difficile 630 and R20291, and C. sordellii 
ATCC 9714, VPI 9048 and 8483 . All strains have their associated Accession number. The figures for C. sordellii 8483 have 
been highlighted in yellow. 
 
The FASTA sequences for the five C. difficile and C. sordellii strains were compared in a 
pairwise analysis using the average nucleotide identity (ANI) calculator22 (Rodriguez-R and 
Konstantinidis, 2014). The identity is predicted using both one-way ANI and two-way ANI 
between two genomic datasets, as calculated by (Goris et al., 2007). Furthermore, the ANI 
calculator supports both complete and draft genomes, estimating the average nucleotide 
identity between two genomes to determine the likelihood that the sequences are from the 
same species or not. If the ANI value is above 95 % then the sequences are predicted to be 
from the same species. 
An example of the results produced by the ANI calculator is provided in Figure 3-26, which 
was gained from the identity predictions between C. difficile 630 and C. sordellii 8483. The 
two genomes generated a similarity of 99.36 %, which classes them as the same species.  
                                                     
2222 http://enve-omics.ce.gatech.edu/ani/  
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Figure 3-26. ANI calculator results of C. difficile 630 compared to C. sordellii 8483 . The histogram displays the 
distribution of the sequence fragments displaying identity between the two strains. The mean value of the histogram is 
at identity 99.36 % indicating that the two strains are highly similar and are in fact the same species.  
 
The ANI results for all five of the tested C. sordellii and C. difficile strains are shown in Table 
3-4. C. sordellii 8483, highlighted in yellow, was classed as the same species as both 
C. sordellii and C. difficile. In contrast to this, the C. sordellii strains, ATCC 9714 and VPI 9048 
were only similar to each other, as were the C. difficile strains, 630 and R20291.  
Table 3-4. The ANI percentages of comparisons made between C. difficile 630, R20291, and C. sordellii ATCC 9714, 
VPI 9048 and 8483 . All percentages above 95 % indicate the strains are the same species. The results for C. sordellii 8483 
have been highlighted in yellow. 
 
The complete C. difficile genomes of strains 630 and R20291 were used as reference 
genomes for the alignment of the contigs present in the three C. sordellii draft genomes. 
The sequences were aligned with CONTIGuator 2 (Galardini et al., 2011)  and an overview of 
the results is provided in Table 3-5. The results show that the two C. difficile sequences 
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displayed excellent alignment, with zero unmapped contigs. Furthermore, as expected due 
to the ANI scores, both C. sordellii VPI 8048 and ATCC 9714 did not align well to C. difficile 
630. In contrast, half of the C. sordellii 8483 contigs align to C. difficile 630.  
Table 3-5. Overview of the CONTIGuator 2 results for the alignments of C. sordellii ATCC9714, VPI 9048 and 8483, and 
C. difficile R20291 , all aligned against the reference genome, C. difficile 630. Also displayed are the percentage of 
unmapped contigs. 
 
When the total length of the mapped contigs was displayed in a pairwise comparison view, 
it was shown that 4,143,197 bp from the C. sordellii 8483 genome mapped to the reference 
C. difficile strain, which is 4,290,252 bp in length. This contig mapping, displays that almost 
the entire reference genome aligns with, and is therefore highly similar to, parts of the 
C. sordellii 8483 DNA sequence.    
 
Figure 3-27. CONTIGuator results of C. sordellii 8483 aligned against C. difficile 630 . There are 622 mapped contigs that 
correlate to 4,143,197 bp aligned with the C. difficile genome.  
 
To investigate the alignment further, an area of the CONTIGuator result was enhanced and 
several contigs were selected for downstream analysis (Figure 3-28). The blue sections 
represent insertions and indicate where the contigs do not map to the reference genome, 
and the red sections are successfully aligned contigs.  
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Figure 3-28. A magnified image of a section the C. sordellii 8483 (bottom strand) alignment to C. difficile 630 (top strand). 
The blue arrows display contigs that did not map to the reference genome and the red arrows show the contigs that 
have mapped to the C. difficile 630 genome. One of each of the mapped and unmapped contigs have been labelled on 
the image. 
 
To clarify the similarity of the aligned contigs (red), the sequences for a number of these 
contigs were searched using NCBI nucleotide BLAST (BLASTN) and were highly similar to only 
C. difficile strains, and displaying very little similarity to the C. sordellii strains (search 
performed 20/11/15). An example of this similarity is shown in the BLASTN results of contig 
AJXR01000622.1, which had 99 % coverage and 99 % identity in C. difficile strains and only 
29 % coverage and 82 % identity to C. sordellii (Figure 3-29).  
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Figure 3-29. BLASTN results of the C. sordellii 8483 contig, AJXR01000622.1, which mapped to C. difficile 630 using 
CONTIGuator 2 . The length of the red lines on the image, display the relative length of the sequence and the colour 
displays the high alignment score. The bacterial strains with the largest query cover and percentage identity with the 
contig are all C. difficile strains (search performed 20/11/15).  
 
Several contigs that were shown to be insertions and not match C. difficile (blue contigs), 
were also analysed using BLASTN (search performed 20/11/15). The results displayed 
similarity to only C. sordellii strains and not to C. difficile. The strain that showed the 
greatest similarity was C. sordellii ATCC 9714, which was the top hit for all unmapped 
contigs that were searched. An example of the BLASTN results is shown for the C. sordellii 
8483 contig, AJXR01000968.1 (Figure 3-30). The sequence input for the C. sordellii 8483 
genome contains close to all of the C. difficile 630 DNA sequence and also almost all the 
C. sordellii ATCC 9714 DNA sequence.  
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Figure 3-30. BLASTN results of the C. sordellii 8483 contig, AJXR01000968.1, which did not map to C. difficile 630 using 
CONTIGuator 2 . The length of the lines on the image indicates the relative length of the sequence, while the colour 
displays the alignment score (where red indicates the highest scores). All sequence similarity hits are seen within the 
C. sordellii species (search performed 20/11/15). 
 
This evidence indicates that the C. sordellii 8483 sequence which was submitted to NCBI was 
not a pure C. sordellii strain, but also contained a contaminant from a C. difficile strain. In 
addition, the data suggests that the two strains within the sample are C. sordellii ATCC 9714 
and C. difficile 630. Consequently, the similarity data of C. sordellii to the SlpA biomarker can 
be disregarded. However, additional C. sordellii strains will require lab-based testing to 
ensure there is no non-specific binding of the detection molecules. Also, it would be useful 
to obtain the C. sordellii 8483 sample from the researchers who submitted the sequence 
and perform in-house next generation sequencing on a single colony taken this sample.  
3.3.7 Verifying the validity of the SlpA biomarker with the 2015 IDRIS system 
The 2015 IDRIS system contained 461,807,691 more distinct tokens, from around 1300 
more organisms, than the 2012 system. Using the C. difficile strains as the GOI the 2012 
system presented 9793 protein IDs that contained at least one unique token whereas, the 
2015 IDRIS system provided 3204 unique token-containing proteins. The 2015 IDRIS system 
contains nine C. difficile strains and therefore a decrease in the number of ‘unique tokens’ 
was expected. A search of the 2015 token list, identified the SlpA biomarker as still present 
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within the ‘unique token’ list (Figure 3-31). Therefore, the increase in sequence data within 
IDRIS did not alter the most promising result.  
 
Figure 3-31. The IDRIS Web browser displaying the results of the 2015 IDRIS search for unique tokens within all 
C. difficile strains within the system as the GOI. A search of the results for the SlpA biomarker ‘AKDGSTKEDQLVDALA’ 
identified it as present, spanning several tokens. A screenshot of this search was provided and shows the token 
sequence, locus tag, gene name, protein name. The results table also displays if a signal peptide is present within the 
protein sequence and the results of several cell-surface localisation tools, SignalP, TMHMM and LipoP. Finally, the 
accession numbers of the proteins are provided in the final two columns.   
 
3.4 Discussion 
A search of the literature confirmed the novelty of the bioinformatics approach used in this 
work. There have been a number of previous studies that have used a “sliding window”-
based approach to break down genomic or proteomic data into tokens.  However, this has 
not occurred for the entire RefSeq dataset, and nor have they been used for the 
identification of protein fragments that are unique to an organism. In these previous 
studies, “tokens” were used in smaller data sets for the identification of insertion sites in 
transposon libraries (DeJesus and Ioerger, 2013) or the identification of prophages (Akhter 
et al., 2012).  
Although C. difficile was used in this project as a case study, the bioinformatics approach 
could be exploited to identify unique regions within any organism contained within the 
database. Furthermore, the IDRIS system not only distinguishes unique bacterial biomarkers 
for whole species, it could also be used to ascertain sequences that distinguish strains within 
species. An example of the IDRIS system providing sequences for inter-species 
differentiation was shown for MRSA strains within the S. aureus species (Flanagan et al., 
2014).  
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3.4.1 Using the IDRIS system with C. difficile species as the GOI 
The original 2012 IDRIS system contained three C. difficile strains which were used as the 
GOI, providing 9793 C. difficile protein IDs that contained unique tokens. With the addition 
of almost double the total number of organisms in the 2015 TokenDB (from 1400 to 2764), 
and an increase from three to nine C. difficile strains within the GOI, there was a decrease in 
the number of unique token-containing proteins. This decrease was roughly a third of the 
results gained from the 2012 system, from 9739 to 3204 unique token containing proteins. 
A decrease in results between the two IDRIS system searches was not surprising. The larger 
the number of organisms within the database, the greater the chance that: (a) a new species 
within the GOI has subtle variations in its sequences that reduce the number of exact token 
matches among the rest of the GOI members, and, (b) that a closely-related strain from 
outside the GOI contains an exact match to a token that is common to the members of the 
GOI. This large increase in tokens from the newly deposited strains therefore decreases the 
likelihood that a token common to the GOI is also unique. Consequently, with the ever 
increasing rate of bacterial sequence submissions to NCBI, it is likely that fewer unique 
tokens will be found for GOIs. Conversely, the more sequences that are searched, the better 
the chance there is of identifying truly unique tokens. Therefore, it is predicted that the 
number of tokens will eventually reach a plateau no matter how many more strains are 
added. Figure 3-32 provides some evidence of this, showing a graph that was produced from 
the unique token results from the GOI of Chlamydia trachomatis. This species was selected 
simply because IDRIS contains sequence data from a high number of strains from this 
species. As the number of strains within the GOI increases, the number of tokens that are 
common, yet unique to this GOI, deceases. After an initial swift decrease, the line begins to 
plateau, showing relatively little difference in the number of tokens between 40-73 strains 
within the GOI.  
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Figure 3-32. The resulting number of ‘unique tokens’ when using GOI's with differing numbers of Chlamydia trachomatis 
strains , ranging from 1-73. As the number of strains within the GOI increases, the number of ‘unique tokens’ decreases, 
initially quite rapidly and then reaching a relative plateau.  
 
3.4.2 Subcellular localisation of the 9739 C. difficile proteins 
The results of the token containing proteins, from the 2012 IDRIS system, were progressed 
to the second step of the bioinformatics approach - the subcellular localisation of the 
proteins (Figure 4-4). Although this was an automated step using ApID2, within the IDRIS 
system, the positive results of proteins predicted to be located on the surface of the cell 
were manually validated with the subcellular localisation tools. The displayed results from 
the individual subcellular localisation tools all analysed the C. difficile SlpA precursor 
sequence, as this was the most promising protein. The SignalP results for SlpA identified a 
signal peptide at amino acid positions 1-24, which correlated with the literature (Calabi et 
al., 2001; Emerson and Fairweather, 2009). This signal peptide indicates that the protein is 
destined for the secretory pathway and therefore is not a cytoplasmic protein (Nielsen et 
al., 1997). The protein sequences that were disregarded did not contain a predicted signal 
peptide. Further analysis of the signal peptide was performed using LipoP, which predicted 
SPI to cleave the SlpA signal peptide and therefore, SlpA is not predicted to be a lipoprotein. 
In prokaryotes, the SPI cleavage motif is most commonly associated with alanine (Payne et 
al., 2012) and the SlpA cleavage site is no different as it’s predicted to be between two 
alanine’s (Appendices, section 9.3). Proteins were disregarded if they were predicted to 
 82 
 
contain signal peptidase II (SPII), an aspartic acid protease that cleaves signal peptides to 
form lipoproteins (Dalbey et al., 2012). Proteins were also disregarded if they were 
predicted to be a cytoplasmic protein (CYT) (Petersen, 2011). 
Analysis of SlpA with both PSORTb and TMHMM, predicted that it is a cell wall protein with 
only one transmembrane helix at the N-terminal. The transmembrane helix and signal 
peptide prediction tools both search for hydrophobic regions within sequences, often 
causing the same sequence region to be predicted as both a signal peptide and a 
transmembrane helix (Kall et al., 2004). Since the signal peptide is cleaved within the 
membrane, it is unsurprising that the signal peptide is often categorised as a 
transmembrane region, which was the case with the C. difficile SlpA. Any proteins that were 
classed as cytoplasmic or cell membrane proteins were disregarded from further analysis. 
From the initial 9793 proteins that contained at least one token that was unique to 
C. difficile, there were 28 that were positive with the criteria as defined in the results 
section. All four subcellular localisation tools and Phobius classed SlpA as cell wall 
associated. Therefore, the protein is likely to be accessible for any detection molecules 
within a PoN sensor, without the need of pre-treatment of cells.  
3.4.3 Identifying a unique biomarker within the 28 C. difficile proteins 
The TokenDB identified a token as unique if the entire 15 amino acid sequence was not 
located within another organism. However, since the TokenDB performs exact sequence 
matching, it is possible that the ‘uniqueness’ of a given token might only be due to a single 
amino acid mismatch. Consequently, in the worst case, a ‘unique token’ could share up to 
14 amino acids with a token in other species.  
Since there are only 20 amino acids (Bettelheim et al., 2015), it was highly unlikely that a 
single token would be completely unique to a group of organisms. As the threshold of 
similarity increases from zero to 14, the likelihood of finding a unique token increases. In 
order to gain the maximum number of tokens, it was decided to set the similarity threshold 
of the TokenDB to 14, for example 14 out of the 15 amino acids could be located in other 
bacteria. For future work, the TokenDB would require testing at a similarity threshold 
decreasing from 14 amino acids, until the optimum number was identified. There would 
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need to be a compromise between a large enough number of tokens within the chosen 
location of a protein, and the threshold being low enough to ensure that the tokens 
contained sections of wholly unique sequences of amino acids.       
Due to this similarity threshold, it was imperative that the 28 proteins predicted as being 
cell wall associated were analysed manually for unique biomarkers, with a minimum length 
of 15 amino acids. Many proteins did not contain unique biomarkers that were 15 amino 
acids or longer. Often there were predicted biomarkers that contained less than 4 unique 
amino acids, which was not deemed adequate for a specific detection molecule. Biomarkers 
were classed as viable candidates if BLASTP analysis determined that the most similar 
sequence to the biomarker, not located within C. difficile, was different by a minimum of 
four amino acids. This number was selected to try and ensure that any biomarker 
recognition molecules would not non-specifically bind to similar sequences. Due to the high 
specificity of antibodies and aptamers, even a residue difference of one is likely to remove 
the specificity of the binding molecules (Zegers et al., 1995; Zheng et al., 1995; Negri et al., 
2012). For future work, epitopes can be produced with differing numbers of amino acid 
changes, using site-directed mutagenesis. The minimum number of changes that removes 
binding of the recognition molecules can then be determined and used as the threshold for 
biomarker similarity. 
Out of the 28 identified, the protein with the most promising biomarker was SlpA, within 
which, a 16 amino acid biomarker was identified using Uniprot BLAST, Jalview and BLASTP. 
This biomarker also contained hydrophilic regions, which indicated that this section of the 
sequence would likely be located on the external surface of the protein (Lodish et al., 2000). 
As a result, these hydrophilic sections were predicted to be more accessible to detection 
molecules, such as antibodies. For a bacterial PoN sensor, it is vital that all strains of the 
species of interest can be detected and consequently, all strains must contain the specific 
recognition region, which will reduce the potential of obtaining false negatives. ACT 
revealed the conservation of the SlpA biomarker in all nine of the fully sequenced C. difficile 
strains. Furthermore, Jalview was used to identify the biomarker within sequences from all 
of the 13 SLT clades. Since these represent all known C. difficile strains, the presence of the 
SlpA biomarker demonstrates that the sequence occurs across the C. difficile species. The 
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SlpA sequence for C. difficile 630 places this strain into SLT clade 4, which is represented in 
the group of sequences provided by Dr Kate Dingle, by SLTS Ox1145. This similarity was 
established with the Jalview results, as well as being revealed in the research performed by 
Kate Dingle and colleagues (Dingle et al., 2013).  
The SlpA biomarker BLASTP search performed in 2012 revealed the non C. difficile strain 
with the closest similarity to be from N. nitrogenifigens. In contrast, when the same search 
was performed in November 2015, there were several organisms that contained sequences 
with greater similarity to the SlpA biomarker than N. nitrogenifigens. This increase in 
organisms with similar sequences to the SlpA biomarker is not a surprise since, as shown in 
Figure 1-2, the number of submitted sequences is rising exponentially. Within the three 
years that the IDRIS system has been running, the number of genomes and related protein 
sequences that it contains has doubled. Many of the similar sequences, identified by the 
2015 BLASTP search, were located in other clostridia species that were sequenced a few 
months preceding the search. The most similar hit to the SlpA biomarker with the 2015 
BLASTP search was within C. sordellii 8483, which is discussed in detail within in section 
4.3.7 . Here, the discussion focuses on two other species that also displayed high similarity 
to the biomarker, C. argentinense and C. senegalense.  
Except for C. sordellii, C. argentinense displayed the greatest similarity to the SlpA biomarker 
with a difference of only three amino acids. C. argentinense is the name for the species that 
was once Group IV C. botulinum and was originally isolated from soil in Argentina in 1970 
(Gimenez and Ciccarelli, 1970) and has not been associated with botulism in humans, 
animals or birds (Peck, 2014). Non-toxigenic samples have been noted to be isolated from 
blood and wounds (Johnson, 2005) but not from faecal samples. Therefore, although there 
is a similarity within these bacteria to the SlpA biomarker, any diagnostic sensor that is 
focussed on faecal samples may not come into contact with this species, thus false positives 
may not be an issue. However, non-specific binding of any recognition molecules with this 
species should be determined. 
C. senegalense also displayed high similarity to the SlpA biomarker within the 2015 BLASTP 
search, with three amino acids different. C. senegalense was originally isolated from the 
faeces of a healthy Senegalese male (Mishra et al., 2012; Ahmed et al., 2014). Since the 
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bacteria were isolated from a faecal sample and similarity to the SlpA biomarker has been 
shown, there may be an issue with a C. difficile PoN sensor made to target this biomarker. 
However, there was no evidence to suggest that C. senegalense has been isolated from 
faecal samples in more developed countries and there was very little literature on this 
strain. Therefore, C. senegalense may not be common enough to cause any false positives 
when detecting C. difficile. However, this issue would need to be investigated in future 
work. If any of the C. argentinense or C. senegalense strains could be obtained for further 
work, these species should be analysed for binding to the detection molecules produced 
against the SlpA biomarker. If it is deemed necessary, it could be possible to use a second 
C. difficile biomarker, as identified using the IDRIS system, to differentiate those samples 
that truly contain C. difficile. 
3.4.4 SlpA is expressed 
Data from microarray experiments was used to provide an idea of the expression of SlpA 
protein, rather than conclusive evidence. The data shows that the slpA gene is one of the 
most highly expressed genes in C. difficile 630. The high slpA expression was shown at two 
different time points, 4 h and 10 h growth and also within a mutant strain lacking SigH, an 
alternative sigma factor, which is a key element in the initiation of sporulation (Saujet et al., 
2011). The main evidence for SlpA protein expression however, was provided with a 
thorough literature search. The SlpA protein forms the C. difficile S-layer that completely 
coats the outer surface of vegetative cells (Reynolds et al., 2011). Therefore, a high rate of 
protein synthesis is required to maintain the intact S-layer (Sleytr and Messner, 1983). There 
is a very high rate of SlpA synthesis in uninhibited cells (Dang et al., 2012) and Fagan and 
Fairweather (2011) state that it is the most highly expressed protein in C. difficile, with 
expression occurring in all stages of growth (Savariau-Lacomme, 2003; Fagan and 
Fairweather, 2011). Researchers have shown that SlpA is vital for cell growth (Dembek et al., 
2015) and it has not been possible to create SlpA mutants (Dang et al., 2010; Fagan and 
Fairweather, 2011). SlpA being an essential protein would explain why SlpA is highly 
expressed in all stages of growth and in mutants. The literature fairly conclusively shows 
that SlpA is expressed, providing the evidence required to continue with SlpA as a potential 
biomarker. Additionally, since SlpA is one of the most expressed proteins and is on the 
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outside of the cell, the literature also highlights the suitability of the protein to provide a 
biomarker for a PoN sensor. The evidence suggests that any biomarker within the SlpA 
protein will be produced in abundance, presenting many epitopes for detection molecules 
to bind to. If definitive proof of the expression of SlpA was required, reverse-transcription 
polymerase chain reaction (RT-PCR) could be utilised. This technique includes the isolation 
of C. difficile RNA, cDNA is then produced with reverse transcriptase and provides the 
sample for traditional PCR amplification of the slpA region (Calabi et al., 2001; Bustin, 2002). 
Although it is less sensitive than RT-PCR another possibility to determine SlpA expression is 
to use Northern blotting, which uses hybridising probes complementary to that of the 
specific SlpA mRNA (Trayhurn, 1996). 
3.4.5 The biomarker is located on the surface of SlpA 
The SlpA protein is post-translationally cleaved into the LMW and HMS SLP (Dang et al., 
2012). The SlpA biomarker is located within the HMW SLP and therefore, to determine the 
location of the biomarker, the HMW SLP structure was required. I-TASSER predicted the 
structure and the biomarker was forecast to be completely accessible on the surface of the 
protein in all five of the models. Since the model structures are predictions, it is difficult to 
say with complete certainty that the biomarker is located on the surface of the HMW SLP. 
However, since all five models predicted the biomarker surface location, including model A 
with the highest C-score, it is likely that the biomarker is exposed on the surface of the 
protein. This indication of surface exposure, along with the hydrophobicity predictions 
shown with Jalview, was enough evidence to proceed with this biomarker as the target 
sequence for detecting C. difficile. The laboratory work was used to determine if this 
biomarker is indeed accessible to detection molecules such as antibodies, and the specificity 
of these to C. difficile.   
3.4.6 Summary of why the SlpA biomarker was selected to differentiate 
C. difficile from other organisms 
Unlike other token containing proteins that did not contain biomarkers over the 15 amino 
acid threshold, SlpA did. The 16 amino acid SlpA biomarker ‘AKDGSTKEDQLVDALA’ was 
determined to be the most promising biomarker for differentiating whole C. difficile cells 
from other bacteria. Selection of this biomarker was due to several reasons, firstly, the 
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protein in which the biomarker resides, SlpA, was predicted by the five subcellular 
localisation tools to be surface associated. Secondly, the biomarker sequence is found 
within all sequenced C. difficile strains, including all SLTS that represent the entire C. difficile 
species. Also, this biomarker, within the 2012 searches, was classed as ‘unique’ to C. difficile 
as it was not entirely located within other species and was different to the closest related 
species by five amino acids. Finally, the biomarker was predicted to be on the surface of 
SlpA, which is expressed in all stages of growth and completely encapsulates the cell, 
therefore, a great number of biomarker epitopes are predicted for recognition molecules to 
bind to. The combination of all of these results provides information that the SlpA 
biomarker was the most promising.  
3.4.7 Analysis of C. sordellii 8483 and the issues that can arise with poor 
sequence data 
As shown with the analysis of the C. sordellii 8483 strain, bioinformatics analyses can only be 
as good as the sequences that are provided. If the initial biomarker search had been 
performed post-addition of the C. sordellii 8483 sequence to NCBI, then the SlpA biomarker 
would not have been identified and yet it was one of the most promising sequences 
provided with the bioinformatics approach. When a database such as the TokenDB is reliant 
on the sequences contained within NCBI, it is vital that the sequences are as accurate and 
true to the species of which it is labelled. One of the main problems is that a huge amount 
of sequence data is submitted and as a result, full reviews of all data are not possible and 
therefore, accuracy is not always achieved. An issue that arose when Keith Flanagan was 
creating the TokenDB was the poorly annotated genomes within RefSeq. A quote taken 
from the NCBI RefSeq page states that: 
‘RefSeq provides a comprehensive, integrated, non-redundant, well-annotated set of 
sequences’23 
However, many of the sequences were not well-annotated and were not suitable for use 
within the TokenDB. The different databases published by the NCBI such as Assembly, 
                                                     
23 http://www.ncbi.nlm.nih.gov/refseq/about/  
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RefSeq and Nucleotide are not always simple to navigate and information is not always well 
linked. With the ever-increasing amount of data being submitted to NCBI and other 
databases, it is important to have well established guidelines that researchers can follow 
when adding data. It is up to the researchers to ensure that sequence data is from a pure 
sample and is accurate to the species it is labelled with. Anomalies such as the huge 
difference in genome size seen with C. sordellii 8483 compared to other C. sordellii strains, 
should be noted and investigated by the researchers in order to prevent fundamental errors 
such as those seen with this submission.   
 
3.5 Summary 
The IDRIS system and the manual steps that were developed within this project were 
combined into a bioinformatics approach. This approach was used to successfully identify a 
biomarker that is common to all members of the C. difficile species, and yet found within no 
other organism. The biomarker was a 16 amino acid sequence within the precursor protein 
SlpA, which was further determined to be within the HMW SLP section of this protein. The 
sequence is predicted to be on the surface of the protein, which is in turn on the surface of 
the bacteria and therefore is forecast to be surface accessible.  However, laboratory 
experiments will have to be performed to determine if the location of the biomarker is 
indeed accessible to antibodies. If the SlpA biomarker is proven unsuccessful, the C. difficile 
token-containing proteins, will be re-visited to identify alternative biomarkers. Although this 
bioinformatics approach has been used to identify C. difficile biomarkers, the IDRIS system 
and downstream analysis can be used to search for biomarkers within any species that has 
been fully sequenced and is annotated. These biomarkers could be used to identify a species 
as a whole or used to differentiate different strains within a species.   
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Chapter 4 The development of monoclonal antibodies for the 
specific detection of Clostridium difficile  
4.1 Introduction 
4.1.1 Bacterial identification 
Traditionally, bacterial identification and taxonomy was based on morphological features, 
using bacterial culture and colony categorisation. However, this phenotypic identification is 
time-consuming and prone to human error (Peng et al., 2010). In the second half of the 21st 
century, great advances were made in the technology available for bacterial taxonomy. In 
1977, Carl Woese utilised 16S ribosomal ribonucleic acid (rRNA) sequences for phylogenetic 
taxonomy, resulting in the creation of the third domain, archaea (Woese and Fox, 1977). In 
the same year, Frederick Sanger developed DNA sequencing, a step that would revolutionise 
bacterial taxonomy (Sanger et al., 1977). With this ability to sequence genes, bacteria could 
be grouped based on their genetic make up. As accessibility to this new DNA sequencing 
technique increased, so too did the amount of data being produced. Subsequently, in 1979, 
the nucleic acid database, GenBank, was established to store genomic data (Choudhuri, 
2014). Another major technological advancement in bacterial taxonomy was the invention 
of polymerase chain reaction (PCR) by Kary Mullis in 1983, which enabled genes and specific 
bacterial identifiers, to be amplified and detected relatively quickly (Saiki et al., 1988; 
Shafique, 2012). These new methods were the first major steps in molecular diagnostics and 
meant that bacteria could be identified and grouped in the space of hours as opposed to 
days, as seen with the use of traditional phenotypic taxonomy. These molecular biology 
techniques also decreased the need for human interpretation, an aspect which often caused 
errors in traditional phenotypic diagnostics (Tang et al., 1998).  
Rapid and accurate identification of bacterial pathogens is an important goal for clinical 
microbiology laboratories and front line clinicians (Tang et al., 1998). However, with 
traditional techniques of time-consuming culture this goal is impossible to acheive. In 
contrast, recent methods of genotypic bacterial identification, such as PCR, has enabled 
more rapid diagnostics. It is not currently practical to use these techniques at the PoN, as it 
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requires specialist skills and laboratory equipment (Kufelnicka and Kirn, 2011; Buchan and 
Ledeboer, 2014). 
4.1.2 C. difficile strain typing 
Over the years, C. difficile strains have been categorised using a variety of techniques, 
leading to the same strain having a number of titles. Serotyping by slide agglutination or 
ELISA was the traditional method of grouping C. difficile, splitting strains into ten groups, 
each denoted by a letter (Karjalainen et al., 2002). As molecular techniques advanced, new 
typing methods have emerged. Pulse field gel electrophoresis (PFGE), the use of alternating 
directions of electrical fields to resolve DNA fragments,  is currently the standard C. difficile 
typing method used in Canada and the USA, providing strains with the nomenclature North 
American Pulsotype (NAP) and a number e.g. NAP1 (Janezic and Rupnik, 2010). Whereas in 
Europe, the standard method used to type C. difficile strains is PCR ribotyping, a form of 
genomic fingerprinting. Every C. difficile strain contains multiple copies of rRNA operons, 
each with a differing length of intergenic spacer between the 16S and 23S ribosomal 
subunits (Figure 4-1A). Ribotyping utilises these differences in intergenic spacer lengths, 
using PCR and primers within the 16S and 23S subunits to amplify these regions (Bidet, 
1999). The PCR products are separated on an agarose gel, producing a band barcode that is 
unique to that particular C. difficile strain (Figure 4-1B). Strains that have been categorised 
using PCR ribotyping are titled R and a number, for example R002 and R050, which are two 
of the strains used in the initial laboratory work within this project.   
 
Figure 4-1. A diagram representing the principle of PCR ribotyping. The different sized intergenic spacers, within one 
strain, are amplified (A) and separated on an agarose gel. The bands on the gel produce a barcode that is specific to that 
C. difficile strain (B) 
 91 
 
4.1.3 C. difficile biomarkers  
Current CDI biomarkers include the C. difficile toxin genes identified using PCR, the toxins 
themselves detected by EIAs and the genomic fingerprints produced by PFGE or ribotyping. 
Other possible biomarkers are produced by the host in response to the infection, such as, 
fecal lactoferrin, calprotectin and cytokines, however, these are not specific to CDI 
(Burnham and Carroll, 2013). Genotyping of SlpA has also been shown as a possible 
biomarker for use in both identification and typing of C. difficile (Karjalainen et al., 2002; 
Dingle et al., 2013). However, the only current CDI biomarker that is rapid enough for PoN 
detection is toxin EIAs and as discussed in Chapter 1. Section 1.14, this method does not 
have the sensitivity required for a stand-alone test.  
4.1.4 C. difficile genome sequencing 
In 2006 the first C. difficile genome, C. difficile 630, was fully sequenced (Sebaihia et al., 
2006), having being isolated from a patient with severe pseudomembranous colitis (Wüst et 
al., 1982). In the literature, C. difficile 630 is used as the reference strain (Kurka et al., 2014) 
and during the bioinformatics section of this work the SlpA precursor protein from C. difficile 
630, was used for the detailed analysis. For these reasons C. difficile 630 was chosen as the 
primary strain for the laboratory work within this project.   
4.1.5 Antibodies 
Antibodies are immunoglobulin (Ig) molecules secreted by the immune cells, B-lymphocytes. 
Monoclonal antibodies are made from identical B-lymphocytes, from the same parent clone, 
and are monovalent, that is, they bind to the same epitope. Monoclonal antibodies have 
been generated in the laboratory since 1975 when César Milstein and Georges J. F. Köhler 
invented the technique (Liu, 2014).  
Antibody binding occurs between the antigen binding fragment (Fab) of the antibody (Figure 
4-2) and the epitope of the antigen. This binding is via transient, non-covalent interactions, 
the strength of which depends on the spatial complementarity of the antibody and antigen 
(Janeway et al., 2001)  
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Figure 4-2. Molecular structure of Immunoglobulin G (IgG) antibody. The heavy and light chains are linked with 
disulphide bonds, as are the two heavy chains. The fragment antigen-binding (Fab) fragment is the region where the 
antibody binds to antigens. The variable region contains the epitope binding sites, whereas the remainder of the light 
and heavy chains are conserved sequence. The fragment crystallizable (Fc) of an IgG is composed of the constant regions 
of the heavy chains. 
 
The regions of the Fab that bind antigens are the variable regions of the light and heavy 
chains, VL and VH respectively. Each of the VL and VH has three hypervariable loops named 
complementary-determining regions (CDRs). It is these CDRs that determine the antigen 
specificity of the antibody (Martin, 2010). Other than the highly variable CDRs, Abs have 
uniform protein structures, including the fragment crystallisable (Fc) region (Janeway et al., 
2001). Antigens can have epitopes that are conformational, where the bound amino acids 
have been brought together via protein folding, or linear, where the protein sequence has 
no tertiary structure and the antibody binds to a single, continuous sequence (Janeway et 
al., 2001).  
Antigen/Ab binding occurs via non-covalent interactions between the side chains of amino 
acids. These non-covalent interactions include hydrogen bonds, van der Waals forces, 
hydrophobic interactions and ionic bonds (Elgert, 2009). Non-covalent interactions are 
generally weak, however, the simultaneous combination of multiple interactions, form a 
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tight bond between antibody and antigen. This tight bond is reversible, enabling the 
complete separation of the two molecules without alteration (Mak and Saunders, 2001).    
The weakest of the non-covalent interactions are the van der Waals forces, which include all 
intermolecular forces between electrically neutral atoms. Van der Waals interactions are 
caused by the fluctuating electron density of nearby atoms (Mak and Saunders, 2001). The 
varying distribution of electrons around an atom can form transient dipoles, which in turn 
can induce a dipole in a neighbouring atom. If close enough together, these dipoles cause 
attraction/repulsion between the atoms (Craig et al., 2010).    
Hydrogen bonds are stronger than van der Waals forces and are formed when a hydrogen 
atom is bound to a highly electronegative atom, such as oxygen, causing the hydrogen atom 
to be δ+. The hydrogen is then attracted to other nearby electronegative atoms that have a 
lone pair of electrons, forming a bond (Lodish et al., 2000). Amino acids with polar, 
uncharged side chains, for example serine (S) or glutamine (Q), have the ability to either 
donate or accept hydrogen atoms, enabling the formation of hydrogen bonds (Lieberman et 
al., 2007).  
Hydrophobic interactions can have similar strengths to hydrogen bonds and are formed by 
the preferential clustering between hydrophobic amino acid regions, when in aqueous 
solution (Troy and Beringer, 2006; Craig et al., 2010). It is estimated that up to fifty percent 
of the interactions between the amino acids of the antibody and the epitope are caused by 
hydrophobic interactions (Elgert, 2009). 
Finally, the strongest of the non-covalent interactions are the ionic bonds, such as salt 
bridges. A salt bridge is an interaction between a negatively charged carboxylate ion and a 
positively charged amino group (Snape et al., 2014). The amino acids with charged side 
chains are able to form salt bridges and include lysine (K) and aspartic acid (D) (Schwarz et 
al., 2004).  
The contribution that each non-covalent interaction has to binding, is dependent on the 
particular Ab, with all interactions working together to confer antibody specificity. Even 
when Abs are raised against the exact same epitope, the affinity and specificity of these Abs 
can vary widely (Janeway et al., 2001).  
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4.1.6 Monoclonal antibody production 
For over 40 years, researchers have utilised animals to produce custom designed Abs that 
bind to antigens with high specificity. To produce Abs, animals such as mice, rabbits or goats 
are immunised with antigens, such as whole organisms, proteins or linear peptides. B-
lymphocytes are presented with these ‘foreign’ antigens and begin producing Abs to bind to 
them. B-lymphocytes are removed from the spleen of the animal and fused with immortal 
myeloma cells. Myeloma cells do not produce any other immunoglobulins and lack the 
hypoxanthine-guanine-phosphoribosyltransferase gene, which is vital for the synthesis of 
nucleotides (Liu et al., 2015a). The fused B-lymphocytes and myeloma cells are known as 
hybridomas. The hybridomas are grown in selective media so that only fused cells, which 
have the immortality from the myeloma cells and the nucleotide synthesising properties of 
the B-lymphocytes, survive. For monoclonal antibodies, antibodies made from single clones, 
the hybridomas are individually cultured in different wells, allowing antibodies from a single 
clone to be produced (Leenaars and Hendriksen, 2005).  
For this project, synthetic, linear peptides were used as the antigen. There is not a definitive 
optimal length for a linear antigen, as there are a number of contributing factors. One of 
those factors is the current technology used for peptide synthesis, which results in 
decreasing yields as peptide length increases (Saper, 2009). Additionally, self-interaction can 
be an issue with larger peptide sequences, as they can form unintended conformational 
epitopes for antibodies to bind to (Hancock and O'Reilly, 2005). If antibodies bind to these 
conformational epitopes, they may not bind to the intended linear epitopes and therefore 
would not bind to the sequence of interest. In contrast, peptides that are too short are 
unlikely to cause an immunogenic reaction and are therefore, unsuitable for antibody 
production. Hancock and O’Reilly state that linear antigens of ten to twenty amino acids in 
length are optimal (Hancock and O'Reilly, 2005). Hansen and colleagues mention four to ten 
amino acids as optimal (Hansen et al., 2013) and Berglund and colleagues affirm that linear 
epitopes usually range from six to nine amino acids (Berglund et al., 2008).  
4.1.7 Species and strains used during the laboratory work 
Throughout the laboratory work, a number of different C. difficile strains were used, there is 
a full list of which in Table 2-3. It is important to note that the C. difficile reference strain, 
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C. difficile 630, was used throughout the work as a positive control. There were three 
species, closely related to C. difficile, which were used to determine any non-specific binding 
of the Abs. These species were ascertained with the phylogenetic analysis within section 
3.3.5. C. hiranonis DSM-13275 and P. anaerobius VPI 4330 contained proteins with similarity 
to the C. difficile SlpA protein so were chosen as controls. C. sordellii 8483 was predicted to 
be a closely related species within PATRIC, however, this strain could not be obtained and 
therefore C. sordellii ATCC 9714 was used. Upon addition of the C. sordellii 8483 genome to 
NCBI in 2015, which was post laboratory work, analysis of this genome was performed in 
section 3.3.6. This bioinformatics investigation confirmed that the sequence is not accurate 
for this organism and contains C. difficile reads. Consequently, it is recognised that the 
PARTIC classification of C. sordellii, being the most closely related species to C. difficile, is 
not accurate. This species does, however, remain a very useful control as it is in the same 
genus and shows some similarity to the biomarker. Throughout this project, all three of 
these strains, C. hiranonis DSM-13275, P. anaerobius VPI 4330 and C. sordellii ATCC 9714 are 
collectively regarded as ‘the closely related strains’. The same strains were used as controls 
throughout the project, so for ease of reading, they will be referred to by species name only, 
within the bulk of the text.      
 
4.2 Results  
4.2.1 Determining the presence of the biomarker within three C. difficile 
strains 
The unique C. difficile biomarker predicted with the bioinformatics workflow is shown in 
Table 4-1. PCR amplification of the SlpA gene from three C. difficile provided products of the 
expected length, which was 1468 for C. difficile 630 and 1469 for C. difficile R002 and R050 
(Figure 4-3A). The sequences of the PCR products were translated into amino acid 
sequences using ExPASY translate (Gasteiger et al., 2003) and the biomarker was shown to 
be present in all three of the sequenced C. difficile strains (Figure 4-3b).  
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Table 4-1. The sequence predicted using the TokenDB and bioinformatics workflow to be a unique biomarker for 
C. difficile. 
C. difficile HMW SLP biomarker sequence (16 amino acids) 
AKDGSTKEDQLVDALA 
 
 
Figure 4-3. PCR products from the SlpA amplification, separated by agarose gel electrophoresis (A) and the sequence 
data of the purified PCR products, with the biomarker underlined (B). 
 
4.2.2 Analysis of the surface layer proteins of C. difficile  
Low-pH glycine extracted SLPs were separated on an SDS-PAGE gel (Figure 4-4). C. difficile 
630 and R002 displayed two distinct protein bands, with a relatively high concentration of 
protein at sizes correlating to the HMW and LMW SLP within the literature. C. difficile R050 
on the other hand, revealed a single band, containing a relatively high protein 
concentration, which was smaller in size than observed in the other C. difficile strains 
however, it remained within the HMW SLP size range (see discussion). The R050 LMW SLP 
was at the same size as the LMW SLP in R002 and 630 however, in comparison it had a 
smaller amount of protein.  
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Figure 4-4. SDS-PAGE gel of the extracted surface layer proteins from C. difficile R002, R050 and 630. The HMW SLP 
varies in size and along with the LMW SLP is labelled. There are several other surface proteins present within the 
samples. 
 
4.2.3 Production of HMW SLP monoclonal antibodies  
AbMART synthesised several epitope sequences and used these linear peptides to produce 
mouse mAbs, via the hybridoma technique, discussed in section 4.1.6. The eight mAbs that 
were provided by AbMART are listed, alongside their ten amino acid epitope sequence 
(Table 4-2). 
Table 4-2. The C. difficile antibodies produced by AbMART and their corresponding epitope sequences. The region 
contained within the C. difficile biomarker is highlighted in yellow. 
Antibody ID Epitope sequence (biomarker highlighted) 
Ab370 KDGSTKEDQL     
Ab521 STKEDQLVDA     
Ab498 STKEDQLVDA     
Ab491 FVAKDGSTKE     
Ab652 KEDQLVDALA     
Ab493 VDALAAAPIA     
AbB31 STKEDQLVDA     
AbB84 STKEDQLVDA     
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4.2.4 Determining mAb binding to the surface layer proteins of C. difficile 
Initial experiments were performed to screen the eight mAbs for successful binding to the 
surface layer proteins of C. difficile. Figure 4-5 shows examples of two mAbs, Ab521 (A) and 
Ab652 (B) successfully bound to both the extracted SLPS (S) and residual pellet (P) of 
C. difficile 630. The dark dots indicate binding, which is not seen for the negative control, 
C. sordellii ATCC 9714. The positive control of the primary antibody (Positive Ab…) produced 
a clear mark. There were four mAbs which revealed positive results, Ab521, Ab652, Ab491 
and Ab493, the latter two are displayed within the Appendices Figure 9-2. 
 
Figure 4-5. Dot blots with Ab521 (A) and Ab652 (B) of low pH glycine extracted surface proteins (S) and the residual 
pellet, post extraction (P) for C. difficile 630 and C. sordellii ATCC 9714. The primary antibody was directly blotted on to 
the membrane as a positive control. The biomarker regions of the antibody epitopes are displayed in red. 
 
Within the dot blots, the remaining four mAbs produced negative binding with two 
examples, Ab370 (A) and Ab498 (B), shown in Figure 4-6. The results for AbB31 and AbB84 
are displayed in the Appendices Figure 9-3. All four of these mAbs do not bind to either the 
C. difficile or C. sordellii surface layer proteins or residual pellet and were excluded from 
further analysis. 
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Figure 4-6. Dot blots with Ab370 (A), Ab498 (B) against low pH glycine extracted surface proteins (S) and the residual 
pellet, post extraction (P) for C. difficile 630 and C. sordellii ATCC 9714. The primary antibody was directly blotted on to 
the membrane as a positive control. The biomarker regions of the antibody epitopes are displayed in red. 
 
4.2.5 Binding of the mAbs to proteins within C. difficile and the closely 
related strains 
Western blots were performed with the extracted SLPs (S) and the residual pellet (P), of 
C. difficile 630 and the closely related species C. sordellii and P. anaerobius (Figure 4-7). 
Concomitant SDS-PAGE gels of the samples were run to show the loading of the proteins 
and if the low pH glycine method extracts any proteins from the closely related species.   
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Figure 4-7. Western blot (right) and concomitant SDS-PAGE gel (left) with Ab521 (A) and Ab652 (B) against the low pH 
glycine extracted surface proteins (S) and residual pellet (P) of C. difficile 630 and the closely related strains C. sordellii 
ATCC 9714 and P. anaerobius VPI 4330. 
 
All four of the mAbs, Ab491, Ab493, Ab521 and Ab652 showed binding to proteins in both 
the extracted surface layer proteins and pellet of C. difficile. The mAbs bound strongly to a 
protein around 50 kDa in size, there was no signal displayed for any of the four mAbs with 
the closely related species. Two of the Western blots for Ab521 and Ab652, are shown in 
Figure 4-7, (A) and (B) respectively, and the blots for Ab491 and Ab493 are displayed in the 
Appendices Figure 9-4.  
4.2.6 Binding of the four mAbs to proteins within commensal bacteria that 
are also found within faecal samples 
Western blots were used to determine binding of the mAbs to denatured proteins from two 
C. difficile strains, 630 and R002, and the Gram-positive commensals, S. aureus ATCC 29213 
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and B. subtilis BSB1. Similarly to the previous Western blots, both the surface extracted 
proteins and the residual pellets were used.  
All four mAbs, Ab491, Ab493, Ab521 and Ab652 produced positive signals for both C. difficile 
strains and not against the commensal strains. The Western blots for two of these mAbs, 
Ab521 and Ab652 are shown in Figure 4-8 with the remaining two displayed in the 
Appendices Figure 9-5. 
 
Figure 4-8. Western blots with Ab652 (A) and Ab521 (B) against the low pH glycine surface layer proteins (S) and 
remaining pellet (P) of C. difficile 630 and R002, S. aureus ATCC 29213 and B. subtilis BSB1. 
 
4.3 Discussion 
4.3.1 The C. difficile biomarker is present in the genome 
The gene that contains the bioinformatics predicted unique biomarker, SlpA, is 2157 bp in 
size. Although, the size of this gene varies within other C. difficile strains, for example CD196 
is 2274 bp and R20291 is 2277 bp in length. A smaller region of the gene, 1468 bp in size, 
which contained the biomarker, was selected for amplification as it enabled the consistent 
use of the same primers for all three strains. The genomes for R002 and R050 have not been 
fully sequenced however the SlpA gene was within the NCBI database and consequently, the 
primers were checked against the sequence prior to use. The product from the SlpA gene 
A B 
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was successfully amplified in all three C. difficile strains, 630, R002 and R050 (Figure 4-3). 
The PCR products when run on the agarose gel were all around the expected size. The lack 
of a fully anotated genome sequence within NCBI meant that the bioinformatics workflow 
did not include R002 and R050, therefore, the biomarker had not previously been shown to 
be present in these strains. The SlpA region was sequenced, translated in to an amino acid 
sequence and the biomarker was shown to be present in all three of the C. difficile strains. 
Although there were not a large number of C. difficile strains sequenced, it was important to 
show the presence of the biomarker within the C. difficile genome of some strains used 
within this project. This was especially important in strains R002 and R050 that were 
previously unknown to contain the sequence. The bioinformatics work showed that the 
biomarker was present in all currently sequenced C. difficile strains. Determining the 
presence of the biomarker was the first step in the laboratory workflow.  
4.3.2 Expression of HMW SLP 
Upon SDS-PAGE separation of the surface proteins of C. difficile 630, R002 and R050, the 
resulting image displayed several protein bands of differing sizes (Figure 4-4). It is stated 
throughout the literature that the HMW and LMW SLPs are the predominant surface layer 
proteins, with sizes that differ between strains, the LMW SLP is often around 37 kDa and the 
HMW SLP 50 kDa (O'Brien et al., 2005; de la Riva et al., 2011). However, these protein sizes 
can range from 30-43 kDa for the LMW SLP and 42-56 kDa for the HMW SLP (Cerquetti et 
al., 2000; Calabi et al., 2001; Fagan et al., 2009). The samples for C. difficile R002 and 630 
clearly displayed two prominent bands, both at sizes corresponding to the same samples 
within the literature (Calabi and Fairweather, 2002; Eidhin et al., 2006). R050 on the other 
hand, displayed one dominant band at around 42 kDa, which is at the lower size of the 
HMW SLP range, and several lesser bands including one at the LMW SLP size of R002 and 
630, 37 kDa. An SDS-PAGE gel of R050 could not be found in the literature, however, there 
are ribotypes that display a single, dominant band within their SLPs. Ribotype 167 has been 
shown to have a single dominant band at the HMW SLP and a very faint band at around the 
size of LMW SLP although, experiments to prove that it is the LMW SLP have not been 
performed (Calabi and Fairweather, 2002). There are also ribotypes R005 and R054 that 
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have a dominant HMW SLP however, these strains do not have bands around the LMW SLP 
(Eidhin et al., 2006).  
The SDS-PAGE performed during this research shows that not only are the LMW and HMW 
SLPs present within the surface layer, but there are also other, less prevalent proteins. 
These proteins are from the cell wall protein (CWP) family, which is formed by the 28 SLP 
paralogs that have been identified in C. difficile (Sebaihia et al., 2006). CWP proteins can be 
visible in surface protein extracts on SDS-PAGE gels, and include the adhesion protein 
Cwp66, and the protease Cwp84 which are named after their size, 66 kDa and 84 kDa 
respectively (Waligora et al., 2001; ChapetonMontes et al., 2011). Cwp84 is responsible for 
cleaving the precursor SlpA protein in to the mature LMW and HMW SLPs (Péchiné et al., 
2005; Pantaléon et al., 2015). The Cwps range in size from Cwp 25 which is 33.8 kDa up to 
CwpV, which is the largest of the cell wall proteins and is 167 kDa in size (Fagan et al., 2011). 
The SDS-PAGE results corroborate the microarray data detailed in section 3.3.3.3 and the 
literature, defining that HMW SLP is expressed in C. difficile (Savariau-Lacomme, 2003; 
Fagan and Fairweather, 2011). 
4.3.3 Production of mouse mAbs  
Eight mouse mAbs were produced against the C. difficile biomarker and closely surrounding 
sequence, using epitopes of ten amino acids in length. From the eight mAbs there were two, 
Ab491 and Ab493 that had epitopes which were not fully conserved within the biomarker 
(Table 4-2). Whilst it was realised that the specificity of these peptides may not be retained, 
these mAbs were kept and used for an exploratory exercise.  Further analysis of the two 
mAbs was required as it was still possible that they could bind to the epitope region 
conserved within the biomarker and, if not, they served to inform about the design criteria 
for future applications of this technique. It was hypothesised that these mAbs would not 
bind as successfully and specifically as the mAbs that had epitopes that were fully conserved 
within the biomarker.  
4.3.4 Binding of mAbs to the native SLPs of C. difficile 
Dot blots were used to ascertain if the mAbs bound to the C. difficile surface layer proteins. 
However, dot blots do not convey information about the size of the biomolecule to which 
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the mAbs bind to, nor about the specificity of antibody binding to individual proteins. 
Therefore this technique was used as an indicator for the successful antibody recognition of 
C. difficile proteins.  
The results from the dot blots displayed four mAbs that successfully recognised and bound 
to C. difficile proteins and not to C. sordellii. Within these four mAbs there was Ab491 and 
Ab493 which have epitopes that are not fully conserved within the biomarker and Ab521 
and Ab652 which do (Figure 4-5). The remaining four mAbs, Ab370, Ab498, AbB31 and 
AbB84 did not display clear binding to C. difficile and were therefore disregarded from 
further experiments (Figure 4-6). The unsuccessful dot blots demonstrated the need for 
positive controls, which showed that the technique was successfully working and the lack of 
binding was not due to error within the experiment. Perhaps the reason for the lack of 
binding was due to the dot blots being performed on proteins in their native state whereas, 
the mAbs were produced against linear epitopes. Consequently, the mAbs may not fit the 
conformational structure of the protein thus binding cannot occur. For a PoN sensor to be 
as rapid and as easy to use as possible, it is important that the mAbs bind to the native 
C. difficile proteins. This native binding would perhaps enable detection without the need 
for pre-treatment of samples. 
The four positive mAbs showed binding to both the surface extracted proteins and the 
residual bacterial pellet. Since HMW SLP is one of the most abundant C. difficile proteins, it 
is likely that some of this protein is retained by the cell pellet, post low-pH glycine 
extraction, providing the mAb its epitope.   
4.3.5 Binding of mAbs to the HMW SLP and not to species related to 
C. difficile 
Within this chapter, there were two closely related species that were used for the 
laboratory analysis of the mAbs. These species were P. anaerobius, chosen due to its 
similarity to the SlpA protein, and C. sordellii which shows some similarity to the biomarker.  
Western blots were used to determine mAb binding to denatured proteins in C. difficile and 
closely related strains. SDS-PAGE gels were run concomitantly to the Westerns so that the 
size of the protein to which the mAb binds to, could be established. Unlike dot blots, 
Western blots can be used with a molecular marker to ascertain the size of the antigen. The 
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SDS-PAGE gels also provided information about the loading of the samples, showing that the 
low pH glycine, surface protein extraction, provided proteins in the supernatant for 
C. difficile but not for C. sordellii and only a small amount for P. anaerobius. This lack of 
protein is evidence for using the cell pellet as well as the extracted proteins, allowing the 
mAbs to be tested for non-specific binding to the majority of proteins within the cell. It is 
unknown if C. sordellii has an S-layer however, Couchman and co-workers predict that 
C. sordellii does (Couchman et al., 2015). Since there is no clear evidence that C. sordellii has 
an S-layer, there is also no extraction method or evidence that the low pH glycine method 
would provide proteins. P. anaerobius on the other hand, has a defined S-layer and is likely 
to be the proteins that were successfully extracted with the low pH glycine method 
(Kotiranta et al., 1995; Bradshaw et al., 2014).  
All four Western blots, the two shown within this chapter and the two within the 
Appendices, demonstrate that the four mAbs bind to C. difficile at a protein size 
corresponding to the HMW SLP, around 50 kDa (Figure 4-7). As well as the C. difficile 
binding, all four of the mAbs show no binding to the closely related strains. 
When analysed using the ExPASy compute pI/Mw tool (Gasteiger et al., 2003) the amino 
acid sequence for the HMW SLP of C. difficile 630 was calculated to be 39.45 kDa. This 
weight is considerably lower than what the protein migrates to on the SDS-PAGE gel, at 
around 50 kDa. This difference in size has been noted in the literature and other studies 
suggesting that it is due to aberrant migration of the protein within the gels (Calabi et al., 
2001). Qazi and colleagues showed that although the HMW SLP runs at a larger size on SDS-
PAGE gels, the actual mass, determined using mass spectrometry, was the same as 
predicted with ExPASy (Qazi et al., 2009).  
4.3.6 Specificity of mAbs to denatured C. difficile proteins 
The four mAbs successfully bound to the two C. difficile strains, 630 and R002 at a band 
corresponding to the HMW SLP and to some smaller proteins that may have been produced 
from degradation of the HMW SLP (Figure 4-8). Additionally, all four mAbs did not bind to 
S. aureus or B. subtilis, which are in the same phylum as Clostridium. S. aureus was chosen 
for testing as it is a common commensal bacterium and also a facultative human pathogen 
that can be found in human faeces (Bhalla et al., 2007; Ibarra et al., 2013; Kim et al., 2015). 
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Although B. subtilis was traditionally viewed as a soil microbe it has also been shown to 
reside in the gastrointestinal tract (Hong et al., 2009) and was therefore also tested for mAb 
binding. None of the four mAbs bound to either S. aureus or B. subtilis and although many 
more bacterial species would need to be tested for non-specific binding, it is promising 
start. For use in PoN sensors, it is vital that the mAbs detect C. difficile only as non-specific 
binding would cause false positives which, could lead to misdiagnosis and mistreatment. 
Ideally, groups of bacteria that would be tested for non-specific binding with the C. difficile 
mAbs would be those that reside in the gastrointestinal tract, those often found in faeces 
and those associated with diarrhoea. However, due to time constraints, this project 
focussed on the three strains closely related to C. difficile. The closely related strains have 
the most similar sequences and proteins to C. difficile. Therefore, if the antibodies do not 
bind to these strains, then they are less likely to bind to more distantly related species, with 
less similar sequences and proteins. 
Since the four mAbs, Ab491, Ab493, Ab521 and Ab652 all bound to the HMW SLP and did 
not bind to any of the four non C. difficile species, they were progressed to the next stage of 
binding analysis. Furthermore, the intellectual property (IP) rights and cell lines for these 
promising mAbs were purchased from AbMART, enabling production of the mAbs to be 
performed in house. 
4.4 Summary 
The C. difficile biomarker was shown to be present within three, tested, C. difficile genomes, 
verifying what was seen in the predictions from the bioinformatics work. Eight mAbs were 
produced spanning the biomarker and from these eight, four were found to bind to the 
native C. difficile proteins within dot blots and the denatured C. difficile HMW SLP. The four 
mAbs did not bind to native C. sordellii proteins nor did they bind to denatured proteins 
from the closely related strains, C. sordellii and P. anaerobius. Additionally, these Abs did 
not bind to the common bacteria S. aureus or B. subtilis. The four putatively specific mAbs 
were, Ab491, Ab493, Ab521 and Ab652 and the IP rights and cell lines that produce these 
mAbs were purchased from AbMART. The remaining four mAbs were disregarded since 
their potential for use in a PoN sensor to detect C. difficile is low.   
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Chapter 5 Characterisation of the relative binding efficiency of 
Ab491, Ab493, Ab521 and Ab652 
5.1 Introduction 
5.1.1 The binding affinities of monoclonal antibodies 
As described in Chapter 4.1.5, antibodies bind to antigens through transient, non-covalent 
interactions. The strength of this binding is termed the binding affinity and the tighter the 
complementary fit of the antibody/antigen complex, the stronger the interaction (Elgert, 
2009). The antibody binding affinity is determined by the equilibrium dissociation constant 
(Kd) and provides a measure for the proportion of unbound antibody and antigen when at 
equilibrium (Laguna et al., 2015). The Kd is expressed in molar units of concentration (M) of 
the free antibody and antigen. The lower the Kd, the fewer dissociated antibody and antigen  
molecules there are and thus, more antibody/antigen complexes are present, indicating a 
stronger binding affinity of the antibody (Craig et al., 2010).  
A. 𝐴𝐴𝐴𝐴 + 𝐴𝐴𝐴𝐴 ⇄ 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 
B. 𝐾𝐾𝐾𝐾 = [𝐴𝐴𝐴𝐴][𝐴𝐴𝐴𝐴][𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴]  
Equation 5-1. The reversible reaction of the bound antibody/antigen (AbAg) complex forming from the individual 
antibody (Ab) and antigen (Ag) molecules (A). The calculation of the Kd, the ratio of the concentration of unbound 
antibody and Ag, and the concentration of the AbAg complex (B). 
 
Several methods can be used to determine the Kd of mAb interactions. One such method is 
isothermal titration calorimetry (ITC), a label-free method to measure the dissipated or 
absorbed heat of a reaction (Jerabek-Willemsen et al., 2011). Using ITC, both enthalpic and 
entropic binders can be differentiated, with the Kd and number of binding sites per 
molecule being obtained (Liang, 2008). However, in order to get a quantifiable reaction, ITC 
requires a high concentration of sample at a minimum of 1 mg/ml. Furthermore, 
interactions with a small enthalpy change cannot be measured with ITC (Jerabek-Willemsen 
et al., 2011). This high-sample consumption and inability to measure small changes are 
limitations of ITC. Another method that can be used to determine molecular interactions is 
surface plasmon resonance (SPR). SPR is a label-free technique that measures changes in 
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binding-induced refractive index. Unfortunately, this method requires the immobilisation of 
one of the sample components to the surface of the SPR chip, which is a time consuming 
process (Sundberg et al., 2007).  
5.1.2 Microscale thermophoresis 
Thermophoresis is the directed movement of molecules induced by temperature gradients 
(Wienken et al., 2010). Microscale thermophoresis (MST) uses this thermophoretic principle 
to characterise the formation of small molecule complexes in solution. During MST analysis, 
one of the samples is labelled with a fluorophore and the movement of this molecule is 
measured using a charge-coupled device camera (Zillner et al., 2012). An overview of how 
the molecular movement is measured is provided in Figure 5-1, which was kindly provided 
by NanoTemper24. The ‘initial state’ of the baseline fluorescence is measured so that 
homogenous distribution of the labelled molecules can be monitored. An infra-red (IR) laser 
is then applied to a focused heating area, causing a temperature jump (T-jump) and the 
molecules typically migrate to a cooler temperature. A steady-state is reached when the 
movement away from the T-jump is counterbalanced by mass diffusion – the spread of 
molecules in a solution (Seidel et al., 2013). In constant buffer conditions, the 
thermophoresis of the antibody complex with the fluorescently labelled antigen differs 
compared to the antigen alone. This change in thermophoresis is caused by the alteration in 
size, charge and solvation entropy of the molecules (Jerabek-Willemsena et al., 2014). When 
the IR laser is switched off, an inverse T-jump occurs along with back diffusion of the 
fluorescent molecules (Entzian and Schubert, 2015).   
                                                     
24 http://www.nanotemper-technologies.com/  
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Figure 5-1. MST measurement of a fluorescently labelled molecule interacting with another molecule, provided by 
NanoTemper. The initial state of the baseline fluorescence is measured prior to the IR laser being turned on. The IR laser 
is applied and a focussed area is heated, causing a T-jump from which molecules generally diffuse. A steady state is 
achieved when the movement of molecules away from the T-jump is counterbalanced by mass diffusion. The IR laser is 
then turned off causing an inverse T-jump and the molecules diffuse back across the cooler temperature. 
 
MST has several advantages over more traditional methods for determining binding 
interactions. Firstly, unlike SPR, MST is immobilisation-free, with a simple protocol that 
reduces the preparation time of samples. Secondly, MST is performed in micrometre-sized 
capillaries. Unlike ITC, only a small concentration of sample is required, often in the 
nanomolar range (Wienken et al., 2010; Liu et al., 2015b). Thirdly, MST measures molecule 
movement optically and is entirely contact-free, minimising possible contamination of the 
sample. Finally, MST is rapid, with measurements and associated Kd calculated within 
approximately 15 minutes (Wienken et al., 2010; Entzian and Schubert, 2015). In 
consideration of the rapidity of testing and minimal sample consumption, MST was used to 
determine the Kd of the mAbs within this project. 
5.1.3 ELISA 
The ELISA technique was invented in 1971 by Eva Engvall and Peter Perlmann (Engvall and 
Perlmann, 1971). An ELISA measures the concentration of an analyte, in its native form, via 
the binding of an antibody. If equal concentrations of analyte are used, then the relative 
rate of antibody binding can be quantified (Ozdemir et al., 2013). ELISAs are often used for 
 110 
 
the analysis of antibody binding. With regards to C. difficile, the majority of Abs analysed 
bind to the toxins (Fraser and Swiencicki, 2013), however, ELISAs have been used with other 
C. difficile antigens. Kandalaft and colleagues used ELISA to determine llama antibody 
binding to the SLPs of whole C. difficile cells. Rather than for use in diagnostics, these llama 
Abs were shown to inhibit C. difficile motility and were hypothesised to be possibly of 
therapeutic value (Kandalaft et al., 2015). Research by Merrigan and co-workers also 
provided evidence that SLP Abs could be used therapeutically, by showing that these Abs 
reduced C. difficile attachment to the host (Merrigan et al., 2013).  
There are several types of ELISA – direct, indirect, sandwich and competitive – with each 
having a slightly different format (Gan and Patel, 2013). Throughout this project the indirect 
ELISA method was performed. The antigen was bound directly onto the surface of the ELISA 
plate, with the primary antibody of interest then being then bound to the antigen and then 
finally an enzyme-conjugated secondary antibody bound to the primary Ab.   
5.1.4 Isotyping and purification of mAbs 
Abs can have multiple variants of both the light and heavy chains. The phenotypic deviations 
in the constant regions of the heavy chains define the Ig isotype, causing differing functions 
and antigen responses (Abbas and Lichtman, 2004). As also observed in humans, there are 
also five mouse antibody isotypes: IgA, IgD, IgE, IgG, and IgM. IgG also has five subclasses: 
IgG1, IgG2a, IgG2b, IgG2c, IgG3 (Michaelsen et al., 2004; Johnson, 2013). Abs are often 
purified using an affinity chromatography method that utilises proteins that bind to specific 
Igs. These proteins are crosslinked to agarose beads and used within a flow through column. 
When the cell culture media, in which the Abs are produced, is washed through the column, 
the Abs form a complex with the proteins attached to the agarose beads (Sugiura et al., 
2000). The non-covalent interactions binding the antibody and protein are then disrupted 
with extreme pH, eluting the mAbs from the agarose beads (Janeway et al., 2001). There are 
two main proteins that are used in immunoprecipitation, Protein A and Protein G. Protein A 
is a cell wall protein from Staphylococcus aureus (Graille et al., 2000) and Protein G, a cell 
wall protein isolated from Group G streptococci (Sjöbring et al., 1991). Both proteins bind 
mammalian IgGs via their fragment crystallisable (Fc) regions however, protein G binds at 
greater avidity than protein A (Akerstrom et al., 1985). 
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5.1.5 The C. difficile SLT clades 
As described in section 3.3.4 all currently sequenced C. difficile strains can be grouped into 
13 SLT clades. Dr Kate Dingle not only provided the sequences of the 13 SLTS for the 
bioinformatics work but also kindly donated the corresponding strains for use within the 
laboratory experiments. A 14th SLTS was also sent, Ox2404, which resides in SLT clade 2, 
along with Ox858. Although the SlpA sequences of the two strains were the same, there 
were differences in other SLPs. Ox2404 lacks Cwp10 and Ox858 lacks the 5' Cwp84, both of 
which are cell wall proteins and therefore may influence binding of the mAbs. Furthermore, 
Cwp84 is the protease that cleaves SlpA into the mature LMW and HMW SLPs (Pantaléon et 
al., 2015) and consequently any alterations to this protein may directly affect the structure 
of the HMW SLP and thus mAb binding. For these reasons, all 14 SLTS were used throughout 
the cell mAb binding analysis.  
 
5.2 Results 
5.2.1 Relative binding of the four mAbs 
Direct ELISAs were performed with whole cells of C. difficile R002 and R050, clinical isolates 
118497G, 128703G, 994535 and the reference strain 630. The closely related strains, 
C. sordellii ATCC 9714 and P. anaerobius VPI 4330 were also used as negative controls. The 
cells were incubated in duplicate with Ab491, Ab493, Ab521 or Ab6521 and the protocol 
was followed as in methods section 2.16. The ELISA results show that the two closely related 
species, P. anaerobius and C. sordellii provided very low absorbance readings for Ab491, 
Ab521 and Ab652 (Figure 5-2). The low absorbance readings indicate that there was little 
binding to these species. When incubated with P. anaerobius, Ab521 had the lowest 
absorbance reading with Ab652 and Ab491 displaying slightly higher values. Ab493 on the 
other hand, bound to P. anaerobius at 0.13, a rate that was double that observed with the 
other three mAbs, Ab652 being the highest at 0.50. This measurement was greater than the 
absorbance of Ab493 against four out of the six C. difficile strains, 630 – 0.09, R050 – 0.08, 
118497G – 0.09, and 994535 – 0.02.  
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Upon incubation with C. sordellii, Ab521 and Ab652 gave the highest absorbance values of 
the four mAbs, however, there is a clear increase in absorbance when incubated with 
C. difficile. Ab521 produces an absorbance value of 0.02 with C. sordellii and 0.26-0.64 when 
incubated with C. difficile and Ab652 0.05 with C. sordellii and 0.23-0.46 with C. difficile. The 
difference in absorbance between the C. difficile and closely related strains was, depending 
on the strain, four to eight times greater for Ab652 and eight to twenty-one times greater 
for Ab521. 
Within the C. difficile strains, Ab521 and Ab652 had the greatest absorbance values. Ab521 
gave the highest C. difficile absorbance values, with the exception of strain 630 where 
Ab652 was greater. For five of the six C. difficile strains, R002, R050, 630, 118497 and 
128703G, Ab491 and Ab493 displayed absorbance measurements that were less than half of 
those seen with Ab521.  
 
 
Figure 5-2. Absorbance readings from an ELISA of antibodies Ab491, Ab493, Ab521 and Ab652 binding to whole cells of 
C. difficile (C. diff) R002, R050. 630, 118497G, 128703G and 994535, and closely related species P. anaerobius VPI 4330 
and C. sordellii ATCC 9714. The error bars show the standard deviation of the two replicates for each sample. 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
A 4
50
nm
C. difficile and closely related strains - whole cells
Ab652
Ab521
Ab493
Ab491
 113 
 
 
These ELISA results show that Ab521 and Ab652 bind with better efficiency and more 
specificity to C. difficile than Ab491 and Ab493. Due to these ELISA results, Ab491 and Ab493 
were disregarded and the remainder of the project was performed focussing on the two 
more promising mAbs, Ab521 and Ab652. 
5.2.2 Production, purification and isotyping of the mAbs 
The isotypes of the mAbs were determined, IgG2b for Ab521 and IgG1 for Ab652. The mAbs 
were purified from the cell culture supernatant, around 3 ml of each mAb was purified at 
concentrations of 2.45 mg/ml for Ab521 and 0.27 mg/ml for Ab652. An example of the 
chromatograph produced with the ÄKTA and Unicorn start software is provided in Figure 5-3 
A and an SDS-PAGE gel of Ab521 and Ab652 is shown in Figure 5-3 B. The gel displays 
protein bands for both mAbs at around 55 kDa and 25 kDa, which approximately equate to 
the heavy and light chains of the antibodies, respectively.  
 
Figure 5-3. Chromatograph from the purification of Ab521 from cell culture media using a protein G agarose column on 
the ÄKTA Start chromatography system (A). The low pH elution buffer is added at elution fraction 1, eluting the antibody 
from the protein G column, as represented by the peak in the UV absorbance (blue line). The elution fractions that are 
predicted to contain antibody were separated on an SDS-PAGE gel to determine the presence and purity of antibody (B). 
Both Ab521 and Ab652 were separated on the reducing gel and show protein bands at around 55 kDa and 25 kDa.   
 
5.2.3 Production of recombinant C. difficile 630 LMW SLP 
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E. coli Rosetta pLMW1-262-1 which was provided by Professor Neil Fairweather25, was 
cultured and the recombinant protein was determined to be in the soluble fraction. Large 
quantities of bacteria were grown and the media was purified using immobilised metal 
affinity chromatography with a nickel column Figure 5-4. This plasmid produces a stable, 
truncated LMW SLP that is 262 amino acids in length and has a molecular weight of 28 kDa. 
As seen with the native HMW and LMW SLPs, the recombinant LMW SLP runs aberrantly on 
SDS-PAGE gels with an apparent molecular weight of 33 kDa.   
 
Figure 5-4. SDS-PAGE gel (10%) of the fractions from the nickel column purification of the recombinant C. difficile 630 
LMW SLP. All fractions were in 25 mM Tris/HCl, 200 mM NaCl, pH 7.5 buffer and the stated imidazole concentration. The 
LMW SLP eluted from the column with 50 mM imidazole and separated on the gel at around between 25 and 35 kDa. 
 
5.2.4 Specificity of the mAbs to the HMW SLP from the 14 SLTS 
As shown in Figure 5-5, Ab521 (5 μg/ml) bound specifically to the HMW SLP of all eight SLTS, 
and did not bind to either naturally occurring or the recombinant LMW SLP. There were 
however, some double bands within these Western blots, corresponding approximately to 
the molecular weight of the HMW SLP (Figure 5-5). The SLTS Ox1145 had a clear double 
band whereas, Ox575 and Ox2404 displayed fainter double bands. The extra Ox1145 band 
could also be seen on the SDS-PAGE gel, therefore, the band contained enough protein to 
                                                     
25 Department of Life Sciences, Imperial College London 
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be detected by the coomassie stain. The molecular weight of the additional band was 
marginally lower than that of the HMW SLP and therefore could be indicative of degradation 
of this protein.  
 
Figure 5-5. SDS-PAGE gel 10 % and corresponding Western blot using Ab521, 5 µg/ml. The samples separated on the gel 
were the low pH extracted surface layer proteins of eight C. difficile S-Layer type strains and the recombinant C. difficile 
630 LMW SLP. The Ab521 binds specifically to the HMW SLP from all SLTS. 
 
Ab652 (5 µg/ml) also bound specifically to the HMW SLP within the extracted surface layer 
proteins, and did not bind to any of the LMW SLPs (Figure 5-6). As seen for Ab521, there 
were also some double bands visible for strains Ox1145, Ox575 and Ox2404 within the 
Ab652 Western blot.  
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Figure 5-6. SDS-PAGE gel 10 % and corresponding Western blot using Ab652, 5 µg/ml. The samples separated on the gel 
were the low pH extracted surface layer proteins of eight C. difficile S-Layer type strains and the recombinant C. difficile 
630 LMW SLP. The Ab521 binds specifically to the HMW SLP from all SLTS. 
 
Rather than test the mAbs against the SLPs of the remaining six SLTS, the whole cell lysates 
for all fourteen SLTS were tested for mAb binding. These results would not only determine 
binding to the HMW SLP in all fourteen SLTS, but they would also provide evidence that the 
mAbs do not non-specifically bind to proteins present within whole cell lysates. 
5.2.5 Specificity of Ab521 and Ab652 to proteins within whole cell lysates  
It was important to test the mAbs against as many proteins as possible from the closely 
related strains. For this reason, whole cell lysates were used as the samples within Western 
blots. C. hiranonis DSM-13275, which displays reasonably high similarity to the SlpA protein 
and to the biomarker, was included as one of the closely related strains. Also used were 
C. sordellii ATCC 9714 and P. anaerobius VPI 4330, along with whole cell lysates from all 
fourteen SLTS. The Western blots were used to test for binding with both Ab521 and Ab652. 
As shown in Figure 5-7, Ab521 at 5 μg/ml binds to the HMW SLP within all fourteen SLTS and 
not to any proteins within the closely related strains. Furthermore, the positive binding 
occurs in one clear band, demonstrating the specificity to the HMW SLP and that the 
previous Western blot (Figure 5-5) may have shown some degradation of the HMW SLP.  
 117 
 
 
Figure 5-7. Western blots and the corresponding SDS-PAGE gels using Ab521 at 5 µg/ml against the whole cell extracts of 
all 14 C. difficile SLTS and the closely related strains, C. hiranonis DSM-13275, C. sordellii ATCC 9714 and P. anaerobius 
VPI 4330. Ab521 binds to the HMW SLP in all C. difficile SLTS and does not bind to proteins in the whole cell lysates of 
the closely related strains. 
 
As seen with Ab521, Ab652 also binds specifically to the fourteen SLTS, with one clear band, 
and does not show binding to the closely related strains (Figure 5-8). The results for the 
Western blot against Ox160 – Ox1424 was performed with 5 µg/ml Ab652, which showed 
clear binding but not as strong as seen with Ab521, although binding was not quantified. 
Therefore, to verify that non-specific binding to the closely related strains was not 
occurring, the Western blot with these strains was performed with Ab652 at a higher 
concentration of 10 µg/ml.  
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Figure 5-8. Western blots and the corresponding SDS-PAGE gels using Ab652 at 5 µg/ml (top) and 10 µg/ml (bottom) 
against the whole cell extracts of all 14 C. difficile SLTS and the closely related strains, C. hiranonis DSM-13275, 
C. sordellii ATCC 9714 and P. anaerobius VPI 4330. Ab652 binds to the HMW SLP in all C. difficile SLTS and does not bind 
to proteins in the whole cell lysates of the closely related strains. 
 
5.2.6 MST analysis of Ab521 and Ab652 binding to the HMW/LMW complex  
The normalised fluorescence (FNorm) is a ratio of the ‘steady state’ fluorescence after 
thermodiffusion (F1) divided by the ‘initial state’ (Figure 5-1) of fluorescence before laser 
heating (F0) (Equation 5-2). If there is binding of the unlabelled and labelled proteins then 
the FNorm creates a binding curve, which displays the unbound molecules and an increase in 
FNorm for the bound molecules. 
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𝐹𝐹𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 = 𝐹𝐹1𝐹𝐹0 
Equation 5-2. The equation used to determine normalised fluorescence (FNorm) from microscale thermophoresis data. 
FNorm is the ratio of the fluorescence after thermodiffusion (F1) divided by the initial fluorescence before laser heating 
(F0). 
 
The binding curve created with the MST measurements of Ab521 interacting with the 
C. difficile 630 HMW/LMW SLP complex (black diamonds Figure 5-9), shows the typical 
sigmoidal curve that is created when binding between molecules occurs (Jerabek-
Willemsena et al., 2014). The unbound HMW/LMW complex at the lower Ab521 
concentrations provides an ‘unbound’ reading of around FNorm [‰] 808 units. As the 
antibody concentration increases so too did the amount of complex bound with Ab521, 
reaching a maximum fluorescence value that plateaus and provided a ‘bound’ reading of 
around FNorm [‰] 832 units. A Kd of 5.21±0.917 nM was calculated from the sigmoidal 
binding curve using the NanoTemper analysis software. .  
The blue triangular markers display the thermophoretic movement of the control, the 
HMW/LMW SLP complex with only PBS with 0.05 % TWEEN and no antibody (Figure 5-9). 
Within all 16 control measurements, the fluorescence readings all remain within the 
‘unbound’ value range. These readings show that the binding curve produced by the 
interaction of the HMW/LMW complex and Ab521 is not an artifact of usual thermophoretic 
movement of the complex alone. 
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Figure 5-9. Binding curve produced by microscale thermophoresis analysis of the fluorescently labelled HMW/LMW 
complex interacting with either PBS with 0.05 % TWEEN (Blue triangles) or increasing concentrations of Ab521 (black 
diamonds). FNORM is the normalised fluorescence  
 
The MST testing of the HMW/LMW SLP complex and Ab652 yielded no significant binding 
results and a Kd was not attained. Perhaps further optimisation of the experimental 
conditions could enable clear interactions between the SLP complex and Ab652. However, 
due to time constraints, it was not possible to perform these optimisation steps within this 
project. 
5.3 Discussion 
5.3.1 Ab521 and Ab652 are the most promising of the four mAbs 
The absorbance values from the whole cell ELISA (Figure 5-2), are directly proportional to 
the amount of primary antibody bound to the whole cell antigens. For PoN sensors it is 
important that the antibodies bind to the organism of interest, with high affinity, allowing 
rapid and clear detection (Ahmed et al., 2014). Weak binding may not clearly identify 
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bacteria from complex samples, such as faecal samples tested for CDI. Thus, the results 
show that due to their stronger binding, Ab521 and Ab652 are the most promising of the 
four mAbs for C. difficile detection. Furthermore, both of these mAbs show very little 
binding to the closely related species, C. sordellii ATCC 9714 and P. anaerobius VPI 4330 – up 
to 21 times less – when compared to the C. difficile strains. Thus, Ab521 and Ab652 would 
be highly unlikely to cause false positives by interacting with these two organisms (Owen, 
2003). In contrast, Ab493 bound to P. anaerobius with greater efficiency than to four out of 
the six tested C. difficile strains. Therefore, accurate diagnosis would not be possible, as this 
binding would produce false positives, at least to this species, within a diagnostic sensor 
setting. The low rate of Ab493 binding to the C. difficile strains also limits the use of this 
molecule within a PoN sensor. Ab493 would be unlikely to detect C. difficile strains with 
similarity to R050, 630, 118497G and 994535, causing any sensor to have poor sensitivity. 
Although slightly higher than Ab493, poor binding to the C. difficile strains was also 
displayed with Ab491. This lack of binding is evidence that neither Ab491 nor Ab493 would 
be useful for use as detection molecules within PoN sensors. 
One possible reason for the difference in mAb binding could be due to the 10 amino acid 
epitope against which they were produced. Ab521 and Ab652 displayed elevated binding, 
and both have epitopes that are 100 % conserved within the predicted C. difficile biomarker. 
Whereas, the epitopes for Ab491 and Ab493 are only partially found within the unique 
biomarker (Table 5-1).  
Table 5-1. The antibody ID and corresponding epitope to which the mAb was produced. The region found within the 
predicted C. difficile biomarker is highlighted. 
Antibody ID Epitope sequence (biomarker highlighted) 
Ab491 FVAKDGSTKE    
Ab493 VDALAAAPIA     
Ab521 STKEDQLVDA     
Ab652 KEDQLVDALA     
 
Only the regions that are fully conserved within the biomarker are predicted to be unique 
and surface exposed. Therefore, regions of the Ab491 and Ab493 epitopes that are not 
located within the biomarker may not be fully surface accessible, causing the lower rate of 
antibody binding. The Jalview hydrophobicity view of the sequences, within the 
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bioinformatics results (Figure 3-11) show that the ten amino acid epitope for Ab493 has only 
two amino acids that are hydrophilic: D and P. Consequently, the epitope may not be 
completely exposed on the surface of the HMW SLP and could be the reason for the low 
antibody binding to the C. difficile strains. The epitope for Ab491 on the other hand has 
seven amino acids that are hydrophilic, which could explain the stronger binding to 
C. difficile than Ab493. Although the number of hydrophilic residues could indicate surface 
exposure of the epitope, Ab521 has seven hydrophilic residues and Ab652 has less, yet both 
mAbs have much greater binding efficiency than Ab493. Therefore, the hydrophilic nature of 
the amino acids is not the only factor in antibody binding to its antigen. The lower binding 
efficiency of Ab491 could perhaps be due to the inability of Ab491 to bind completely to the 
native protein. 
The regions outside of the biomarker may not be unique to C. difficile and could cause cross-
reactivity of the mAbs with other organisms. A BLASTP search of the Ab493 epitope 
identified that eight from the ten amino acid sequence are located within a surface protein 
of P. anaerobius (Figure 5-10). Therefore, it is possible that Ab493 recognised this sequence 
within P. anaerobius, causing the non-specific binding. The BLASTP results for Ab491, Ab521 
and Ab652 epitopes did not identify sequences with a high percentage identity within 
P. anaerobius, data shown in the Appendices section 9.8. This lack of sequence identity was 
predicted, as there was little binding of the three mAbs to P. anaerobius. 
 
Figure 5-10. Most similar BLASTP result of the Ab493 epitope 'VDALAAAPIA' searched within P. anaerobius. Eight out of 
the ten amino acids are matched to a surface protein within the organism. 
 
5.3.2 Purification of Ab521 and Ab652 
The cell lines for two of the mAbs, Ab521 and Ab652, were grown in large quantity and cell 
death was permitted to produce antibody. Upon isotyping, Ab521 was found to be IgG2b 
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and Ab652 was IgG1. Since Protein A has extremely poor reactivity with mouse IgG1 
(Kronvall et al., 1970), Protein G was chosen as the affinity chromatography protein. For 
both Ab521 and Ab652, 260 ml of culture supernatant was purified, producing 3 ml at 
2.45 mg/ml and 0.27 mg/ml respectively. Therefore, the minimum starting concentration of 
the mAbs within the hybridoma supernatant was 28 µg/ml for Ab521 and 3 µg/ml for 
Ab652, which are within the expected range of 1-60 µg/ml (Pandey, 2010). 
5.3.3 Specific binding of the mAbs to HMW SLP in all 14 SLTS 
For the initial Western blots within this chapter, the extracted SLPs of the SLTS were used as 
the protein samples, with both mAbs displaying binding to more than one band on some of 
the strains. The same protein samples were used in the Western blots for both mAbs, 
therefore, it seems likely that the extra bands were due to HMW SLP degradation rather 
than non-specificity of the mAbs. The Western blots performed with whole cell lysates were 
immediately loaded onto an SDS-PAGE gel, to reduce the likelihood of any degradation. 
Within these Western blots, both Ab521 and Ab652 bound to a single band at the 
corresponding HMW SLP size for all fourteen SLTS. This binding showed specificity to the 
HMW SLP and consequently established that the previous double bands were due to 
degradation. 
The SDS-PAGE gels for the extracted C. difficile SLPs and the whole cell lysates all displayed 
the HMW and LMW SLP, apart from Ox1523, which only had a single predominant band 
consistent with the HMW SLP. As described in section 6.3.2, C. difficile strains, such as 
ribotype 167, have been shown in the literature to contain a single dominant band (Calabi 
and Fairweather, 2002). To determine their similarity, the R167 SlpA sequence was taken 
from NCBI and aligned with the SlpA sequence for Ox1523. Only 2 out of 610 amino acids 
were different so, R167 belongs to SLT clade 11 along with Ox1523, with this similarity 
displaying that the single dominant band was not an anomaly. Whilst Kate Dingle and 
colleagues were creating the SLT clades they determined that R050 also belongs within SLT 
clade 11 (Dingle et al., 2013). As seen with Ox1523 and R167, R050 also displayed a single 
dominant band, shown in the SDS-PAGE gel within Figure 4-4. 
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Using the sequences from the full C. difficile genome, the biomarker was shown to be 
unique to the HMW SLP and not present within any other C. difficile proteins. As predicted 
the mAbs produced against this biomarker bound solely to the HMW SLP. The mAbs did not 
bind to the 28 SlpA paralogs that are present within C. difficile (Sebaihia et al., 2006) 
showing specificity to the HMW SLP even when compared to closely related C. difficile 
proteins. These proteins were denatured and so the Western blots do not provide evidence 
for HMW SLP specificity with native C. difficile proteins.  
For the whole cell Western blots with SLTS Ox160 to Ox1424, both mAbs were used at 
5 µg/ml. The signal for Ab652 appears weaker compared to Ab521 however, the signals 
were not quantified because more accurately quantifiable tests will be used to determine 
relative binding affinities in chapter 8. When the Ab652 concentration was increased to 
10 µg/ml for the whole cell Western blot of Ox1437a to Ox2404 and the control strains, the 
signal seemed to be similar to that seen in the same Western blot for Ab521 used at a  
concentration of 5 µg/ml. This concentration difference indicates that Ab521 may have a 
better binding efficiency than Ab652, however, further experimental work was performed in 
chapter 8 to determine if this was correct. 
All of the C. difficile strains, which have currently had their genome sequenced, fall within 
one of the 13 SLT clades, therefore, the SLTS represent the entire C. difficile species. Both 
Ab521 and Ab652 bind to all of the SLTS, indicating that the mAbs would bind to the 
denatured HMW SLP of any C. difficile strain. This detection of all strains within the species 
is pivotal in preventing false negatives within a PoN sensor. The next step was to determine 
whether Ab521 and Ab652 could detect strains from all of the native SLTS. The lack of 
binding to the closely related strains, as shown by the mAbs, is also vital, as it will help 
prevent false positives in a PoN sensor. There were three closely related strains tested for 
mAb binding, P. anaerobius, C. sordellii and C. hiranonis. Therefore, further specificity 
testing of Ab521 and Ab652, with more bacterial species is required. To investigate the mAb 
specificity fully, testing of C. difficile and other species was performed under native 
conditions.  
5.3.4 Ab521 displays a high binding affinity with the HMW/LMW SLP 
complex 
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Attempts were made to produce recombinant HMW SLP, as this could be used directly 
within MST, however, these attempts were unsuccessful. Upon discussion with Dr Paula 
Salgado26, an expert on the C. difficile S-Layer, it was recognised that the HMW SLP is 
unstable and recombinant production achieved only a minimal amount of the protein. In 
contrast, when the HMW SLP forms the native HMW/LMW SLP complex, it is stable and can 
be isolated directly from C. difficile cells, in a quantity sufficient for MST analysis (Fagan et 
al., 2009). Therefore, the HMW/LMW complex was used for mAb binding analysis, with the 
protein complex being fluorescently labelled and the mAb titrated against it.  
The MST analysis of Ab521 interacting with the HMW/LMW complex provided a binding 
curve, from which the binding affinity was determined to be 5.21±0.917 nM. In general 
terms, antibodies with a Kd less than 1 µM have high affinity (Laguna et al., 2015), therefore, 
Ab521 is likely to have a very strong affinity to the HMW/LMW SLP complex. Optimisation of 
the experiment may provide improved ‘unbound’ measurements that show less fluctuation 
than seen within these results. Further optimisation may too provide readings that fit closer 
to the binding curve and therefore, provide a Kd with increased accuracy. Optimisation 
could include, the buffer used, agents used to prevent non-specific binding and the 
cappillaries used.  
Unfortunately, the MST yielded no significant results with Ab652. One of the issues with 
using Ab652 is the low concentration in comparison to Ab521, 0.21 mg/ml and 2.41mg/ml 
respectively. Further antibody production may provide a higher concentration or the Ab652 
sample could be concentrated using a centrifuge concentrator or vacuum concentrating 
system, such as a SpeedVac. If optimisation of the MST analysis is not successful, then more 
traditional methods could be used to determine the Kd of the mAbs. Since the HMW SLP 
cannot be produced in large quantities, the sample availability is relatively limited and 
therefore, SPR would be performed as opposed to ITC. 
Another possible explanation for the lack of good quality MST data could be due to the 
presence of the fluorophore label of the HMW SLP potentially inhibiting the Ab521 binding 
                                                     
26 Institute for Cell and Molecular Biosciences, Newcastle University 
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site. The protein was labelled with the fluorophore via amine coupling. Another 
NanoTemper kit is available that couples the fluorophore via cysteine residues, however, 
the HMW/LMW SLP complex does not contain cysteine and consequently this kit could not 
be used.     
Since the MST technique was not successfully optimised for interactions between the mAbs 
and HMW/LMW SLP complex, the analysis of the mAb interaction with the recombinant 
LMW SLP also could not be performed. This interaction would be a vital control for any 
binding analysis of the mAbs and would be performed with the optimised MST method or 
using SPR for future work. The LMW SLP produced was a truncated version of the protein, 
missing the latter 59 residues. As a result of this truncation a stable protein is formed that 
could be used for downstream analysis. A consequence of the missing amino acids is that 
when used as a negative control for mAb binding, the full LMW SLP is not tested. Therefore, 
there is a possibility that the mAb could be binding to these residues when analysed for 
binding to the HMW/LMW SLP complex.  
5.4 Summary 
Using whole-cell ELISAs, the four promising mAbs were reduced to two, Ab521 and Ab652. 
These two mAbs displayed greater binding to the C. difficile strains and demonstrated 
greater specificity when compared to Ab491 and Ab493. For these reasons, Ab491 and 
Ab493 were disregarded from further suitability testing.  
The successful antibodies, Ab521 and Ab652 displayed specific binding to the HMW SLP 
within representatives from the entire C. difficile species, and not to the closely related 
strains. Although not fully determined, it was indicated that Ab521 had a very strong binding 
affinity. The two mAbs displayed binding to both the denatured and native C. difficile 
proteins and therefore showed potential for use as detection molecules. The suitability of 
these molecules for PoN sensors will be investigated further in the next chapter. 
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Chapter 6 Specific whole cell binding of Ab521 and Ab652 to the 
C. difficile SLTS 
6.1 Introduction 
6.1.1 Whole cell detection 
Rapid identification of bacteria can be critical to the clinical outcome of patients (Ahmed et 
al., 2014). PoN diagnosis of CDI would reduce severe outcomes and complications by 
enabling quicker, more accurate treatment, and reducing transmission by implementing 
more prompt isolation measures (Barbut et al., 2014). However, testing for CDI generally 
does not occur at PoN. Clinical decisions regarding patient treatment and isolation, often 
have to be made before the results are received from more laborious testing (Goldenberg et 
al., 2014). This treatment of CDI, without full clinical results, often leads to inappropriate 
treatment, with one study showing that 74 % of people on empirical therapy, subsequently 
had negative CDI test results (Saade et al., 2013). The turnaround time for CDI testing varies 
greatly, depending on the setting. In some hospitals, results are provided within eight hours 
(Culbreath et al., 2012), whereas others take 17-32.3 h (Grein et al., 2014) and long-term 
care facilities can take up to four days (Guerrero et al., 2011). Several studies have shown 
that rapid diagnosis, of either positive or negative CDI cases, results in fewer days in 
isolation, fewer hospital days, and a reduction in associated costs for both result groups 
(Barbut et al., 2014; Sewell et al., 2014). PoN sensors that detect whole bacteria, without 
the need for pre-treatment of samples, would enable this much needed rapid diagnosis to 
occur (Ahmed et al., 2014).    
Non-toxigenic C. difficile – strains that do not produce toxins - can reside in the colon 
without causing infection. Therefore, in order to diagnose CDI, it is not enough to detect the 
organism alone and the C. difficile toxins must also be detected (Kachrimanidou and 
Malisiovas, 2011). Current UK recommendations for CDI diagnosis state that both the 
organism and the C. difficile toxins should be detected, using a two-step algorithm of either 
a GDH EIA or NAAT, followed by toxin EIA (Robotham and Wilcox, 2012). Since NAAT 
requires specialist equipment and skills (Freifeld, 2012), in its current form it cannot be 
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performed PoN easily, whereas simplified EIAs could be. Cepheid GeneXpert®27 is a NAAT 
that was successfully trialled at PoN diagnostic, however, not only is specialist equipment 
needed but the turnaround time was longer than EIAs, around 1.85 h (Goldenberg et al., 
2014). Many diagnostics companies have their own versions of toxin or GDH EIA (Barbut et 
al., 2014; Davies et al., 2015), however, Alere has the European and US patent for the dual 
use of both GDH and toxin detection together in a single EIA (Boone et al., 2013). Due to this 
monopoly on dual use tests, diagnostic companies are interested in identifying a biomarker, 
other than GDH, that rapidly detects the C. difficile organism. A successful whole cell 
biomarker, and associated detection molecules, would allow companies to manufacture a 
double EIA of their own. 
Chapter 6 describes the specificity of C. difficile Ab521 and Ab652 when binding to the 
native, surface extracted proteins of C. difficile using the dot blot technique Figure 4-5. The 
chapter also describes how the mAbs specifically bound to the HMW-SLP within the whole 
cell extracts of all 14 SLTS, albeit in its denatured form. These initial, specific binding results 
indicate that the C. difficile target is a promising biomarker. However, to explore the 
potential of this biomarker for use in a rapid PoN sensor, it is important that the mAbs bind 
to whole C. difficile cells. Although initial data indicated that Ab521 and Ab652 do indeed 
bind to the native HMW SLP within whole C. difficile strains (Figure 5-2) the strains tested 
were not the SLTS and therefore did not represent the C. difficile species as defined by the 
Dingle study. If these mAbs bind to the whole cells of all 14 SLTS then it would indicate that 
they could bind to any C. difficile strain, without the need for time consuming pre-treatment 
of cells.  
6.1.2 Immunofluorescence microscopy and flow cytometry 
Immunofluorescence (IF) is based on pioneering work performed by Coons and colleagues in 
the 1940s/50s (Coons et al., 1941; Coons and Kaplan, 1950) and utilises fluorescently 
labelled antibodies to detect molecules, such as a specific bacterial surface antigen (Abbas 
and Lichtman, 2004). There are two main types of IF firstly, direct IF, which uses a single 
                                                     
27 http://www.cepheid.com/us/cepheid-solutions/systems/genexpert-systems/genexpert-iv 
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fluorescently labelled antibody that binds directly to the antigen, providing a fluorescent 
signal where the binding occurs (Storch, 2000). Secondly indirect IF, which utilise an 
unlabelled, primary antibody that binds to its antigen before a fluorescently labelled, 
secondary antibody binds to the Fc region of the primary (Odell and Cook, 2013). For several 
reasons, such as cost, amount of signal and flexibility, indirect IF is the most predominantly 
used method (Robinson et al., 2009). Within this project, indirect IF was utilised and 
measured using two techniques, fluorescence microscopy and flow cytometry. Both of these 
techniques enabled single-cell analysis, with flow cytometry also providing information at 
population level and microscopy delivering the visualisation of specific binding (Godfrey et 
al., 2005).  
Within the literature, the majority of the flow cytometry work with C. difficile uses the 
toxins rather than the organism itself (Lanis et al., 2010; Monaghan et al., 2013). One of the 
projects that used flow cytometry with whole C. difficile cells, applied the method to 
determine adherence of C. difficile to gut epithelial cells (Drudy et al., 2001). Using whole 
C. difficile cells with IF microscopy is slightly more abundant in the literature, with several 
papers utilising indirect IF. Fagan and colleagues labelled the LMW SLP of C. difficile cells to 
determine the importance of the secretory proteins SecA1 or SecA2 (Fagan and 
Fairweather, 2011). Also, Kovacs-Simon and co-workers used indirect IF to determine the 
adherence properties of the C. difficile lipoprotein CD0873 (Kovacs-Simon et al., 2014). The 
literature search also identified a paper from 1982 that had trialled direct IF microscopy as a 
method to detect C. difficile in faecal samples (Wilson et al., 1982). 
6.1.3 Transmission Electron Microscopy 
Transmission electron microscopy (TEM) employs electron beams to convey an image of an 
object at much greater magnification than light microscopy, which is achieved by the 
considerably smaller wavelength of electron beams compared to visible light (Serdyuk et al., 
2007; Leadley, 2010). Electrons scatter when passing through a specimen and the denser 
the specimen, the more the electrons scatter, producing a darker image (Leadley, 2010).  
Immunogold labelling of samples prior to TEM utilises gold conjugated Abs to define specific 
localisation of antigens (Kaur et al., 2002). When imaged, the gold particles appear as dark 
 130 
 
circular, uniform dots, as the electrons cannot pass through the gold and is conveyed to the 
imaging screen as darkness (Hoppert and Holzenburg, 1998).    
6.2 Results 
6.2.1 Qualitative whole cell binding of Ab521 and Ab652 to the SLTS  
Both Ab521 (A) and Ab652 (B) (Figure 6-1) produced a signal, indicating binding to the whole 
cells from all 14 C. difficile SLTS, C. difficile 630 and also the positive controls. Neither 
antibody produced a signal against the three closely related species, C. hiranonis DSM-
13275, C. sordellii ATCC 9714 and P. anaerobius VPI 4330. The Ab521 signal for the 
undiluted cells of SLTS Ox160, was much weaker than the more dilute samples. The Ab521 
signal for all but Ox160 and Ox858 was positive across all of the cell dilutions whereas, 
Ab652 had strong positive signals for the undiluted cells and when cells were diluted 1 in 
100. However, the signal was much weaker for the 1 in 1000 dilution of all C. difficile strains. 
This difference in binding between the two mAbs indicates that Ab521 has a stronger 
binding affinity than Ab652. 
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Figure 6-1. Whole cell dot blots of all 14 C. difficile SLTS, C. difficile 630, C. hiranonis DSM-13275, C. sordellii ATCC 9714 
and P. anaerobius VPI 4330. The cells were bound directly to the membrane at differing dilutions, the closely related 
strains were all applied undiluted. Positive controls were used of the primary antibody and low pH glycine extracted 
surface layer proteins from C. difficile 630, bound directly to the membrane. The blots were probed with 5 µg/ml Ab521 
(A) and Ab652 (B) followed by HRP conjugated anti-mouse IgG. 
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6.2.2 Semi-quantitative whole cell binding of mAbs to the C. difficile species 
Statistical analysis of the results was performed using the, IBM SPSS version 21, and a one-
way ANOVA with Bonferroni and Tukey post hoc tests. A statistical significance value of 
P= < 0.05 was used throughout the analysis. Unless stated, the P value provided is from both 
the Bonferroni and Tukey tests. 
When tested using whole cell ELISA, Ab521 at concentrations 5 µg/ml to 100 ng/ml 
displayed a significant increase in absorbance values between the C. difficile strains, the 14 
SLTS (Ox…) and strain 630, when compared to the closely related species, C. hiranonis DSM-
13275, C. sordellii ATCC 9714 and P. anaerobius VPI 4330 P = < 0.05 (Figure 6-2). The lowest 
of the absorbance values for any of the C. difficile strains was 1.54 whereas the highest for 
the closely related species was significantly less at 0.12. The lower concentrations, 
100 ng/ml and 1 µg/ml showed almost no binding to the closely related species. There was 
some binding of Ab521 at 5 µg/ml to the closely related species however, even the species 
with the greatest absorbance, P. anaerobius, showed binding that was significantly lower 
than the C. difficile strains. Therefore, Ab521 showed specificity to C. difficile when tested 
against C. hiranonis DSM-13275, C. sordellii ATCC 9714 and P. anaerobius VPI 4330. The 
Ab521 dilutions provided very similar readings for each C. difficile strains, with 5-0.1 µg/ml 
showing very little difference in absorbance. The binding displayed across the C. difficile 
strains was quite uniform, with a difference of around 25 % between the strain with the 
maximum absorbance, Ox160, and the C. difficile strain with the minimum, Ox1396. On 
account of this clear binding to all C. difficile strains, Ab521 demonstrated its potential for 
sensitive detection of whole C. difficile cells.     
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Figure 6-2. Absorbance readings at 450 nm for the Ab521 ELISA at concentrations 5 μg/ml to 100 ng/ml, with whole cells 
from all 14 C. difficile SLTS, C. difficile 630 and the closely related species, C. hiranonis DSM-13275, C. sordellii ATCC 9714 
and P. anaerobius VPI 4330. The error bars show the standard deviation seen between the two replicates of each 
sample. 
Since Ab521 at 5-0.1 µg/ml bound to C. difficile cells at an apparently similar saturating load, 
further dilutions of the antibody were tested, down to 0.1 ng/ml. Ab521 produced a 
significant difference in absorbance, P= < 0.05, between C. difficile and the closely related 
strains at concentrations as low as 1 ng/ml ( 
Figure 6-3). At the lowest concentration of 0.1 ng/ml, the absorbance values were not 
significantly different between the control species and C. difficile strains, P= > 0.05. 
Therefore, this Ab521 concentration would not be suitable to detect C. difficile cells with the 
required sensitivity.  
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Figure 6-3. Absorbance readings at 450 nm for the Ab521 ELISA at concentrations 100-0.1 ng/ml, with whole cells from 
all 14 C. difficile SLTS, C. difficile 630 and the closely related species, C. hiranonis DSM-13275, C. sordellii ATCC 9714 and 
P. anaerobius VPI 4330. The error bars show the standard deviation seen between the two replicates of each sample. 
The absorbance results of each Ab521 concentration from the whole cell ELISAs, from 
5 µg/ml to 0.1 ng/ml, were plotted on a graph for each bacterial strain (Figure 6-4).  At 0.1 
ng/ml the absorbance values are very similar for all strains, displaying why P= > 0.05 at this 
antibody concentration. The three closely related strains, C. hiranonis, C. sordellii and 
P. anaerobius are grouped together at the lower absorbance values, across the antibody 
dilutions. Conversely, the C. difficile strains are grouped together with increasing 
absorbance values as the antibody concentration increases. The graph shows an apparent 
antibody saturating load at concentrations of 100 ng/ml to 5 µg/ml, however, an increase in 
absorbance is still seen with Ox1396 between these concentrations. The Ab521 
concentration at which the absorbance difference between the closely related species and 
the C. difficile strains is at its greatest is 100 ng/ml. Although there remains a clear 
differentiation between these groups at the lower concentrations of 1-10 ng/ml.   
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Figure 6-4. Absorbance readings at 450 nm for the Ab521 ELISA from concentrations 5 μg/ml to 0.1ng/ml , with whole 
cells from all 14 C. difficile SLTS (Ox…), C. difficile 630 and the closely related species, C. hiranonis DSM-13275, C. sordellii 
ATCC 9714 and P. anaerobius VPI 4330. The Ab521 concentrations 5 μg/ml to 0.1ng/ml are along the x-axis and each line 
on the graph denotes the absorbance values for a bacterial strain. The closely related species are grouped at the lower 
absorbance values whereas, the C. difficile strains are grouped and increase in absorbance as the antibody concentration 
increases. The mean of the two repeats were used and the standard deviation was not shown for ease of visualisation of 
the curves. 
As shown within Figure 3-19 C. difficile 630 resides within SLT 7, which is represented by 
Ox1145. The statistical analysis revealed that there was no significant difference P = > 0.05 
between the absorbance values for C. difficile 630 and Ox1145 at Ab521 concentrations 1 
µg/ml to 0.1 ng/ml. Furthermore, the same lack of significant difference in binding was 
shown between the two strains that represent SLT clade 2, Ox2404 and Ox858.   
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The absorbance values for the whole cell ELISA when performed with Ab652, are 
substantially lower for the C. difficile strains than those seen for Ab521 (Figure 6-5). Even at 
a higher starting concentration of 10 µg/ml, the absorbance readings were around 45 % less 
than Ab521, with means of lower than one absorbance unit. There was a marked decrease 
in absorbance for each C. difficile strain as the antibody concentration decreased, with 
values for 100 ng/ml less than half of those seen for 10 µg/ml.  
There was a clear difference in values between the controls and the C. difficile strains, for 
10, 5 and 1 µg/ml, although, the difference was smallest with Ox1396. There was no 
significant difference between SLTS Ox1396 and P. anaerobius at any Ab652 dilution, 
P = > 0.05. Although, the difference in absorbance for the other C. difficile strains was 
significant at 1-10 µg/ml. When the Ab652 concentration was reduced to 100 ng/ml there 
was no significant difference in absorbance between the C. difficile strains and the closely 
related species P = > 0.05. 
 
Figure 6-5. Absorbance readings at 450 nm for the Ab652 ELISA at concentrations 0.1-10 μg/ml , with whole cells from all 
14 C. difficile SLTS, C. difficile 630 and the closely related species, C. hiranonis DSM-13275, C. sordellii ATCC 9714 and 
P. anaerobius VPI 4330. The error bars show the standard deviation seen between the two replicates of each sample.  
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Similar to Ab521, a graph was produced from the absorbance values for each strain at 
differing Ab652 concentrations along the x-axis. The three closely related species are 
consistently at the lowest absorbance values, however, there are also C. difficile strains 
close to these readings. The bacterial strains that are grouped at the higher absorbance 
readings are all C. difficile strains, demonstrating increased antibody binding to these 
strains. There is not the clear differentiation between all C. difficile strains and the closely 
related species, as displayed by the Ab521 results. 
 
Figure 6-6. Absorbance readings at 450 nm for the Ab652 ELISA for all concentrations, 5 μg/ml to 0.1ng/ml , with whole 
cells from all 14 C. difficile SLTS (Ox…), C. difficile 630 and the closely related species, C. hiranonis DSM-13275, C. sordellii 
ATCC 9714 and P. anaerobius VPI 4330. The Ab652 concentrations 5 μg/ml to 0.1ng/ml are along the x-axis and each line 
on the graph denotes the absorbance values for a bacterial strain. The closely related species are grouped at the lower 
absorbance values whereas, the C. difficile strains are grouped and increase in absorbance as the antibody concentration 
increases. The mean of the two repeats were used and the standard deviation was not shown for ease of visualisation of 
the curves. 
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6.2.3 Analysing whole cell interactions of Ab521 and Ab652 using flow 
cytometry 
Flow cytometry was applied to further investigate the binding of the mAbs to whole cells. 
The histogram peaks for C. difficile 630 and all 14 SLTS have a marked increase in 
fluorescence intensity when they are incubated with Ab521 and the secondary antibody, 
than the cells incubated with the secondary antibody alone (Figure 6-7). All C. difficile strains 
were tested with the secondary antibody only and there was almost no fluorescence for all, 
with median, as calculated with the FlowJo software, peaks of around zero fluorescence 
intensity (AU). To avoid repetition, only the peaks for the controls of C. difficile 630, Ox1145, 
Ox1437a (Figure 6-7) are shown.  
The C. difficile SLTS Ox1192c has the lowest fluorescence intensity peak for both Ab521 and 
Ab652, with a median fluorescence intensity peak of 730 AU and 264 AU respectively (Table 
6-1). For Ab521, the fluorescence intensity peaks ranged from the low Of Ox1192c to the 
high of Ox1145, which had a median value of 4257 AU, over five times as much as Oc1192c. 
The flow cytometry results were statistically analysed with IBM SPSS version 21. Mann-
Whitney U and Wilcoxon Signed Ranks tests were performed between the fluorescence 
values of the C. difficile strains and the closely related species. When incubated with both 
Ab521 and the secondary antibody, the P values for both tests were < 0.05 and therefore 
the results were significantly different. When the same tests were performed with the 
closely related species, incubated with both antibodies, and the C. difficile strains incubated 
with only the secondary antibody, there was no significant difference between the values 
P = > 0.05. Therefore, all controls provided similar fluorescence readings which were around 
0 AU.  
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Figure 6-7. Fluorescence intensity histograms of Alexa Fluor 594 conjugated anti-mouse IgG, bound to Ab521 , which in 
turn was bound to whole C. difficile SLTS cells. Controls (red line) are of C. difficile cells incubated with the conjugated 
anti-mouse IgG but not Ab521. All three histograms, A, B and C were performed under the same experimental 
conditions but with different C. difficile strains, which are labelled in the relative key.  
The flow cytometry results for whole cells, incubated with Ab652 (Figure 6-8), were similar 
to the results for incubation with Ab521. The plots displayed a distinct difference in 
fluorescence values between the C. difficile cells incubated with Ab652 and Alexa Fluor 594, 
anti-mouse IgG, compared to the cells without Ab652 incubation. However, the median 
fluorescence intensity values for all strains incubated with Ab652 were lower than those 
incubated with Ab521 with a summary of median fluorescence intensity peaks being 
displayed in Table 6-1. For example Ox1145 had the highest median fluorescence for both 
mAbs, yet there was a large difference between them, with Ab521 having a value of 4257 
AU and Ab652 just 1660 AU.    
Another observation was the difference in the width of the fluorescence peaks for both 
mAbs, with Ab652 having wider peaks, which are quantitatively displayed by the larger 
percentage of robust coefficient of variation (%rCV), than Ab521 (Table 6-1). The %rCV, 
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calculated with FlowJo software, was used because it is not as skewed by outlying values as 
the coefficient of variation (CV). 
“%rCV = 100 * 1/2( Intensity[at 84.13 percentile] – Intensity [at 15.87 percentile] ) / 
Median” (Treister and Roederer, 2015) 
All strains incubated with Ab652 had a larger dispersion of fluorescence values as measured 
by the %rCV, than those with Ab521. For example for Ab652 and Ab521, Ox1396 had 248 AU 
and 186 AU respectively, Ox1533, 170 AU and 149 AU and finally Ox1896 had 130 AU and 
91.2 AU.  
 
 
Figure 6-8. Fluorescence intensity histograms of Alexa Fluor 594 conjugated anti-mouse IgG, bound to Ab652 , which in 
turn was bound to whole C. difficile SLTS cells. Controls (red line) are of C. difficile cells incubated with the conjugated 
anti-mouse IgG but no Ab652. All three histograms, A, B and C were performed under the same experimental conditions 
but with different C. difficile strains, which are labelled in the relative key. 
The closely related species, C. hiranonis and P. anaerobius had a median fluorescence of 
around zero when incubated with either Ab521 (A) or Ab652 (B), and the secondary 
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antibody (Figure 6-9). Furthermore, Ab521 also had a median fluorescence intensity of zero 
for C. sordellii, whereas Ab652 had a slightly increased positive median value of 26.8 AU and 
what appeared to be a larger %rCV however, this could not be quantified due the negative 
fluorescence values within the population. Although the median fluorescence value for 
Ab652 with C. sordellii was positive it remained 10 % less than the C. difficile strain with the 
lowest median value when incubated with Ab652, Ox160. The C. sordellii value was less than 
1.5 % of the highest median fluorescence intensity displayed by a C. difficile strain incubated 
with Ab652, which was Ox1533. 
 
Figure 6-9. Fluorescence intensity histogram of the closely related strains, C. hiranonis DSM-13275, C. sordellii ATCC 
9714, and P. anaerobius VPI 4330 with C. difficile 630 as a positive reference. All cells have been incubated with Alexa 
Fluor 594 anti-mouse IgG and Ab521 (A) or Ab652 (B). C. difficile 630 has much higher fluorescence values than the 
closely related strains. Therefore showing binding of the mAbs to C. difficile 630 and not to the closely related strains.   
 
Table 6-1. Fluorescence intensity values provided with flow cytometry for all 14 C. difficile SLTS, C. difficile 630 and the 
closely related species C. hiranonis DSM-13275, C. sordellii ATCC 9714 and P. anaerobius VPI 4330. The bacterial cells 
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were fixed and incubated with either Ab521 or Ab652 followed by the secondary antibody Alexa Fluor 594 conjugated 
anti-mouse IgG. The median fluorescence intensity is given as well as the robust coefficient of variance. 
 Median fluorescence intensity (AU) Percentage robust coefficient of 
variation (%) 
Bacterial strain Ab521 Ab652 Ab521 Ab652 
C. hiranonis 
DSM-13275 
0.3 0.25 N/A N/A 
C. sordellii 
ATCC 9714 
-0.506 26.8 N/A N/A 
P. anaerobius 
VPI 4330 
0.956 -1.15 N/A N/A 
630 1182 903 105 254 
Ox160 2419 268 73.1 121 
Ox575 2773 685 157 277 
Ox858 1582 401 66.1 118 
Ox1121 1122 999 96.7 230 
Ox1145 4257 1660 109 162 
Ox1192c 730 264 89 128 
Ox1342 2318 636 92.9 123 
Ox1396 2413 558 152 240 
Ox1424 2781 941 135 193 
Ox1437a 2799 1615 120 140 
Ox1523 3413 755 121 138 
Ox1533 4047 1899 106 166 
Ox1896 2525 1009 73.4 114 
Ox2404 2580 675 59 85.5 
Statistical analysis was performed on the flow cytometry data and a Mann–Whitney test 
confirmed that the fluorescence values of all of the C. difficile strains, for both Ab521 and 
Ab652, are significantly difference to the fluorescence values displayed in the closely related 
species, P = < 0.05.  
 
6.2.4 IF imaging of the interaction of Ab521 and Ab652 with whole cells 
To gain images of the mAbs interacting with whole cells, IF microscopy was performed. 
Whole cells were labelled with a fluorescent antibody (see methods section 2.20) using 
either Ab521 or Ab652 as the primary antibody. The resulting images displayed clear 
fluorescence at the surface of the C. difficile cells, demonstrating positive binding of both 
Ab521 (B) and Ab652 (F) with Ox1396 (Figure 6-10), however, the fluorescence intensity for 
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Ab652 (F) was lower than Ab521 (B) for SLTS Ox1342 (Figure 6-11). Both of these figures also 
show images of the C. difficile strains when incubated with the fluorescently labelled 
secondary antibody only and not the mAbs. The images were displayed with brightfield (C) 
to reveal presence of the cells and mCherry filter (D), which showed a lack of fluorescence in 
both C. difficile strains without either Ab521 or Ab652. A total of six C. difficile strains and 
three closely related strains were tested for mAb binding using IF microscopy and an 
overview of the results are provided in Table 6-2. Further IF images of C. difficile strains, 
Ox858, Ox1437a and strains 630 incubated with the mAbs are displayed in the Appendices 
Figure 9-8, 9-9 and 9-10 respectively. 
 
Figure 6-10. Immunofluorescence microscopy images of Ox1396 incubated with Alexa Fluor 594 anti-mouse IgG and 
Ab521, brightfield image (A), mCherry filter (B). Alexa Fluor 594 anti-mouse IgG and Ab652 brightfield image (E), 
mCherry filter (F). Control of Ox1396 with Alexa Fluor 594 anti-mouse IgG and no primary antibody brightfield image (C), 
mCherry filter (D). 
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Figure 6-11. Immunofluorescence microscopy images of Ox1342 incubated with Alexa Fluor 594 anti-mouse IgG and 
Ab521, brightfield image (A), mCherry filter (B). Alexa Fluor 594 anti-mouse IgG and Ab652 brightfield image (E), 
mCherry filter (F). Control of Ox1342 with Alexa Fluor 594 anti-mouse IgG and no primary antibody brightfield image (C), 
mCherry filter (D).  
 
The closely related species, C. sordellii (Figure 6-12), C. hiranonis and P. anaerobius 
(Appendices Figure 9-11 and 9-12) did not display fluorescence when incubated with Ab521 
(B) or Ab652 (D) and the secondary antibody (Figure 6-12 D). The actual fluorescent values 
are provided in For Table 6-2 the average cell fluorescence was calculated using ImageJ. The 
fluorescence values were used from a minimum of five random cells from C. difficile or the 
closely related species and the average was calculated. The background fluorescence was 
also calculated from a minimum of five areas, which were the same size as the cells that 
were analysed. The background for the cells incubated with the secondary antibody only 
and not the mAbs were calculated, again using ImageJ. The cells were marked on the 
brightfield image and the markers were transferred to the corresponding fluorescence 
image, enabling calculation of fluorescence values at the specific cell site. 
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Table 6-2 and show that the there is some slight binding of Ab652 to C. sordellii. However, 
the binding is negligible, as the value is a minimum of four times lower than the 
fluorescence value of Ab652 with the C. difficile strains. For the other two closely related 
species and all three for Ab521 the resulting fluorescence is less than 1.5 AU. The non-
specific binding is insignificant when compared to binding with C. difficile, which the lowest 
value is seen with Ox8585 and is 366.19 AU for Ab652 and 548.27 AU for Ab521. 
 
Figure 6-12. Immunofluorescence microscopy images of C. sordellii  incubated with Alexa Fluor 594 anti-mouse IgG and 
Ab521 brightfield (A) mCherry (B) or Ab6521 brightfield (C) mCherry (D).  
 
For Table 6-2 the average cell fluorescence was calculated using ImageJ. The fluorescence 
values were used from a minimum of five random cells from C. difficile or the closely related 
species and the average was calculated. The background fluorescence was also calculated 
from a minimum of five areas, which were the same size as the cells that were analysed. The 
background for the cells incubated with the secondary antibody only and not the mAbs 
were calculated, again using ImageJ. The cells were marked on the brightfield image and the 
markers were transferred to the corresponding fluorescence image, enabling calculation of 
fluorescence values at the specific cell site. 
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6.2.5 TEM analysis of Ab521 and Ab652 with C. difficile and C. sordellii 
TEM enables cells to be seen at great magnification and was used with indirect immunogold 
labelling to image antibody interaction with whole C. difficile and C. sordellii cells. The cells 
were paraformaldehyde fixed and incubated with either Ab521 or Ab652 and the secondary, 
gold conjugated, anti-mouse IgG.  
When incubated with Ab521, both C. difficile 630 (A) and Ox575 (B) displayed gold 
nanoparticles, which can be seen as dense, dark, uniform circles, attached to the surface of 
the cells (Figure 6-13). To assist with visualisation of some of the more difficult to see 
nanoparticles, they were marked with white arrows. There are several factors affecting the 
ability to see the gold nanoparticles firstly, they can only be seen when the focus of the 
electron beam is nearby. Secondly, the sample being viewed must not be too dense and 
finally, the negative stain, used to enable visualisation of the cells, must not be too dark. 
 
Figure 6-13. Transmission electron microscope image of C. difficile 630 (A) and Ox575 (B) incubated with Ab521 and gold 
conjugated anti-mouse IgG. The white arrows indicate gold nanoparticles that are within the denser region of the cell 
and are therefore more difficult to see. The S-layer completely encapsulates the bacterium and is at the same position as 
the cell wall at the surface of the rod shaped cells. 
 
Gold nanoparticles were also seen on C. difficile 630 cells when incubated with Ab652 (Figure 
6-14). However, it was noted that there were fewer particles with Ab652 than on the cells 
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incubated with Ab521 (Figure 6-13). Quantification of the gold nanoparticles was not 
performed and consequently, the particle number was purely observational. 
 
Figure 6-14. Transmission electron microscope image of C. difficile 630 incubated with Ab652 and gold conjugated anti-
mouse IgG. The white arrows indicate gold nanoparticles that are within the denser region of the cell and are therefore 
more difficult to see. The S-layer completely encapsulates the bacterium and is at the same position as the cell wall at 
the surface of the rod shaped cells. 
 
For a negative control, C. difficile 630 was incubated with the secondary antibody only and 
no primary antibody. These cells did not display gold nanoparticles attached to the surface 
of the cells (Figure 6-15) and therefore showed that the gold conjugated anti-mouse IgG 
does not non-specifically bind to C. difficile. 
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Figure 6-15. Transmission electron microscope image of C. difficile 630 without primary antibody and incubated with 
only gold conjugated anti-mouse IgG. There are no gold nanoparticles displayed on the cells. 
 
C. sordellii was also incubated with either Ab521 (A) or Ab652 (B) and the gold conjugated 
anti-mouse IgG, and viewed using TEM (Figure 6-16). Although one or two gold nanoparticles 
were seen on the images, they were not on the surface of the organism, which was 
completely clear of gold particles.  
 
Figure 6-16. Transmission electron microscope image of C. sordellii incubated with Ab521 (A) and Ab652 (B) and gold 
conjugated anti-mouse IgG and  
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6.2.6 The potential of Ab521 for use in a diagnostic assay or sensor 
Initially, the intention of the project was to produce the antibodies for use in a 
Microelectromechanical systems (MEMS) PoN diagnostic sensor, However, as the project 
progressed, lateral flow strips were investigated as a potential sensor for use with the 
C. difficile mAbs. Leteral flow strips were selected due to their ease of use and the low 
production costs. One of the limitations of using lateral flow strips with whole bacteria is the 
availability of membranes with large enough pore sizes. The largest available pore size for 
nitrocellulose membrane was found to be 15 µm from Sartorius28 and strips that were 
successful at detecting S. aureus were made using membranes of this pore size (data not 
shown). However, after several optimisation attempts, the lateral flow strips were found to 
be incapable of flowing C. difficile down the membrane.  
For proof of principle of Ab521 working within lateral flow strips, a test line of purified 
HMW/LMW complex was bound to the membrane and  gold conjugated Ab521 was flowed 
along the strip (Figure 6-17). As a positive control, anti-mouse IgG was bound to the 
membrane. With this set up the Ab521 successfully moved through the membrane and 
bound to the SLP complex and the anti-mouse IgG positive control line (A). As a simple 
control a gold conjugated prostate-specific antigen (PSA) antibody was also used on a 
HMW/LMW SLP bound lateral flow strip and did not bind to the complex (B).  
                                                     
28 https://www.sartorius.co.uk/en/product/product-detail/1un95er100025nt/ 
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Figure 6-17. Lateral flow strips with a control line (top red line) of anti-mouse IgG 1 mg/ml and a test line of purified 
C. difficile 630 HMW/LMW complex. Gold conjugated Ab521 was then flowed down strip A, providing a positive red line 
at the HMW/LMW complex. Gold conjugated prostate-specific antigen antibody was flowed down strip B and did not 
produce a positive signal for the HMW/LMW complex. 
 
6.3 Discussion 
6.3.1 Dot blots indicate that mAbs bind to whole C. difficile cells 
Whole cell binding of the mAbs is advantageous for their integration into rapid PoN sensors 
(Ahmed et al., 2014) as it would reduce the need for time consuming pre-treatment, such as 
lysis of cells. The dot blots displayed positive signals for both Ab521 and Ab652, binding to 
all 14 SLTS and C. difficile 630. Since these 14 SLTS are representatives of the 13 SLT clades 
that all C. difficile strains can be clustered into, theoretically, Ab521 and Ab652 should bind 
to the C. difficile species as a whole, at least with dot blot analysis. For SLTS Ox160, the 
signal for the undiluted cells, with Ab521, was much weaker than the more dilute samples. 
In all likelihood this was due to the experimental procedure as opposed to the undiluted 
cells not providing a positive result as further diluted samples were positive. Since the more 
dilute Ox160 samples provided a positive result, and the mAb binding to this strain was 
going to be investigated further, it was decided not to repeat the dot blot. 
The signal for Ab521 remained strong with the C. difficile cells at a dilution of 1 in 1000, 
whereas, Ab652 displayed poor binding, implying that Ab521 may bind to C. difficile with 
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greater affinity than Ab652. Neither Ab521 nor Ab652 produced a positive signal for any of 
the three closely related strains, C. sordellii, C. hiranonis or P. anaerobius, indicating that the 
mAbs do not bind to whole cells from these control species. The closely related species were 
used to test for non-specific binding of the mAbs, since they have sequences that are similar 
to C. difficile or SlpA, described in detail within the bioinformatics results section 5.2.6 and 
thus are more likely to interact with the antibodies. To prevent PoN sensors providing false 
positives, it is imperative that the mAbs do not bind to anything other than C. difficile. 
Subsequently, testing of non-specific binding began with the species that the mAbs are most 
likely to erroneously bind to, however it is recognised that many more species will require 
testing. Since dot blots provide only semi-quantitative information and are not sensitive 
enough to draw conclusions from alone (Jin et al., 2011), complementary methods of 
examining positive and non-specific binding were pursued.  
6.3.2 Ab521 binds to whole C. difficile cells with greater efficiency than 
Ab652 
To gain semi-quantitative evidence of whole cell binding, the mAbs were tested using whole 
cell ELISAs. The results for Ab521 showed that when incubated with each of the 15 
C. difficile strains, the absorbance values were saturated between with 100 ng/ml of 
antibody and 5 µg/ml. In order to produce the most cost efficient PoN sensor, it is important 
to use the minimum amount of detection molecule that still provides clear recognition of its 
specific antigen. At 0.1 µg/ml, Ab521 distinguished between all C. difficile strains and the 
closely related species with a significance of P = 0.000 therefore, providing the specificity 
required for PoN testing. Since the tested SLTS represent the entire C. difficile species, in the 
context of SlpA, the significant binding of Ab521 to all of these strains indicate that the 
antibody would bind to all C. difficile strains. This binding indicates the high sensitivity of 
Ab521, which would be useful for a PoN sensor. Even at 1 ng/ml Ab521 there remained a 
significant difference P = < 0.05 between all of the C. difficile strains and the closely related 
species. This antibody concentration enabled clear differentiation between these two 
groups, therefore, the limit of detection (LOD) of the antibody was 1 ng/ml. However, at this 
concentration, the difference in absorbance values between the C. difficile strains and the 
closely related species was substantially lower than the difference displayed with the higher 
concentrations of antibody. The decreased absorbance difference may not be enough to 
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retain the distinction between the groups once the antibody is integrated in to a PoN 
sensor. The type of sensor that the antibody is used within, would in-part determine the 
concentration of the antibody required for specific detection of C. difficile. Within the whole 
cell ELISA results, the optimal antibody concentration for C. difficile detection lies between 
1 and 10 ng/ml. For future work, dilutions of Ab521 between 1 and 10 ng/ml could be tested 
and the optimal concentration resolved. 
In contrast, Ab652 displayed a significant decline in binding to the C. difficile strains as the 
antibody concentration reduced from 10-0.1 µg/ml. Even at 10 µg/ml, Ab652 bound to the 
cells with an efficiency that was around 40 % less than Ab521. The lowest concentration of 
Ab652 which displayed a significant binding difference between most C. difficile strains and 
the controls was 1 µg/ml, ten times more concentrated than Ab521. Furthermore, at all 
concentrations, Ab652 did not display a significant difference between the binding with 
C. difficile SLTS Ox1396, compared with the closely related species, P. anaerobius. The 
results of the C. difficile strains grouped in with closely related species meant that a limit of 
detection could not be obtained.  
These results corroborated the initial findings from the dot blots, that Ab521 has a higher 
binding efficiency to C. difficile than Ab652. Therefore, Ab521 is the more promising 
detection molecule for use in a PoN sensor. 
Within a PoN sensor it is recognised that the samples would not be pure C. difficile and 
would include other organisms and faecal matter. The optimal Ab521 concentration could 
differ with more complex samples and therefore, further testing of the antibody is required. 
A useful experiment for future work would be to determine the range at which the antibody 
still efficiently detected the C. difficile cells, by altering the OD or cell number and keeping 
the antibody concentration constant. It is possible to count the cells, using a bacterial 
haemocytometer, and calculate roughly how many cells are present. Within this project 
however, the OD was used because the cell size varied between strains. The larger cells 
would likely have more HMW SLP epitopes compared to the smaller cells, as they have a 
larger surface area to cover, so an equal cell count would provide an unequal number of 
antibody binding sites across the strains. Also, different strains could differentially express 
SlpA and have a differing density of S-Layer, which could both alter the amount of HMW SLP 
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epitope that is present within the samples. To test the antibody binding further, mixed 
samples would be used. These samples would include imitated faecal samples using 
bacteroidetes and firmicutes (Parks et al., 2013), to ensure the antibodies can still detect 
C. difficile within complex samples. It would be important to first test the individual bacterial 
species within the ‘faecal sample’ to confirm that they do not non-specifically bind the 
mAbs. 
Within the ELISAs for both Ab521 and Ab652, the lowest absorbance reading for the 
C. difficile strains was displayed with Ox1396. This decrease could be due to both mAbs 
binding more weakly to this strain, a lack of epitopes/epitope exposure, or fewer cells 
bound to the ELISA plate providing less antigen. All three ELISAs were set up with the same 
samples and as a result from the ELISAs alone, it was impossible to tell which of the three 
possibilities caused the lack of binding. The difference in absorbance between the control 
strains and Ox1396 was significant for Ab521 at all concentrations from 5 µg/ml to 0.1 
ng./ml, consequently this antibody could accurately differentiate between Ox1396 and the 
closely related species. On the other hand, the values for all Ab652 concentrations were not 
significantly different, showing that under these conditions, Ab652 would not differentiate 
between Ox1396 and P. anaerobius. In order to investigate the lower binding to Ox1396 
compared to the other SLTS, further examination was performed with different 
experimental techniques, the results of which will be discussed in detail in the upcoming 
sections. 
Presumably due to IP protection, information regarding the concentration of antibodies 
used in commercial C. difficile diagnostic ELISAs was not found. The recommended starting 
dilution of the detection antibody for ELISA is 0.5-5 µg/ml (Kemeny and Challacombe, 1988; 
Thermo, 2010) and since the optimum Ab521 concentration is below that range, it 
demonstrates the mAb’s strong binding ability.  
6.3.3 Quantitative evidence that Ab521 binds to whole C. difficile cells at a 
greater efficiency than Ab652 
Flow cytometry enables the quantitative analysis of antibody binding to individual cells, 
whilst also providing information on antibody binding to the population as a whole (Abbas 
and Lichtman, 2004). Both mAbs bound to all 14 SLTS and C. difficile 630 with clear, positive 
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results when compared to the controls, including C. difficile with no mAb and the closely 
related species with both antibodies. This binding was shown by the significant increase in 
median fluorescence intensity, which was caused by Ab521/Ab652 binding to whole 
C. difficile cells and the subsequent binding of Alexa Fluor 594 secondary antibody. The lack 
of fluorescence for the C. difficile strains without mAb incubation showed that there was no 
non-specific binding of the secondary Alexa Fluor 594 antibody to C. difficile and that the 
mAbs are necessary to gain a positive fluorescent signal.  
The median fluorescence values for all C. difficile strains were greater for Ab521 than Ab652, 
corresponding with the ELISA and dot blot results. These quantitative flow cytometry results 
determine that Ab521 binds with higher efficiency to C. difficile cells than Ab652. The %rCVs 
for each C. difficile strain were substantially greater for Ab652 than Ab521, indicating a 
more distributed range of fluorescence intensities across the sample population. On account 
of this contrast in %rCV value, it can be established that Ab521 binds more reproducibly to 
each cell type than Ab652.   
Unlike the whole cell ELISA results, binding of the mAbs to Ox1396 was not substantially less 
than the binding to other C. difficile strains. In fact the peak fluorescence for Ox1396 was 
greater than that of five C. difficile strains for Ab521 and three for Ab652. As a result of this 
binding observed in a sample of 1,000,000 cells, it was noted that the lack of binding to 
Ox1396 within the ELISA results, was likely due to either the technique itself or the poor 
adhesion of Ox1396 to the ELISA plate.  
The three control strains, C. hiranonis, C. sordellii and P. anaerobius were incubated with 
either Ab521 or Ab652 and anti-mouse Alexa Fluor 594. All three strains for both mAbs were 
within the fluorescence intensity range of negative binding, close to zero. These results 
demonstrate the specificity of both Ab521 and Ab652 to C. difficile when compared to the 
three closely related species. When incubated with C. sordellii, Ab652 produced a slightly 
increased median fluorescence intensity of 26.8 AU. Although this fluorescence value is 
higher than those seen with the other control strains, it remains significantly lower than any 
fluorescence value observed with C. difficile, P = < 0.05. 
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These control species do not provide conclusive evidence that the mAbs do not bind to 
bacterial strains other than C. difficile, however, due to their similarity to C. difficile, they 
were a good starting point. With additional time, perhaps more species would be tested for 
non-specific binding, to further demonstrate the specific binding of the mAbs to C. difficile.  
6.3.4 Visualisation of the antibody binding to whole cells using IF 
microscopy 
To enable visualisation of the mAb binding to C. difficile cells, IF microscopy was used. The 
resulting images clearly displayed fluorescence on the surface of the C. difficile strains, when 
incubated with both Ab521 and Ab652. There were six C. difficile strains that were tested, 
the reference strain 630 and the SLTS Ox858, Ox1396, Ox1342, Ox1437a and Ox1533. When 
incubated with Ab521, all six of these strains displayed greater fluorescence than when 
incubated with Ab621, providing yet more evidence of the stronger binding affinity of 
Ab521.  
Similarly to the flow cytometry results, IF microscopy also displayed clear binding of both 
mAbs to Ox1396. From the six C. difficile strains, Ox1396 showed the second highest 
fluorescence value for both Ab521 and Ab652. This binding provided visual confirmation 
that the ELISA results for Ox1396 were not an accurate depiction of antibody binding to this 
strain. Furthermore, the IF images also confirmed the flow cytometry results for the closely 
related species, agreeing that the mAbs did not bind to C. hiranonis and P. anaerobius, 
although, Ab652 did show some, albeit slight, binding to C. sordellii. The clear binding to 
C. difficile and absence of binding to the closely related strains, allow the specificity of 
Ab521 and Ab652, and the surface localisation of the binding to be visualised.   
6.3.5 Specific surface binding of the mAbs at the epitope site 
TEM enables visualisation of the antibody epitope sites, using gold nanoparticles to mark 
the binding, at greater magnification than is possible with IF microscopy. Although not 
quantified, a greater number of nanoparticles were observed when C. difficile 630 was 
incubated with Ab521 than with Ab652. This binding further supports the increased binding 
capability of Ab521 and reveals the specific surface localisation of this binding, which 
coincides with the, HMW SLP containing, S-Layer.  
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The control images of C. difficile 630 without primary mAb, displayed cells that have not 
successfully been immunogold labelled, owing to the absence of primary antibody to which 
the secondary antibody would bind to. The two sets of images are starkly different, with the 
controls lacking any gold nanoparticles in contrast to the primary incubated C. difficile 630, 
which has an abundance of particles. This disparity in binding exposes the need for the 
presence of the Ab521 or Ab652 in order to produce a positive signal with C. difficile. The 
lack of binding was also shown with the closely related species, C. sordellii which, when 
incubated with both Ab521 and Ab652 displayed no gold nanoparticles, indicating that the 
mAbs do not bind non-specifically to C. sordellii.   
Within the literature on C. difficile TEM, cells are always fixed prior to immunogold labelling 
(Takeoka et al., 1991; Emerson et al., 2009; Piepenbrink et al., 2014). C. difficile 630 cells 
without paraformaldehyde fixing were immunogold labelled, with the same protocol as the 
fixed cells, and the resulting image showed clear cell lysis and loss of cellular material, data 
shown in Appendices Figure 9-13.  
The TEM images within this project were gained using whole cells, however, thin cross-
sections of the cells could be used for future work. As shown by Emerson and colleagues, 
when immunogold labelling surface proteins in whole C. difficile cells, cross sections enable 
the clear visualisation of the presence of antigen on the external surfaces only (Emerson et 
al., 2009). This technique would be useful for future TEM analysis of the mAb interactions 
with whole cells, as it should enable the visualisation of the gold nanoparticles specifically to 
the cell surface only. 
6.3.6 The potential of Ab521 for use in a diagnostic assay or sensor 
Lateral flow strips were explored with Ab521 as a possible PoN sensor to detect C. difficile, 
however, the whole cells did not flow freely down the strips. C. difficile cells vary in size 
from 2-8 µm (George et al., 1979), which is smaller than the 15 µm pore size of the 
membrane, however, C. difficile cells can clump and form biofilms (Ethapa et al., 2013; 
Hammond et al., 2014) perhaps blocking the pores. It may be possible within future work to 
develop custom membranes with pores large enough to flow whole C. difficile cells through.  
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The strips enabled the flow of gold-conjugated Ab521 to flow freely through the pores and 
bind to the HMW/LMW SLP complex, providing yet more evidence for the positive binding 
of this antibody to the HMW SLP. The control lateral flow strip which again used 
HMW/LMW SLP bound to the membrane and a gold-conjugated prostate-specific antigen 
(PSA) antibody to not bind to the complex. This simple control was used to show that the 
SLP complex did not bind all IgGs and that Ab521 had to be specific to the complex. It is 
recognised that more significant controls could be performed with these strips. For 
example, closely related whole cells or proteins could be bound to the membrane and the 
mAbs flowed down the strip, to determine non-specific binding. However, for the brief test 
to prove that the Ab521 will bind to the complex within lateral flow strips, it was successful.   
The promising aspect of lateral flow strips are the associated ease of use and low cost of 
production (Sajid et al., 2015). Also, it is possible to lyse cells and detect intracellular 
biomarkers with lateral flow strips, which perhaps would not be applicable for other types 
of PoN sensors, for example microelectromechanical systems (MEMS) .The bioinformatics 
approach used within this project was tailored to identify cell-surface associated proteins, as 
the initial intention was to use any antibodies produced in a MEMS PoN diagnostic sensor. 
MEMS sensors utilise electrical current to resonate at a particular frequency, and when a 
significant weight, such as whole bacteria, is bound to the sensor via an antibody, the 
resonating frequency alters (Arlett et al., 2011). If the unique biomarker was identified to be 
within the cell and was only accessible post cell lysis, it is unlikely that the additional weight 
of a protein, rather than the weight of an entire bacterial cell, would be enough to record a 
significant difference in frequency and provide a positive signal.  
6.4 Summary 
The five techniques that were used within this chapter to determine antibody binding, 
verified that both Ab521 and Ab652 bound to whole C. difficile cells. Paraformaldehyde-
fixed cells were used for flow cytometry, IF microscopy and TEM whereas, native, non-fixed 
cells were utilised for dot blots and whole cell ELISAs, revealing that binding occurred 
irrelevant of the fixing status of the cells. The whole cell ELISAs indicated that the mAbs may 
bind to Ox1396 less than the other SLTS. However, upon further analysis of this binding 
using flow cytometry and IF microscopy, it was revealed that the mAbs actually bind to 
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Ox1396 at a more significant rate than some of the other SLTS. Consequently, the poorer 
binding shown with the ELISAs was not down to the mAbs, having less affinity to this strain, 
and more likely to have be caused by a lack of cells being bound to the surface of the ELISA 
plate.   
All five techniques determined that both Ab521 and Ab652 bound to all 14 SLTS and 
C. difficile 630, and do not show significant, non-specific binding to the three closely related 
strains. The results presented in this chapter are not absolute proof that Ab521 and Ab652 
are specific to C. difficile. However, since the three closely related strains have similar 
protein sequences to C. difficile, the results provide preliminary evidence for C. difficile 
specificity. What is absolutely evident is the ability of Ab521 to positively detect any 
C. difficile strains regardless of SLT clade. 
The results from all five methods provided both qualitative and quantitative data, which 
determined that Ab521 had a stronger binding affinity to whole C. difficile cells, than Ab652. 
Overall, this chapter revealed that Ab521 is the better candidate for use in a PoN sensor as it 
bound with specificity and sensitivity to whole C. difficile cells. 
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Chapter 7 General discussion 
7.1 The bioinformatics approach to biomarker prediction 
The results presented within this thesis provide evidence that the bioinformatics approach 
offers a promising method for the identification of species specific bacterial detection 
biomarkers. The bioinformatics approach integrated the pre-designed, novel IDRIS system 
with the manual bioinformatics workflow, the latter being created as part of this work. The 
IDRIS system, incorporates the TokenDB and subcellular localisation tools, enabling the 
mining of a large amount of genome data, an exercise which would not be possible to 
perform manually. With the 2015 IDRIS system and the integrated Web-based browser, all 
of the annotated whole genome sequence data, within NCBI RefSeq, can be mined for 
protein sequences that are unique to a bacterial group of interest (GOI), within minutes. The 
experimental verification of the expression of the epitopes identified and the corresponding 
development of monoclonal antibodies shows the value of this predictive approach for the 
production diagnostic detection molecules.  
The IDRIS system can be tailored to identify unique biomarkers within any GOI, containing 
any organisms with whole genome sequences within RefSeq. Furthermore, the system can 
be used to identify biomarkers within a protein with the subcellular localisation of choice, 
although only surface associated proteins have so far been investigated. The manual 
workflow within the bioinformatics approach can also be tailored for user needs. For 
example, it may be required that the biomarker is unique to the GOI, when compared to 
only a select choice of other organisms. Or there could be the need to identify biomarkers 
that are expressed under particular conditions. The manual validation of the IDRIS system 
and literature search also provides the user with a knowledge base that enables the 
selection of the most promising biomarker. 
Manual confirmation also enables the user to search for biomarker ‘uniqueness’ against the 
most recent sequence data, including the partial sequences contained within NCBI. This 
search is vital, especially since the reducing cost of sequencing technology is aiding the 
exponential increase in bacterial sequence data (Land et al., 2015). As shown in this work, 
within the space of a few years, the addition of new sequences to the databases can 
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dramatically alter the predictions about unique biomarkers. However, the accuracy of the 
approach demonstrated here will only increase as the number of complete and annotated 
bacterial genome sequences increases.  
The top-down approach, designed within this project, of searching the sequence databases 
prior to laboratory-based procedures, reduces the need for time-consuming and costly 
laboratory identification of biomarkers by avoiding the conventional approach of large-scale 
screening of many bacterial strains. Whilst the IDRIS system was previously used to identify 
a biomarker to differentiate between methicillin-resistant Staphylococcus aureus (MRSA) 
and non-resistant strains (Flanagan et al., 2014), this study was only a proof-of-concept 
exercise. The IDRIS system prediction of MecA as a target and subsequent identification of a 
conserved MecA sequence in MRSA, could have been achieved simply by reference to the 
literature. It is well documented that MecA is modified in MRSA (Llarrull et al., 2009), a 
simple sequence alignment of MecA protein sequences from all S. aureus species could then 
be used to reveal the section of the MecA protein that is unique to MRSA. 
However, in this project, the discovery of peptide sequences unique to C. difficile represents 
a novel finding, since the SlpA biomarker described here has not previously been 
documented as being unique to C. difficile. Nor has the SlpA biomarker been documented as 
being conserved across all sequenced C. difficile strains. Furthermore, the SlpA detection 
biomarker was not easily identifiable, as the S-layer proteins are not wholly unique to 
C. difficile. In fact there are hundreds of bacteria, within all of the major phylogenetic groups 
that have S-layers (Sara and Sleytr, 2000) making these proteins one of the most common 
prokaryote surface structures (Pum et al., 2004).  
In this project the IDRIS system was extended with the addition of tools for the systematic 
manual curation of the biomarkers. With the successful production of antibodies, and their 
use in proof of concept lateral flow devices, this work therefore represents the first time this 
full bioinformatics approach has been used to identify and characterise promising 
biomarkers for PoN sensors. Furthermore, the localisation predictions of the bioinformatics 
approach were also experimentally tested. The SlpA biomarker was predicted to be on the 
surface of the protein and the cell, and the successful binding of Ab521 and Ab652 to whole 
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cells, showed that the epitopes are surface accessible, thus confirming the predictions of the 
bioinformatics approach.  
In summary, the entire bioinformatics approach, incorporating IDRIS, the manual 
bioinformatics workflow and the laboratory work, is a highly versatile biomarker prediction 
system. It is envisaged that this approach could be used to predict and characterise 
biomarkers for many different organisms, not only C. difficile.  
 
7.2 Identification of novel monoclonal antibodies 
The identification of the 16 amino acid SlpA sequence, demonstrates the power of the 
system to rapidly sift and highlight promising candidate biomarkers. In the work presented 
here, these unique linear peptide biomarker sequences were used to develop monoclonal 
antibodies (mAbs). These biomarkers could also be used to develop other diagnostic 
reagents such as peptide aptamers. Given the small, linear nature of the peptide epitopes, 
the mAbs were produced to bind specifically to a sequence and not to a conformation. 
Whilst the antibodies were developed against the sequence of linear peptide, which is 
unique to a group of interest, there remains the possibility that the mAbs may bind non-
specifically to the conformational structure within other bacteria (Zegers et al., 1995). 
Additionally, there is the possibility that the mAbs may bind to a bacterial strain that has not 
yet had its genome sequenced. 
 
Polyclonal antibody sera against the HMW/LMW SLPs has been produced in previous 
studies, however, it was not identified as specific to C. difficile, nor has a study of the 
binding across the C. difficile species been investigated. Antibodies were not purified from 
the sera and several types of anti-sera were developed within two previous studies, both of 
which were performed by Calabi and colleagues. Firstly, anti-sera was produced against the 
HMW/LMW SLP complex from three different C. difficile strains, R8366 (ribotype 001), 
R7404 (ribotype 017) and there reference strain 630 (Calabi et al., 2001). These anti-sera 
were used to characterise the cleavage of the precursor SlpA protein into the HMW and 
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LMW SLPs. Secondly anti-sera was produced against the individual HMW and LMW SLPs to 
determine binding of the SLPs to gastrointestinal tissues (Calabi et al., 2002). Unlike the 
method used within this project, the antibodies within the anti-sera were polyclonal, and 
thus were unlikely to bind to the same epitope or have epitopes that are unique to 
C. difficile. Also, unlike this project, the anti-sera were not investigated for their use as 
C. difficile detection molecules. Since the anti-sera were produced against whole proteins, 
not short linear peptides, any antibodies within the sera could bind via conformational 
epitopes, unlike the specific linear epitope of Ab521.  
Due to the novelty of Ab521 and the successful binding to whole C. difficile cells, with 
C. difficile sensitivity and specificity against the bacterial strains tested, a decision was made 
to patent the antibody. The author of this work is currently working with Newcastle 
University’s Research and Enterprise unit to design a patent application for Ab521.  
7.3 Characterisation of monoclonal antibodies produced against the 
SlpA biomarker 
Although there were initially eight mAbs produced against the SlpA biomarker, several of 
these mAbs did not bind to the whole protein in its native form and since this recognition 
would be vital in a PoN sensor, those mAbs were disregarded. Two mAbs were deemed to 
be promising, Ab521 and Ab652, as they bound to the whole cells of representatives from 
each of the different C. difficile surface layer type strain (SLT) groups. There are 13 SLT 
groups to which all sequenced C. difficile strains belong to, with the position of each strain 
determined by the composition of the SlpA sequence (Dingle et al., 2013). Since both Ab521 
and Ab652 mAbs bind to all 13 SLTS then theoretically they will also bind to all C. difficile 
strains. The ability to comprehensively bind all C. difficile strains is required to provide high 
sensitivity in a PoN sensor.  
Experimental characterisation of the binding efficiency of Ab521 and Ab652 to a variety of 
C. difficile strains determined that Ab521 bound to C. difficile with greater efficiency than 
Ab652. However, both mAbs bound to all C. difficile strains tested, within all techniques 
used. The efficiency of Ab521 and Ab652 binding to each strain varied according to the 
method used to estimate it. For example, whole cell ELISAs indicated that both mAbs bound 
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to Ox1396 with a lower affinity than the other C. difficile strains. However, with other 
techniques, such as flow cytometry, Ab521 and Ab652 were shown to bind efficiently to 
Ox1396. It is possible that the discrepancies in binding were a result of natural variability in 
the techniques employed. The ability of ELISA to detect antibody binding to whole cells, 
depends on the successful adhesion of the bacterial cells to the surface of the ELISA plate 
(Thermo, 2010). The ELISA plates were observed using an inverted microscope to determine 
if cells had bound to the plate. The limited capabilities of this kind of microscopy, however, 
meant that quantification was not possible. The main use for the inverted microscope was 
to determine that the closely related species had successfully bound to the plate. Therefore, 
it is possible that Ox1396 did not adhere as efficiently as the other strains. The three 
different ELISA experiments for both Ab521 and Ab652 determined Ox1396 to be the strain 
with the lowest absorbance. It could be possible that the C. difficile strains differentially 
express SlpA, accounting for the differences in antibody binding observed with the whole 
cell biding techniques. However, since Ab521 and Ab652 was determined by flow cytometry 
and immunofluorescent (IF) microscopy to bind to Ox1396 at a higher affinity than other 
C. difficile strains, it is unlikely that this strain expresses SlpA at a lower rate. The levels of 
SlpA expression within each C. difficile strain could be investigated in future work using 
techniques such as Northern blotting (Beckmann et al., 2010), two-dimensional gel 
electrophoresis (Twyman, 2014) or Liquid chromatography–mass spectrometry (LC-MS) 
(Boetzkes et al., 2012). 
When comparing the data from the strains used in both IF microscopy and flow cytometry, 
Ab521 displayed binding to Ox1437a at the highest level and Ox858 the least with IF 
microscopy and Ox1533 at the highest level and 630 the least with flow cytometry. These 
disagreements could have been caused by the limited measuring accuracy of the 
fluorescence measurements that was performed with the IF microscopy results. For the IF 
results, ImageJ was used to measure a minimum of five random cells whereas, the flow 
cytometry measured fluorescence readings from 1,000,000 cells, providing a much greater 
representation of the sample. The multiple measurements from flow cytometry greatly 
increased the number of observations and is partly why flow cytometry is stated to be a 
more sensitive and accurate, quantitative measurement of the activity different antibodies 
(Bolanos et al., 1988). Although the strains to which Ab521 binds to with the greatest or 
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least efficiency was found to be variable, the significant binding difference that distinguishes 
C. difficile strains from the closely related species does not alter.  
The laboratory validation work was limited by the inability to test all bacterial strains for 
non-specific binding to the biomarker antibodies. Due to resource availability and time 
constraints, a set of bacteria had to be selected as an initial screen. The antibodies were 
produced against small linear peptides and, therefore, were unlikely to recognise epitopes 
via conformational binding. As a result the bacteria for the screen were chosen via their 
sequence similarity to C. difficile or to the protein in which the biomarker was located, SlpA. 
Bacteria with similar sequences were chosen since the specific nature of monoclonal 
antibody binding indicates that the mAbs should not bind to sequences of bacterial strains 
with decreased similarity. The testing of the three species closely related to C. difficile, 
C. sordellii, C. hiranonis and P. anaerobius showed that the most promising antibody, Ab521 
did not show any non-specific binding. Two commensal bacteria were also tested for mAb 
binding to their denatured proteins, with Ab521 not binding to either S. aureus or B. subtilis. 
It is recognised that the size of the bacterial screen for non-specific binding was limited 
within this project.  
There are other species that could be tested, including the species identified in the most 
recent BLASTP search that contain the most similar sequence to the biomarker, 
C. argentinense and C. senegalense. The species that encodes proteins with the closest 
similarity to the SlpA biomarker was C. argentinense of which non-toxigenic samples have 
been isolated from blood and wounds (Johnson, 2005) but not from faecal samples. 
Although there is a similarity to the SlpA biomarker, any diagnostic sensor that is designed 
for faecal samples may not encounter C. argentinense and false positives may not be an 
issue. The genome of C. senegalense also encodes a protein with similarity to the SlpA 
biomarker and was isolated from the faeces of a healthy Senegalese male (Mishra et al., 
2012; Ahmed et al., 2014). Since the bacteria were isolated from a faecal sample, a 
C. difficile PoN sensor may come into contact with the species so it requires testing for 
binding to Ab521. However, there was no evidence to suggest that C. senegalense has been 
isolated from faecal samples in more developed countries and there was very little 
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literature on this strain. Upon correspondence with Professor John Perry29, the head of 
research and development in microbiology at the Newcastle upon Tyne hospitals, it was 
noted that neither C. senegalense no C. argentinense had been previously isolated within UK 
hospitals. Therefore, C. senegalense may not be common enough to cause any false 
positives when detecting C. difficile. Nevertheless, if available, this species would require 
testing with Ab521 for non-specific binding. Further strains for non-specific testing would 
also include strains such as C. bartlettii that are recorded in the pathogen database PARTIC 
as being closely related to C. difficile.  C. bartlettii has also been isolated from human faeces 
(Song et al., 2004)and therefore, may be present in the samples being tested for C. difficile 
and could be an important bacterium to test.  
Other bacterial species that require testing for non-specific binding with Ab521 includes 
organisms that may be present in human faeces. These organisms include Escherichia coli, 
Yersinia enterocolitica, Bacillus cereus and Aeromonas hydrophila (Poojary et al., 2014). 
Since the main symptom for CDI is diarrhoea and it is recommended that only samples 
exhibiting diarrhoea are tested, therefore, the mAbs will especially require testing against 
organisms that cause diarrhoea. Organisms that cause diarrhoea include Shigella, 
Salmonella and Campylobacter (Stallmach et al., 2015). Testing of the Ab521 to these 
species would be essential to ensure that these samples would not provide false positives, 
but ideally should be carried out in the form of the final assay in which Ab521 was deployed.  
7.4 The binding affinity of Ab521 
The Kd for Ab521 binding to the HMW/LMW complex was determined using microscale 
thermophoresis to be 5.21±0.917 nM. Antibodies with a Kd less than 1 µM have high affinity 
(Laguna et al., 2015), therefore, Ab521 has a very strong affinity to the HMW/LMW SLP 
complex. Antibodies described in the literature against C. difficile are usually against the 
C. difficile toxins and often, as seen with Ab521, also have binding affinities within the 
nanomolar range (Demarest et al., 2010; Hussack et al., 2011). Other methods could be 
used to confirm the binding affinity of Ab521, and also measure a Kd for Ab652, to the 
                                                     
29 https://www.newcastlelaboratories.com/people/john-d-perry/ 
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HMW/LMW complex. Due to the limited amount of sample available SPR would be an 
appropriate technique, however, it is unlikely that this method could determine the binding 
affinity to whole C. difficile cells. In order to attain a Kd for the binding of Ab521 or Ab652 to 
whole cells, different techniques that enable the use of whole cells would be required. The 
capillaries used with MST are likely to be too thin to allow the free movement of C. difficile 
cells and although whole cell ITC was performed by Howe and colleagues, it was not used to 
determine a Kd (Howe et al., 2007). Furthermore, SPR is not frequently used with whole 
cells (Stojanovic et al., 2014) and therefore other techniques would have to be taken into 
consideration to determine the Kd of Ab521 with whole cells. Flow cytometry has been 
previously used to determine binding affinities with similar results to those attained with 
SPR (Geuijen et al., 2005). In this technique, the antibody is titrated against the cells and 
binding curve is made using the antibody concentration against the mean log fluorescence 
intensity. ELISAs could also be used to determine a Kd using either traditional or 
displacement ELISA (Friguet et al., 1985; Orosz and Ovadi, 2002; Bobrovnik, 2003). 
7.5 Specific binding to the HMW SLP 
Although the Western blots clearly showed Ab521 binding to the HMW SLP, the protein was 
in its denatured form. The antibody also displayed clear binding to both whole C. difficile 
cells and the HMW/LMW SLP complex, however, further evidence would be needed to 
definitively prove that Ab521 is binding to the biomarker within the HMW SLP. Since the 
mAbs were produced against the biomarker, the logical conlusion would be that Ab521 
bound to the biomarker epitope within the HMW SLP. Mutant strains could be made that 
lack the gene, or specific sequence of interest, and used to show that the antibody no longer 
binds. However, production of SlpA mutants have so far not been successful (Fagan and 
Fairweather, 2011; Pantaléon et al., 2015), most likely due to the protein being essential for 
C. difficile viability (Dembek et al., 2015). Furthermore, producing any form of C. difficile 
mutant was not possible until 2006 when O’connor and colleagues ‘knocked-out’ two 
putative response regulator genes, rgaR and rgbR (O'Connor et al., 2006). A tool published 
in 2007, named ClosTron30 enables the directed construction of stable mutants in C. difficile 
                                                     
30 http://www.clostron.com/clostron1.php  
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using a bacterial group II intron (Heap et al., 2007). Although a full C. difficile slpA mutant 
has not been successfully produced, perhaps using ClosTron a mutant lacking the specific 
HMW biomarker could be made. This mutant strains would enable to testing of the antibody 
to confirm the specific amino acid sequence to which Ab521 binds.   
7.6 Using Ab521 for CDI diagnosis 
It has been reported that 15-25 % of all antibiotic associated diarrhoea (AAD) cases are 
caused by CDI (Cohen et al., 2010; Peterson et al., 2011) therefore, it can be deduced that 
there are up to 85 % of AAD cases that are negative for CDI. The initial step of a two-step 
algorithm for diagnosing CDI should be an inexpensive and rapid test that accurately 
reduces the number faecal of samples requiring additional investigation, without providing 
false negatives. Currently EIAs are often recommended for use as they are inexpensive with 
GDH EIAs being recommended due to the high sensitivity and low false negative prediction 
of the test (Cohen et al., 2010; Wilcox, 2013).  
There is evidence, that GDH EIAs are not as effective at detecting the C. difficile ribotype 027 
as other ribotypes (Tenover et al., 2010). In the 2007/08 epidemic, the 027 ribotype was 
responsible for 40 % of all CDI cases in the UK (Brazier et al., 2008) and within Tenover and 
co-worker’s research, 28.6 % of C. difficile isolates were ribotype 027. It is therefore vital 
that a C. difficile PoN sensor is able to detect this ribotype. In the detection systems 
developed in this work, it was shown that both Ab521 and Ab652 bind to C. difficile Ox160, 
which is strain R027 (Dingle et al., 2013). Both mAbs bound to the denatured HMW SLP 
within Ox160 cell lysates and also bound to whole Ox160 cells using ELISA and flow 
cytometry. The flow cytometry results indicated that the Ab521 and Ab652 clearly bind to 
all C. difficile SLTS and to Ox160 with greater efficiency than six of the other strains. 
Therefore, it is unlikely that Ab521 or Ab652 would be less effective in detecting the 
epidemic strain, ribotype 027.  
Furthermore, GDH EIAs are not specific, that is they do not provide low false positive results, 
which is likely due to the GDH enzyme being produced by many different bacteria, including 
C. sordellii, which demonstrates cross-reactivity with GDH EIAs developed for C. difficile 
(Commichau et al., 2008; Harper et al., 2010; Burnham and Carroll, 2013). The 
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bioinformatics approach used within this project promises to identify epitopes that are 
much less susceptible to cross reactivity. The unambiguous nature of the genome data and 
the ability to rapidly carry out a systematic, comparative analysis of epitopes from a wide 
range of strains reduces the likelihood of any cross reactivity. Ab521 was produced against 
the SlpA biomarker and did not bind to three closely related species, or two commensal 
species, S. aureus and B. subtilis, showing specificity to C. difficile. Within the closely related 
species was C. sordellii ATCC 9714 to which Ab521 did not bind, either as whole cells, native 
proteins or denatured cell lysates. Therefore, under these particular conditions, Ab521 is 
predicted to be more specific than the antibodies used in GDH EIAs. Although a PoN sensor 
incorporating Ab521 would not differentiate between toxigenic and non-toxigenic C. difficile 
and thus, testing for toxin A and B would still be required, it could reduce the false positives 
produced from recognising biomarkers from bacteria other than C. difficile. However, this 
would also rely on the sensitivity of the selected sensor. There is therefore, a possible use 
for the mAb within a PoN sensor, providing the first step of a two-step algorithm, and 
removing up to 85 % of samples from further testing. 
Although Ab521 displays sensitivity by detecting representatives of all C. difficile strains, the 
type of sensor employed would also influence the sensitivity of a C. difficile diagnostic test 
and therefore need to be taken into account. For example, the limit of detection (LOD) of 
lateral flow strips range from mg/ml to µg/ml (Liu et al., 2006; Posthuma-Trumpie et al., 
2009), whereas, ELISAs can detect antigens in the range of ng/ml or even pg/ml (Tang and 
Hewlett, 2010; Khalil et al., 2011; Chiodo et al., 2013). Many other aspects of the test can 
alter the sensitivity of sensors, including conjugates used, membrane/plate type and 
complexity of the sample  (Sajid et al., 2015).  
Using ELISA as the sensor technique, with equal optical densities of bacterial cells, Ab521 
was shown to have a LOD of 1 ng/ml however, this was against pure samples of C. difficile, 
the concentration of which would not occur within patient faecal samples. Therefore, the 
LOD of the mAb would be dependent on the antigen concentration within samples. 
Attempts could be made to determine the LOD of Ab521 with cells at differing ODs, 
however, it would not provide an accurate antigen concentration. Known concentrations of 
the HMW/LMW complex could be used to determine the LOD for each antibody 
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concentration, although it is unlikely this would translate to whole cells. Ultimately, the LOD 
of Ab521 would have to be determined within the PoN sensor of choice and with varying 
numbers of C. difficile cells.  
Another use for Ab521 would be to incorporate it into a dual PoN test that detects both the 
organism and the toxins. Currently a diagnostic company called Alere has the European and 
US patent for the dual use of both GDH and toxin detection together in a single EIA (Boone 
et al., 2013). Diagnostic companies with their own versions of toxin EIAs (Barbut et al., 2014; 
Davies et al., 2015) are interested in a second biomarker to detect C. difficile cells, to 
circumvent the patent and use in a dual test of their own. This need for a biomarker specific 
to C. difficile opens up the possibility of licencing Ab521 to these diagnostic companies.   
A factor that would affect the sensitivity of any PoN sensor integrating Ab521, is the number 
of vegetative C. difficile cells compared to spores within faecal samples. C. difficile is an 
anaerobic, sporulating organism, yet Ab521 was produced against a biomarker that was 
prevalent on the surface of vegetative cells and thus would not detect spores. Several 
studies have shown that there are more vegetative cells than spores within faeces, with one 
study stating there were ten times more vegetative cells within CDI patients (Jump et al., 
2007). A second study performed with mice also found more vegetative cells than spores 
within faeces (Howerton et al., 2013). Therefore, Ab521 would be likely to successfully 
detect C. difficile within faecal samples.  
Identification of a PoN sensor that could successfully incorporate Ab521 would be required 
if this antibody was going to be used to detect C. difficile. The initial work with lateral flow 
strips had issues with the flow of bacteria, as the C. difficile was too large to flow through 
the pores. If lateral flow strips were to be investigated further, additional product searching 
would be required to identify a membrane with pores large enough to fit C. difficile samples 
through. Further optimisation of the strips could also be performed with dilution of the 
sample, perhaps enabling successful use of the current membranes. However, any dilution 
deemed successful would also have to be noted as a pre-treatment requirement within a 
PoN sensor, thus decreasing the rapidity of the test.  
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Other sensors that could be explored with Ab521 include electrochemical, mass-based, 
magnetic and optical sensors. Electrochemical sensors convert a biological event, such as 
C. difficile cells being captured by Ab521 into an electronic signal (Grieshaber et al., 2008). 
Mass-based sensors such as Piezoelectric biosensors or microelectromechanical systems 
operate on the principle that a change in mass can cause a change in resonance frequency 
(Byrne et al., 2009; Arlett et al., 2011). Magnetic sensors can be used by coating antibodies 
onto magnetic beads, which bind to the antigen (C. difficile cells) and can be separated from 
samples using magnets (Jaffrezic-Renault et al., 2007). Finally, optical sensors, including 
surface plasmon resonance can be used as biosensors (Wijaya et al., 2011). Although the 
work within this project determined Ab521 to be a sensitive recognition molecule, that is it 
bound to all tested C. difficile samples, the choice of sensor used with the mAb could affect 
the overall sensitivity of the test. It would be interesting to test whether the antibodies 
produced in this project could be deployed in these additional formats.  
7.7 Possible therapeutic use of Ab521 
In the work described here, mAbs were investigated for use as C. difficile detection 
molecules. However, antibodies are also used as therapeutic molecules (Chames et al., 
2009). There have been several studies that have shown that C. difficile SLPs play a critical 
role in bacterial adherence to host cells (Calabi et al., 2001; Drudy et al., 2001; Merrigan et 
al., 2013). This adherence promotes C. difficile colonisation of the gut and enables the 
infection to persist (Spigaglia et al., 2013). Additionally SLPs have been shown to modulate 
immune responses (Ausiello, 2006; Collins et al., 2014). Research has been performed that 
suggests antibodies against C. difficile SLPs could be a potential therapeutic agent. O’Brien 
and colleagues showed that SLP anti-sera protected hamsters from CDI (O'Brien et al., 2005) 
and also Kandalaft and co-workers reported that SLP antibodies reduced the mobility of 
C. difficile (Kandalaft et al., 2015). Therefore in future studies, the HMW SLP mAbs could be 
examined for the ability to reduce C. difficile adherence and mobility. The traditional 
method of treating CDI is the use of antibiotics, which can alter the composition of the gut 
microbiome and promote antibiotic resistance. Therapeutic antibodies could reduce the 
need for the use of antibodies in CDI cases.   
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There are currently no vaccines available for C. difficile (Vindigni and Surawicz, 2015), 
however, there are several groups investigating a possible toxin based vaccine that utilises 
detoxified toxins (Foglia et al., 2012; Donald et al., 2013; Karczewski et al., 2014). Since the 
S-layer is the predominant surface antigen, there is potential for its use in a C. difficile 
vaccination (Spigaglia et al., 2013). It is therefore anticipated that a possibility for successful 
C. difficile vaccination could be an integrated S-layer and detoxified toxin vaccine.  
7.8 Summary 
The bioinformatics approach was identified as a novel system that characterises biomarkers 
from organisms within a particular group of interest. Laboratory production of antibodies 
against the C. difficile biomarker, which bound to whole C. difficile cells with high affinity, 
confirmed the value of the bioinformatics approach. The most promising mAb, Ab521, 
successfully identified all strains from representative groups of the entire C. difficile species, 
and did not non-specifically bind to the closely related species that were tested. This 
antibody displays potential as a diagnostic tool and could also be investigated as a 
therapeutic agent. To protect both the novelty and value of Ab521, a patent application is 
currently being written. There is huge promise that the combination of bioinformatics 
driven biomarker identification and antibody generation, could be applied to PoN sensors 
for many other pathogenic microorganisms. 
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Chapter 8 Conclusions and future work 
The aim of this project was to establish a bioinformatics approach for the identification of 
protein sequence biomarkers that are unique to a given strain, or group of strains of 
interest. The aim was that these biomarkers could act as suitable epitopes for the 
development of diagnostic reagents, such as antibodies. In the work presented here, the 
species group for C. difficile was chosen as the group of interest to which the system would 
be applied. 
There were two main aspects of the bioinformatics approach for the identification of 
diagnostic biomarkers. The initial step involved the application of an automated system, 
named the IDRIS system, which was designed by Dr Keith Flanagan and colleagues in a 
previous study (Flanagan et al., 2014). The IDRIS system had been used by Keith Flanagan to 
mine the fully sequenced genomes of 2764 organisms and provide sequence regions that 
were unique to C. difficile. A list of the associated proteins containing these unique regions 
and predictions from four protein subcellular localisation tools were provided for use in this 
project. Since an objective of this work was to produce biomarkers for use in rapid point of 
need (PoN) sensors, only proteins that were predicted to be surface associated were 
selected from this list. The second step, a manual bioinformatics workflow, was designed 
within this project to operate on the results from the IDRIS system and used a combination 
of sequence similarity searches, protein structure prediction and expression data analysis. 
All of these analysis tools were used to determine biomarkers of at least 15 amino acids that 
were conserved across the C. difficile species. These biomarkers were required to be 
different to the next most similar sequence, not found within C. difficile, by a minimum of 
four amino acids, in order for the biomarker to be classed as unique to C. difficile. 
Application of this bioinformatics approach successfully identified a very promising, unique, 
surface associated, peptide sequence biomarker, within the SlpA protein of C. difficile. 
The second objective for validating the success of the bioinformatics approach was to use 
laboratory methods, to confirm the SlpA biomarker for potential use in a PoN sensor. 
Several monoclonal antibodies (mAbs) were produced against the biomarker and two of 
these successfully bound to all tested C. difficile strains. Of these two mAbs, Ab521 was 
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deemed the most promising as it showed the strongest binding affinity to whole C. difficile 
cells. Furthermore, Ab521 displayed novelty by binding to strains across the C. difficile 
species and specifically to C. difficile, amongst the species tested. These results did indeed 
validate the bioinformatics analysis for three reasons. Firstly, the biomarker was displayed 
on the surface of C. difficile as predicted. Secondly, the biomarker was present in all tested 
C. difficile strains, including the surface layer type strains that represent the entire 
sequenced C. difficile species. Finally, the biomarker was shown to be specific to C. difficile 
when tested against the closely related strains. The novelty of Ab521 highlights the value of 
the bioinformatics approach, as the system could be used to provide similar results for other 
bacteria, including other pathogens. 
Traditional biomarker identification tends to use laboratory data, from techniques such as 
protein analysis or microarrays, to perform large-scale searches for unique information 
within this data, for example a particular protein or increase in gene expression (Freiberg et 
al., 2006; Natesan and Ulrich, 2010; Yousef et al., 2014). Often this requires the production 
of a lot of experimental data, which may not identify a unique biomarker. Although 
bioinformatics has recently emerged as a major tool in bacterial biomarker identification (Li 
et al., 2002; Zhang et al., 2014), tools are usually used for comparisons of subject genomes 
to reference genomes (Shao et al., 2010). Whereas, the bioinformatics approach described 
within this project mines a huge amount of sequence data, with thousands of bacterial 
genomes, to determine biomarkers that are unique before laboratory work begins. This top-
down method increases the likelihood of a discovering a truly unique biomarker and 
reduces the need for expensive, time-consuming laboratory work. The workflow also 
searches for fragments as small as 15 amino acids in length unlike traditional methods 
where entire proteins are searched for (Rabilloud and Triboulet, 2013). 
A thorough literature search was performed and a bioinformatics approach of this kind had 
not been previously described, not including the IDRIS system predecessor (Flanagan et al., 
2014). A similar fragmenting technique has been used before for population genomics, 
however, the fragmenting technique was used with a subject genome sequence against a 
known reference sequence (Catchen et al., 2013). This system is novel due to the 
integration of mining entire genome data-sets, with the computational prediction of unique 
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surface biomarkers that are accessible to antibodies and are constitutively expressed. 
Although this system has been used with C. difficile, it would be possible to mine for 
biomarkers of GOI’s containing other organisms.    
8.1 Limitations of the bioinformatics approach 
Several limitations of the bioinformatics workflow were addressed within this project and 
will be discussed. Firstly, the automated IDRIS system mines only the fully annotated 
genome sequences within RefSeq which equates to 2764 organisms. There are many more 
organisms with partial genomes or smaller sequences, within NCBI, that would require 
analysis of their sequences. For example, there could be bacterial strains that should ideally 
be within the group of interest and, therefore, these strains must also be analysed for the 
presence of the biomarker. Also, the tokens that are classed as unique via the IDRIS system 
could possibly be present within these other sequences and thus not be unique. The BLASTP 
searches within the bioinformatics workflow were used to address these two issues, 
enabling all of the bacterial sequence data within NCBI to be searched. Using BLASTP 
searches increases the likelihood that the identified biomarkers are truly unique. The issue 
remains that only data that has been sequenced could be searched for biomarker similarity, 
however, this is the case with all methods that involve computational mining. Increasing 
availability of sequence data will enable the constant improvement of this project’s 
bioinformatics workflow, with the more data that is added, the increased likelihood that the 
predicted biomarkers are truly unique. 
8.2 Future work 
To further improve the bioinformatics workflow a number of tolerance tests could be 
performed. Firstly, the IDRIS system currently classes a token (15 amino acid sequence) as 
unique, even if up to 14 of the 15 amino acids are present within a bacterium outside of the 
GOI. This ‘uniqueness threshold’ was selected to provide the largest number of ‘unique’ 
tokens for the down-stream analysis. Future work could include determining the maximum 
number of unique amino acids, within the token, that provides an acceptable number of 
tokens yet increases the likelihood of them being truly unique. 
 176 
 
Secondly, biomarkers are currently required to have a minimum of four amino acids 
different to the closest related sequence, not in the GOI. This minimum difference was 
selected to retain specificity of any recognition molecules, such as antibodies, to the strains 
within the GOI. However, due to the highly specific nature of monoclonal antibodies, it may 
be possible to decrease this minimum amino acid difference while retaining GOI specificity. 
Further work could be performed testing antibody binding against sequences of decreasing 
similarity to the epitope. The minimum number of amino acid changes needed to inhibit 
mAb binding can then be established. Several other variables to will also have to be taken 
into account such as position and proximity of the variations in the sequence.  
Future work will also require thorough testing of the bioinformatics approach with the 
prediction and validation of a biomarker for another GOI. However, within the context of 
this work, the bioinformatics approach produced accurate identification of unique 
biomarkers for the development of diagnostic reagents for use in PoN sensors.   
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Chapter 9 Appendices 
9.1 Example of a BSA standard curve for a BCA assay 
 
Figure 9-1. An example of a BCA assay, BSA standard curve. Absorbance measured at 550 nm is plotted against 
concentration of standard BSA samples 
 
9.2 Bioinformatics results 
The 28 C. difficile proteins that were successful for all tools within the surface association pipeline, 
SignalP, LipoP, PSORTb and TMHMM, with SlpA highlighted. 
Protein ID GI: NCBI Accession  
260683411 YP_003214696.1   
260684371 YP_003215656.1   
260684408 YP_003215693.1  
126700403 YP_001089300.1  
126700410 YP_001089307.1  
126699809 YP_001088706.1  
126699358 YP_001088255.1  
260687007 YP_003218140.1  
126697956 YP_001086853.1  
260684362 YP_003215647.1   
260688032 YP_003219166.1  
260687059 YP_003218192.1  
260688067 YP_003219201.1  
260688028 YP_003219162.1  
260684369 YP_003215654.1  
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0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0 500 1000 1500 2000 2500
O
D
 (5
50
nm
)
BSA concentration (ug/ml)
 178 
 
260688030 YP_003219164.1  
126701015 YP_001089912.1  
260684373 YP_003215658.1  
126700414 YP_001089311.1  
260683463 YP_003214748.1  
260684356 YP_003215641.1  
260683792 YP_003215077.1   
126700409 YP_001089306.1 SlpA 
260688015 YP_003219149.1  
126700398 YP_001089295.1  
126700447 YP_001089344.1  
260687452 YP_003218586.1   
126700412 YP_001089309.1  
Table 9-1. The 28 C. difficile proteins that were successful for all tools within the surface association step of the 
bioinformatics approach . The proteins are listed with the NCBI accession number, which were successful for all tools 
within the surface association pipeline, SignalP, LipoP, PSORTb and TMHMM, with SlpA highlighted 
 
9.3 C. difficile 630 SlpA protein sequence 
The C. difficile 630 protein sequence, NCBI Accession YP_001089306, with the signal 
peptide, LMW SLP, HMW SLP and unique biomarker highlighted.   
MNKKNIAIAMSGLTVLASAAPVFAATTGTQGYTVVKNDWKKAVKQLQDGLKDNSIGKITVSFNDGVVGEV 
APKSANKKADRDAAAEKLYNLVNTQLDKLGDGDYVDFSVDYNLENKIITNQADAEAIVTKLNSLNEKTLI 
DIATKDTFGMVSKTQDSEGKNVAATKALKVKDVATFGLKSGGSEDTGYVVEMKAGAVEDKYGKVGDSTAG 
IAINLPSTGLEYAGKGTTIDFNKTLKVDVTGGSTPSAVAVSGFVTKDDTDLAKSGTINVRVINAKEESID 
IDASSYTSAENLAKRYVFDPDEISEAYKAIVALQNDGIESNLVQLVNGKYQVIFYPEGKRLETKSANDTI 
ASQDTPAKVVIKANKLKDLKDYVDDLKTYNNTYSNVVTVAGEDRIETAIELSSKYYNSDDKNAITDKAVN 
DIVLVGSTSIVDGLVASPLASEKTAPLLLTSKDKLDSSVKSEIKRVMNLKSDTGINTSKKVYLAGGVNSI 
SKDVENELKNMGLKVTRLSGEDRYETSLAIADEIGLDNDKAFVVGGTGLADAMSIAPVASQLKDGDATPI 
VVVDGKAKEISDDAKSFLGTSDVDIIGGKNSVSKEIEESIDSATGKTPDRISGDDRQATNAEVLKEDDYF 
TDGEVVNYFVAKDGSTKEDQLVDALAAAPIAGRFKESPAPIILATDTLSSDQNVAVSKAVPKDGGTNLVQ 
VGKGIASSVINKMKDLLDM 
 
SlpA precursor protein is 719 amino acids, 2157 bp 
373 amino acids – HMW SlpA – Mr = 39.45 kDa 
322 a.a – LMW SlpA – Mr = 34.3 kDa   
24 amino acids - Signal peptide  
Amino acid position 641-656 = SlpA biomarker 
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9.4 DNA sequencing results 
C. difficile 630 DNA sequence results (biomarker highlighted) 
AATTACTATTATACATTAAAAATCCATAATAGTAGACAATTATTTTGATTTATAGTATAATGATTTTACTTAAAT
AAATTAAACATCTTTTTATTTAGGGATTTCTCACATAAAATAGAGGCTATTTATAGCCTCTATTTTATTTTATATT
TATTTTAAATAAAAAAGACTTCTCATGAGAGAAGCCTTTTTCTATTTAAAGTTTTATTAAAACTTATATTACATAT
CTAATAAATCTTTCATTTTGTTTATAACTGAAGAAGCTATACCTTTACCTACTTGAACTAAGTTAGTTCCACCATC
TTTAGGAACTGCTTTACTTACAGCTACATTTTGGTCAGAAGATAAAGTATCAGTAGCTAGTATGATTGGAGCTG
GAGACTCCTTAAATCTACCTGCTATTGGTGCTGCTGCTAAGGCATCTACTAATTGATCTTCTTTAGTAGAACCAT
CTTTTGCAACAAAGTAATTCACAACTTCACCATCTGTGAAATAATCATCTTCTTTTAAAACTTCAGCATTAGTTG
CTTGTCTATCATCTCCACTTATTCTATCTGGAGTTTTTCCAGTTGCACTATCTATTGACTCTTCAATCTCTTTAGAT
ACGCTATTTTTTCCACCTATTATATCAACATCAGAAGTTCCTAAGAAACTCTTAGCATCATCACTTATTTCTTTTG
CTTTTCCATCTACAACTACTATTGGAGTAGCATCTCCATCTTTAAGTTGAGAAGCAACTGGAGCTATACTCATA
GCATCTGCTAATCCAGTACCACCAACTACAAATGCTTTATCATTATCAAGACCTATTTCATCAGCTATTGCTAAA
GAAGTTTCGTATCTGTCTTCTCCTGATAATCTAGTAACTTTAAGACCCATGTTTTTCAATTCATTTTCTACATCTT
TAGATATAGAATTAACTCCACCAGCTAAATAAACTTTTTTAGAAGTATTTATACCAGTGTCACTCTTTAGTTCAT 
ExPASY Translate of C. difficile  630 sequencing results (biomarker highlighted) 
3'5' Frame 3 
E L K S D T G I N T S K K V Y L A G G V N S I S K D V E N E L K N Met G L K V T R L S G E D R Y E T S L A I A 
D E I G L D N D K A F V V G G T G L A D A Met S I A P V A S Q L K D G D A T P I V V V D G K A K E I S D D 
A K S F L G T S D V D I I G G K N S V S K E I E E S I D S A T G K T P D R I S G D D R Q A T N A E V L K E D D 
Y F T D G E V V N Y F V A K D G S T K E D Q L V D A L A A A P I A G R F K E S P A P I I L A T D T L S S D Q N 
V A V S K A V P K D G G T N L V Q V G K G I A S S V I N K Met K D L L D Met Stop Y K F Stop Stop N F K 
Stop K K A S L Met R S L F Y L K Stop I Stop N K I E A I N S L Y F Met Stop E I P K Stop K D V Stop F I 
Stop V K S L Y Y K S K Stop L S T I Met D F Stop C I I V I 
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9.5 Dot blots 
 
Figure 9-2. Dot blots for Ab493 and Ab491 against C. difficile . Samples used were low pH glycine extracted surface 
proteins (S) and the residual pellet, post extraction (P) for C. difficile 630 and C. sordellii ATCC 9714 with Ab493 (A) and 
Ab491 (B). The primary antibody was directly blotted on to the membrane as a positive control. The biomarker regions 
of the antibody epitopes are displayed in red. 
 
Figure 9-3. Dot blots for AbB31 and AbB84 against C. difficile . Samples used were low pH glycine extracted surface 
proteins (S) and the residual pellet, post extraction (P) for C. difficile 630 and C. sordellii ATCC 9714 with AbB31 (A) and 
AbB84 (B). The primary antibody was directly blotted on to the membrane as a positive control. The biomarker regions 
of the antibody epitopes are displayed in red. 
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9.6 Binding of the mAbs to proteins within C. difficile and the closely 
related strains 
 
Figure 9-4. Western blot analysis of Ab491 and Ab493 against species closely related to C. difficile. Western blot (right) 
and concomitant SDS-PAGE gel (left) of the low pH glycine extracted surface proteins (S) and residual pellet (P) of 
C. difficile 630 and the closely related strains C. sordellii ATCC 9714 and P. anaerobius VPI 4330 with Ab491 (A) and 
Ab493 (B). 
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9.7 Binding of the mAbs to proteins within commensal bacteria that are 
also found within faecal samples 
 
 
Figure 9-5. Western blot analysis of Ab491 and Ab493 against S. aureus and B. subtilis . The low pH glycine surface layer 
proteins (S) and remaining pellet (P) of C. difficile 630 and R002, S. aureus ATCC 29213 and B. subtilis BSB1 were 
analysed with Ab491 (left) and Ab493 (right). 
 
9.8 BLAST results of the mAb epitopes against the closely related 
species, P. anaerobius  
 
Top BLASTP result for Ab491-FVAKDGSTKE against P. anaerobius 
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Top BLASTP result for Ab521-STKEDQLVDA against P. anaerobius 
 
Top BLASTP result for Ab652-KEDQLVDALA against P. anaerobius 
 
 
9.9 Specific whole cell binding of Ab521 and Ab652 to the C. difficile 
SLTS 
Whole cell ELISA, raw data. 
 
Figure 9-6. Raw data of whole cell ELISA with Ab521. The ELISA used whole cells of C. difficile SLTS and 630, and the 
closely related species, C. hiranonis DSM-13275, C. sordellii ATCC 9714 and P. anaerobius VPI 4330. The cells were 
incubated with Ab521 at varying concentrations. 
 
 
 
 
 
 
<> Ox1424 Ox1437a Ox1523 Ox1533 Ox1896 Ox2404 630 no cells C. hiranoni C. sordelli P. anaerobControls
10μg 521 1.8495 1.8989 1.872 1.8964 1.9021 1.9746 1.8914 0.049 0.4196 0.9925 1.0294 0.0506 No 1AB
10μg 521 1.7932 1.6908 1.6974 1.6713 1.6753 1.7257 1.5786 0.0419 0.3483 0.8934 1.2017 0.0519 No 1AB
5μg 521 1.7547 1.7156 1.6896 1.6904 1.7263 1.7258 1.7000 0.105 0.2158 0.5737 0.6337 0.0456 No 2Ab
5μg 521 1.7982 1.7057 1.7016 1.6294 1.7111 1.7119 1.6544 0.1438 0.1642 0.5821 0.6702 0.0428 No 2Ab
1μg 521 1.7553 1.8271 1.6853 1.5708 1.7723 1.8197 1.7733 0.0801 0.0773 0.1752 0.2074 0.0349 No OPD
1μg 521 1.7854 1.8106 1.6843 1.6017 1.8128 1.7601 1.8037 0.0535 0.0714 0.1888 0.2149 0.034 No OPD
0.1μg 521 1.654 1.7101 1.6649 1.6017 1.6642 1.7788 1.6475 0.0552 0.0422 0.0586 0.0803 1.2528 1Ab
0.1μg 521 1.6934 1.8992 1.81 1.6204 1.7386 1.8784 1.8341 0.0428 0.0525 0.0681 0.091 1.2964 2Ab
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Statistical data of the one-way ANOVA analysis of the Ab652 5 µg/ml whole cell ELISA data.  
 
Figure 9-7. One-way ANOVA analysis, performed with IBM SPSS version 21, of the whole cell ELISA data from Ab652 at 5 
µg/ml, with post hoc Tukey test. The significance value was set to P = < 0.05.  
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9.10 Immunofluorescent microscopy results of C. difficile strains and 
closely related species incubated with the mAbs 
 
Figure 9-8. Immunofluorescence microscopy images of Ox858 incubated with Alexa Fluor 594 anti-mouse IgG and Ab521, 
brightfield image (A), mCherry filter (B). Alexa Fluor 594 anti-mouse IgG and Ab652 brightfield image (E), mCherry filter 
(F). Control of Ox858 with Alexa Fluor 594 anti-mouse IgG and no primary antibody brightfield image (C), mCherry filter 
(D).  
 
Figure 9-9. Immunofluorescence microscopy images of Ox1437a incubated with Alexa Fluor 594 anti-mouse IgG and 
Ab521, brightfield image (A), mCherry filter (B). Alexa Fluor 594 anti-mouse IgG and Ab652 brightfield image (E), 
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mCherry filter (F). Control of Ox1437a with Alexa Fluor 594 anti-mouse IgG and no primary antibody brightfield image 
(C), mCherry filter (D). 
 
Figure 9-10.  Immunofluorescence microscopy images of 630 incubated with Alexa Fluor 594 anti-mouse IgG and Ab521, 
brightfield image (A), mCherry filter (B). Alexa Fluor 594 anti-mouse IgG and Ab652 brightfield image (E), mCherry filter 
(F). Control of 630 with Alexa Fluor 594 anti-mouse IgG and no primary antibody brightfield image (C), mCherry filter (D). 
 
Figure 9-11. Immunofluorescence microscopy images of C. hiranonis incubated with Alexa Fluor 594 anti-mouse IgG and 
Ab521 brightfield (A) mCherry (B) or Ab6521 brightfield (C) mCherry (D). 
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Figure 9-12. Immunofluorescence microscopy images of P. anaerobius incubated with Alexa Fluor 594 anti-mouse IgG 
and Ab521 brightfield (A) mCherry (B) or Ab6521 brightfield (C) mCherry (D). 
 
9.11 Transmission electron microscopy 
 
Figure 9-13.Transmission electron microscope image of non-fixed C. difficile 630  incubated with Ab521 and gold 
conjugated anti-mouse IgG. 
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Chapter 10 Publications, patents and attended meetings  
10.1 Publications 
Flanagan, K., Cockell, S., Harwood, C., Hallinan, J., Nakjang, S., Lawry, B. and Wipat, A. (2014) 
'A distributed computational search strategy for the identification of diagnostics targets: 
application to finding aptamer targets for methicillin-resistant staphylococci', J Integr 
Bioinform, 11(2), p. 242. 
10.2 Publications in writing 
‘Determining unique biomarkers that are conserved across the C. difficile species using a 
bioinformatics approach’. Author list and journal to be determined. 
10.3 Patents in writing 
A patent is currently in writing for the specific C. difficile antibody Ab521. 
10.4 Attended meetings 
ICDS – May 2015 – Poster presentation 
i-sense IRC meeting - June 2014 – Oral presentation 
i-sense IRC meeting – Jan 2016 – Poster presentation 
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